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Fibroblast growth factor 2 (FGF-2) is known to be released from cartilage upon injury 
and is able to influence chondrocyte gene expression in vitro. In cartilage, FGF-2 
regulates E11/podoplanin expression in murine joints following surgical 
destabilisation (DMM model of osteoarthritis (OA)), and in cartilage explant injury 
models. In bone, E11 is critical for the early stages of osteocytogenesis and is 
responsible for the acquisition of the osteocyte dendritic phenotype. This dendritic 
phenotype is dysregulated in OA and given the known role of the osteocyte in 
controlling bone remodelling, this may contribute to the subchondral bone thickening 
observed in OA. Hence, the aim of this study was to elucidate the nature of FGF-2-
mediated E11 expression and osteocytogenesis in skeletal health and disease.  
This thesis has shown that FGF-2 dose-dependently increased E11 mRNA expression 
in MC3T3 cells, primary osteoblasts and in primary calvaria organ cultures, which 
was confirmed by E11 protein western blotting data. The FGF-2 induced changes in 
E11 expression were accompanied by significant increases in the mRNA expression 
of the osteocyte markers Phex and Dmp1, and significant decreases in the mRNA 
expression of the osteoblast markers Col1a1, Postn, Bglap and Alpl expression. This 
thus supports the hypothesis that FGF-2 drives osteocytogenesis.  
The acquisition of osteocyte phenotype involves the re-organisation of the 
cytoskeleton, such as F-actin. This step is important for the transition of cuboidal-
shaped osteoblasts to the stellate-shaped osteocyte phenotype. FGF-2 stimulation of 
MC3T3 cells and primary osteoblasts revealed more numerous and longer dendrites, 
as visualised by phalloidin staining for F-actin and indicative of the acquisition of the 
osteocyte phenotype. In contrast, control cells had a typical rounded morphology 
with fewer and shorter dendrites. Furthermore, immunofluorescence labelling for 
E11 in control cells revealed uniform distribution throughout the cytoplasm, 
especially in the perinuclear region. In contrast, FGF-2 treated cells showed a 
modified distribution where E11 was negligible in the cytoplasm, but concentrated in 
the dendrites. The use of siRNA knockdown of E11 achieved a 70% reduction of basal 
E11 mRNA expression. This knockdown also effectively abrogated FGF-2-related 
changes in E11 expression and dendrite formation as disclosed by mRNA and protein 
expression, immunofluorescence and F-actin staining with phalloidin. Despite these 
FGF-2 driven increases in E11 and osteocyte dendrite formation in vitro, 
immunohistochemical labelling revealed no differences in E11 expression in 
subchondral, trabecular and cortical osteocytes from naïve Fgf-2 deficient mice in 
comparison to wild-type mice. Similar results were observed upon sclerostin 
immunolabelling.  
FGF-2 stimulation of MC3T3 cells elicited activation of ERK1/2, Akt and p38 MAPK. 
However, inhibition of the aforementioned pathways failed to reduce FGF-2-
mediated E11 expression and as such, the specific signalling pathway responsible 
remains unclear. Upstream, the expression of Fgfr1 was increased (>10-fold) over 24 
h time point, while a reduction was seen in Fgfr2/3 expression over same time point 
especially in the FGF-2 treated cultures. This suggests that increased E11 expression 
and the acquisition of the osteocyte phenotype may be speculatively though 
upregulation of Fgfr1.   
The expression of E11 and sclerostin in OA pathology in mice, human and dogs were 
investigated. Initially sequence homology using the Clustal Omega alignment 
program showed both proteins to be homologous in the domestic animals under 
study. A comparative study using canine subchondral bone osteocytes revealed 
increased E11 expression in the OA samples relative to the control. This feature may 
be related to newly embedded osteocytes during sclerosis. However, E11 and 
sclerostin were unchanged in both murine (DMM) and human OA subchondral bone 
osteocytes in comparison to controls.  In mice, this may be due to limited OA 
development; whilst in humans the sample size, age, stage of the disease and sourcing 
from same diseased joint may be important in the interpretation of the results. 
The expression of E11 and sclerostin during OA pathology was also investigated in 
Fgf-2 deficient mice in which OA was induced using the DMM model. There was no 
difference in E11 expression between the OA and control (sham-operated) samples, 
suggesting that compensation of E11 expression may be mediated by growth factors 
from the FGF family. Surprisingly, increased E11 expression was observed in the 
control Fgf-2 deficient mice, in comparison to the wild-type control mice. This 
suggests a potential adjustment to loading by the contralateral knee, as this was not 
observed in naïve mice from both groups.  
Together, these data show that FGF-2 promotes the osteocyte phenotype, and that 
this is mediated by increased E11 expression. These results may help explain (1) the 
altered osteocyte phenotype and (2) increased subchondral bone thickening observed 
in OA. This knowledge will be of interest in the search for disease modifying 
therapeutics for skeletal health, including OA and osteoporosis.   
Lay Abstract 
The mammalian skeleton, which supports body weight, aids locomotion and protects 
important organs like the heart and lungs, is a dynamic organ. Inside the skeleton are 
three types of cells that are regularly changing form and function, enabling the 
skeleton to adapt to changes in body weight, recover from fracture, or even help the 
kidney in mineral balance control. One of these cell types are called osteoblasts. 
Osteoblasts have a rounded shape and make new bone. Eventually, the osteoblast 
surrounds itself with new bone and then undergoes a transition into a smaller star-
like cell, called an osteocyte.  
The osteocyte is the most abundant bone cell and makes up about 95% of the total 
number of bone cells. The osteocyte is now regarded as the master regulator cell, 
regulating how bone adapts to changes in shape and size. The formation of the 
osteocyte’s star-like projections, called dendrites is controlled by a molecule called 
E11. E11 helps the osteocyte to communicate with other osteocytes, and other bone 
cell to regulate bone health and diseases. These dendrites are reportedly malformed 
in some bone related diseases like osteoarthritis. However, how E11 helps in the 
transition from osteoblast to osteocyte in healthy bone is largely unknown and 
similarly what factors might increase or reduce E11 expression are also unknown.  
One growth factor that plays an important role in skeletal growth and development 
is called FGF-2. In this thesis, it was shown that FGF-2 is able to increase E11 
expression. Furthermore, FGF-2 was able to promote the formation of osteocyte 
dendrites, though these increases in E11 expression. The findings of this thesis help 
to expand the knowledge surrounding the process of osteocyte formation in healthy 
bone. Importantly, this knowledge will contribute towards our understanding of 
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The skeleton has been considered by some to be a dull and lifeles tissue however it is 
actually a dynamic organ constantly adapting to demands placed upon it. The 
skeleton is essential for locomotion and soft tissue protection, and is involved in other 
body homeostasis responses such as the regulation of mineral and energy 
metabolism. It is accepted that the bone is constantly modelling itself in response to 
changes in weight bearing activities during locomotion. The adaptation to loading is 
regulated by osteocyte expressed signals that influence the activities of osteoblasts 
and osteoclasts. Osteocytes are terminally differentiated osteoblasts, formed though 
a process termed osteocytogenesis. This process is under the influence of various late 
osteoblast/osteocyte-expressed molecules such as E11 (podoplanin). E11, is essential 
for osteocyte dendrite formation and its expression is known to be regulated by 
growth factors such as fibroblast growth factor (FGF)-2 in cartilage. Despite this, the 
regulation of E11 expression in bone is completely unknown. This work reported in 
this thesis investigates the role of FGF-2 during osteoblast to osteocyte transition, and 
test the hypothesis that FGF-2 regulates E11 mediated osteocytogenesis. The 
importance of understanding this is highlighted by the central role that dendrites play 
in osteocyte communication in health, and their dysfunction in some skeletal 
disorders like osteoarthritis (OA). Understanding the role of E11 during osteocyte 
formation in subchondral bone (SCB) of healthy and OA joints will contribute 
immensely to the search for therapeutic targets in OA. 
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1.1 Bone structure and function 
The skeleton is a highly complex but organised organ structurally specialised for 
locomotion, protecting critical internal organs, mineral homeostasis and energy 
metabolism regulation (Weiner et al., 1999, Feng, 2009, Oldknow et al., 2015). Bone is 
a composite structure made up of organic and inorganic material and together the 
hydroxyapatite (HA) mineral (stiff and brittle) and the organic collagen (tough and 
soft) provide a structure that is tough, stiff, and resistant to fracture (Staines et al. 
2012). The resident cells that are responsible for maintaining this structure are the 
osteoblasts, osteocytes and osteoclasts. Whilst collagen type 1 is the major organic 
component of the extracellular matrix (ECM), there are  many other osteoblast 
secreted non-collagenous proteins (NCPs) such as glycosaminoglycans, osteopontin, 
and dentine matrix protein 1 (DMP1) (Sommerfeldt and Rubin, 2001).   
The skeleton is comprised of compact or cortical (compact) and trabecular 
(cancellous) bone. The trabecular bone located within the marrow compartment has 
an open lattice network making it light but strong (Fig. 1.1A).  It has a higher bone 
turnover rate than cortical bone and its lamellar organisation does not contain osteons 
(Sommerfeldt and Rubin, 2001). It can adapt to loading in various directions and its 
surrounding marrow is the site for haematopoiesis.  
 The cortical bone, which makes up ~ 80% of the bone mass, is found on the external 
aspect of bone shaft. Cortical bone is relatively hard and dense; but well organised 
into osteon building units of the Harversian system (Sommerfeldt and Rubin, 2001, 
Brandi, 2009). The mineralised osteonal rings have resident osteocytes (encased 
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within a lacuna) which are characterised by dendritic cytoplasmic projections 
radiating from the cell membrane. They run though a canaliculi network, which 
connects neighbouring osteocytes and osteocytes with bone surface osteoblasts and 
osteoclasts.  The central Harversian canal has blood vessels, lymphatics and nerve 
traversing though (Fig. 1.1B). Cortical bone is specialised for weight bearing 
especially along the vertical axis of the body.   
1.2  Bone formation  
Bone development and formation involves two distinct mechanisms - 
intramembranous and endochondral ossification (Shapiro, 2008, Yang, 2009). While 
intramembranous ossification involves the differentiation of mesenchymal cells into 
osteoprogenitor cells on collagen surfaces, endochondral ossification is the 
replacement of hyaline cartilage anlagen by osteoprogenitor cells and bone 
(Henrikson et al., 1997, Percival and Richtsmeier, 2013). The fate of osteoprogenitor 
cells during bone formation is under tight signalling regulation. Upregulation of 
Wingless integration (Wnt)/β-catenin signalling in the region of mesenchymal 
condensations drive osteoblast differentiation, hence intramembranous ossification. 
Conversely, the initial decrease in Wnt/β-catenin signalling in mesenchymal 
condensations promotes the formation of the chondrocyte anlagen for endochondral 
ossification. In advanced stages of endochondral ossification, upregulated Wnt/β-
catenin signalling drives subsequent osteoblast differentiation in the cartilage 
 




















Figure 1.1 The structure of cancellous and cortical bone 
Low power scanning electron microscopy of normal cancellous bone design (A), 
showing bone trabecular and open lattice shape, which contains bone marrow. Cortical 
bone architecture found in the diaphysis of long bone (B). The centrally located 
Haversian canal provides passage for nerves and blood vessels. Note the concentric 
layers of bone matrix and osteocytes surrounding it. Images sourced from the Bone 
Research Society, by kind permission of (A) Alan Boyde (B) Tim Arnett. 
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periphery (Yang, 2013). The role of transcription factors SRY-box 9 (Sox9) and Runt-
related transcription factor 2 (Runx2), which are master regulators of chondrocyte 
and osteoblast differentiation from mesenchymal cells respectively, have also been 
documented (Ducy et al., 1997, Bi et al., 1999).   Fibroblast growth factor receptor 2c, 
is expressed by early mesenchymal cells where it is activated by FGF-18 during both 
endochondral and intramembranous bone formation (Eswarakumar et al., 2002).   
1.2.1 Intramembranous Ossification 
Intramembranous ossification is responsible for the development and formation of 
flat bones like the maxilla and palate in the skull (Netter, 1987, Mackie et al., 2011, 
Jiang et al., 2014). It also occurs during natural fracture healing of flat bones (Brighton 
and Robert, 1991). Intramembranous ossification involves four distinct but 
continuous stages: (i) formation of ossification centres and differentiation of 
mesenchymal cells into osteoblasts (ii) matrix formation and vascular invasion of the 
bone anlagen (iii) periosteum and trabeculae formation (iv) lamellar bone formation 
around trabeculae (Thompson et al., 1989).  
1.2.2 Endochondral ossification 
Endochondral ossification is responsible for the formation of the long bones of the 
body and in the natural fracture healing process (Brighton and Robert, 1986, Jiang et 
al., 2014). In this process, a hyaline cartilage model is established from mesenchymal 
cell condensation, and later replaced by osteoblasts from the vascular system (Horton, 
1990, Yang, 2009). This process is critically regulated by factors such as growth 
hormone, insulin like growth factor 1, thyroid hormone, bone morphogenic proteins 
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(BMPs), vascular endothelial growth factor, Indian hedgehog, FGFs and Wnts 
(Mackie et al., 2011, Yang et al., 2012). In short, the process involves condensation of 
the mesenchymal cells and their  differentiation to chondrocytes under the influence 
of Sox 5,6 & 9 to form the cartilage anlagen (Bi et al., 1999). This is quickly followed 
by hypertrophy of the chondrocytes and their subsequent vascular invasion and 
matrix mineralisation leading to the establishment of primary centres of ossification. 
The establishment of the secondary ossification centre within the epiphyses results in 
the formation of the epiphyseal growth plates at the proximal and distal ends of the 
newly formed bone (Fig. 1.2) (Kanczler and Oreffo, 2008, Mackie et al., 2011). The 
growth plate regulates the pace on bone growth until it closes in humans at puberty. 
1.2.3 Bone mineralisation 
The hardness of bone can be attributed to the product of HA crystal deposition on 
collagen fibrils.  The mineralisation process which is initiated by the precipitation of 
calcium ions (Ca2+), and inorganic phosphate (Pi),  at discrete sites of the skeleton is 
regulated by several factors which include NCPs, sibling proteins,  nucleotide 
pyrophosphate phosphodiesterase 1, ankylossis protein and phosphatases such as 
PHOSPHO1 and alkaline phosphatase (ALP) (Anderson, 2003, Yadav et al., 2011). 
The mineralisation of the ECM is initiated with membrane limited bound matrix 
vesicles (MV), formed by hypertrophic chondrocytes and osteoblasts. The MV 
provide a protected microenvironment for the concentration of Ca2+  and  Pi 
(Anderson, 2003). On reaching appropriate concentrations within MV, the two 
minerals precipitate HA crystals. These HA crystals increase in size, and perforate the 
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MV membrane when they are subsequently deposited onto the collagen fibrils of the 
ECM. Matrix mineralisation is a key step during osteoblast differentiation into 
osteocyte (Clarke, 2008, Staines et al., 2012, Prideaux et al., 2012).  
1.3 Bone modelling and remodelling 
Bone modelling results in changes to the shape and size of bone due to uncoupled 
bone formation and resorption.  This is required for bone to adapt to changes in the 
mechanical load it senses i.e. the tennis players serving arm.  In contrast, bone 
remodelling involves coupled bone formation, resorption, and no change in bone 
mass i.e. the same amount of bone removed is replaced by new bone (Seeman, 2009). 
Bone turnover is an active remodelling process spanning the entire life of mammals 
where the human adult skeleton is replaced every 10 years (Palumbo et al., 2003). The 
process is precisely regulated by autocrine, paracrine and endocrine factors to 
prevent osteoporosis and osteopetrosis (Manolagas, 2000). While bone formation is 
principally a function of the osteoblast, osteoclasts mediate bone resorption. Bone 
remodelling is also under active regulation by osteocyte synthesised proteins such as 
sclerostin, secreted frizzled-related protein 1 (sFRP1); and the Dickkopf-related 
protein 1 (DKK1) which negatively regulate the differentiation of osteoblasts from 
osteoprogenitor cells (Fig. 1.3).  In contrast, prostaglandin E2 (PGE2), nitric oxide (NO) 
and adenosine triphosphate (ATP) promote osteoblast differentiation (Bakker et al., 
2001, Watanuki et al., 2002, Li et al., 2005a, Wang et al., 2013). Osteocyte derived 
factors also regulate osteoclast formation.  Examples of this are receptor activator of 
nuclear factor kappa-B ligand (RANKL) and macrophage colony stimulating factor 
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(M-CSF) which both activate osteoclast differentiation (Fig. 1.3). Other factors such as 
osteoprotegerin (OPG), a RANKL decoy receptor and NO inhibit osteoclast formation 
(Nakashima et al., 2011a, Xiong et al., 2011, Dallas et al., 2013).  
1.3.1 Osteoclasts 
Osteoclasts are multinucleated cells that poses the capacity for bone resorption 
(Hotokezaka et al., 2002). Bone resorption, as stated earlier, is an integral part of bone 
modelling and remodelling, that is closely regulated to prevent bone disorders like 
periodontal diseases, osteoporosis and osteopetrosis (Hotokezaka et al., 2002). 
Osteoclasts differentiate from the monocyte/macrophage cell lineage within the bone 
marrow under the influence of MCSF and RANKL (Nakagawa et al., 1998, Kong et 
al., 1999). RANKL is expressed mostly by osteocytes and to leser degree by osteoblasts 
(Nakashima et al., 2011b, Xiong et al., 2011). The receptor activator of nuclear factor 
kappa-B (RANK) is expressed on osteoclast precursor cell surfaces and has an 
intracellular domain called tumour necrosis factor (TNF) receptor-associated factor 
(TRAF). RANK, when phosphorylated by the attachment of RANKL, mediates the 
activation of downstream molecules via TRAF to initiate the osteoclast differentiation 
program. This cascade of events involves nuclear factor kappa B (NF-kB), mitogen 
activated protein kinases (MAPKs), and phosphatidylinositol 3-kinase/ protein kinase 
B (PI3K/Akt) (Wong et al., 1998, Lee et al., 2002). These downstream signals are 
involved in activating the expression  of tartrate-resistant acid phosphatase (TRAP) - 
which is a hallmark marker of osteoclast differentiation (Ishida et al., 2009).  
 





















Figure 1.2.  The process of endochondral ossification.  
(A) Mesenchymal condensation to form the hyaline cartilage model or anlagen (B). 
(C) Chondroprogenitor cells differentiate into chondrocytes that proliferate and 
secret extracellular matrix (ECM). (D) Stage of chondrocyte enlargement, vascular 
invasion, and matrix mineralisation. (E) Primary ossification centre formation. (F) 
Elongation of diaphysis and bone marrow. (G) Establishment of epiphyseal plate 
and, (H) secondary centre of ossification in the epiphysis (Gilbert, 2006).  





















Figure 1.3. Diagrammatic model of osteocyte regulation of bone remodelling. 
Note the central role of signalling molecules expressed by osteocytes to promote or 
inhibit differentiation of osteoblast and osteoclasts from their respective precursor cells 
(Dallas et al., 2013). While PGE2, NO, and ATP activate osteoblast differentiation and 
bone formation, expression of sclerostin, DKK1 and SFRP1 inhibit this process and less 
bone is formed. Osteocyte factors like RANKL, M-CSF activate osteoclast formation, 
subsequently increasing bone resorption. However, OPG and NO antagonise this 
pathway leading to less bone loss. These factors have established the osteocyte as the 
master regulator of bone remodelling.    
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Osteoclasts have a specialised plasma membrane modified to increase its surface area 
to aid the breakdown of both organic and inorganic material.  To do this, its 
membrane assembles into folds and invaginations at the bone interface and this is 
known as the osteoclast-ruffled border. During bone resorption upon activation by 
RANKL, osteoclastic proteolytic enzymes such as TRAP and cathepsin K are released 
at the ruffled border where they degrade collagen and other bone matrix proteins; a 
process that is favoured by an acidic micro resorption environment (de Vernejoul, 
1998). This acidic micro-compartment is made possible by the release of protons by 
carbonic anhydrase-II at the ruffled border (Schlesinger et al., 1997). The large acid 
production by osteoclasts dissolves bone mineral in the Howship lacunae (Vaananen 
et al., 2000). 
1.3.2 Osteoblasts 
Osteoblasts are differentiated from multipotent mesenchymal bone marrow stromal 
cells, which are also the progenitors for chondrocytes and adipocytes (Manolagas, 
2000, Xiao et al., 2010b). Osteoblasts secrete osteoid - the bone matrix - which when 
mineralised offers rigidity and strength to the skeleton. At the cellular level, the 
osteoblast is characterised by well-developed and abundant mitochondria, Golgi 
body, ribosomes and smooth endoplasmic reticulum, reflecting the high need for 
bone matrix synthesis (Dudley and Spiro, 1961). 
Mesenchymal cell differentiation into the osteoblast is a complex process and is 
tightly regulated. Osteoblast differentiation requires the actions of  the transcription 
factors Runx2, Osterix and Twist-1 and -2 and also other growth factors and signalling 
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molecules such as transforming growth factor beta (TGFβ), Sonic hedgehog, Indian 
hedgehog, Bone morphogenic proteins (BMPs) and FGF-2 (Yamaguchi et al., 2000, 
Ducy, 2000, Behr et al., 2010, Marie, 2012). The two major Wnt signalling pathways 
are also recognised to be critical role for osteoblast form and function. The Wnt –β-
catenin pathway also called the canonical Wnt signalling pathway, whilst the non-
canonical pathway involves Wnt–planar cell polarity and the Wnt-calcium pathways 
(MacDonald et al., 2009, Baron and Kneissel, 2013). The canonical Wnt signalling 
pathway is critical for osteoblastogenesis and bone mass; and is regulated by FGF-2 
(Xiao et al., 2009). This pathway is activated by the Wnt ligand binding to the Frizzled 
receptor (Frz), in the presence of a co-receptor; low-density lipoprotein related 
protein (LRP) 5/6 complex. This prevents the axin-complex induced ubiquitination of 
β-catenin and the avoidance of proteasomal degradation (MacDonald et al., 2009). 
The stabilised β-catenin then relocates to the nucleus, and activates T-cell 
factor/lymphoid enhancer factor (TCF/LEF) transcription factor for upregulation of 
Wnt target genes, which drives recruitment of osteoblasts for bone formation 
(MacDonald et al., 2009, Baron and Kneissel, 2013). This canonical Wnt pathway can 
be inhibited by secreted frizzled-related protein 1 (sFRP1); the dickkopf (DKK1) 
proteins; and the master negative regulator of bone formation – sclerostin (Kawano 
and Kypta, 2003, Bodine et al., 2004, Semenov et al., 2005). The marker genes of the 
osteoblast phenotype include the Col1a1, Bglap, Alpl, and Postn (Fakhry et al., 2005).   
After deposition of bone matrix by mature osteoblast and its subsequent 
mineralisation, the  fate of the osteoblast includes cell death (apoptosis), reversion to 
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surface lining cells or terminal differentiation into osteocyte by a process known as 
osteocytogenesis (Dallas and Bonewald, 2010).  
1.3.2.1 Alkaline phosphatase  
ALP is the family name for a group of enzymes found in various tissues.  Each have 
different properties and functions and the ALP expressed in bone is also expressed in 
liver and kidney.  Traditionally this ALP isoform was called bone/liver/kidney ALP 
but today it is more commonly referred to as Tissue non-specific ALP (TNAP) and in 
mice is encoded by the Alpl gene.  TNAP is a prominent osteoblast marker that is 
critical for matrix mineralisation as it degrades extracellular inorganic pyrophosphate 
(PPi), an effective inhibitor of mineralisation. TNAP hydrolyses PPi to generate 
optimum Pi/PPi ratio that enhances HA formation (Meyer, 1984, Anderson, 2003). 
The loss of the Alpl gene in experimental KO mice or with humans with 
hypophoshatasia showed decreased ECM mineralisation which was not unexpected 
but surprisingly mineral was still found within the MVs of long bones (Anderson et 
al., 1997, Anderson et al., 2004).  This implied that another phosphatase was present 
to provide Pi for the initiation of mineralisation within the MVs.  One such enzyme is 
PHOSPHO1, a bone specific phosphatase essential for the initiation of matrix 
mineralisation (Houston et al., 2002) The double knockout of both Alpl and Phospho1 
genes led to complete absence of bone mineralisation in embryonic mice  (Houston et 
al., 2002, Yadav et al., 2011).    
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1.3.2.2 Osteocalcin  
Osteocalcin, encoded by the gene Bglap in mice is an abundant osteoblast protein 
expressed later on in the differentiation process.  It downregulates bone formation, 
and it is now regarded as having an endocrine function where it has been shown to 
regulate energy metabolism (Zanatta et al., 2014). Erroneously thought to be involved 
in bone mineralisation, as osteocalcin null mice phenotype presented increased bone 
mass with adequate mineralisation, and excessive visceral adipose tissue deposition 
(Ducy et al., 1996, Wei and Karsenty, 2015).  
1.3.2.3 Collagen type 1 alpha 1  
Collagen type 1 protein (encoded by Col1a1 in mice), secreted by mature osteoblasts, 
is the principal organic component of the bone ECM (Mizuno et al., 2000, Uchihashi 
et al., 2013, Florencio-Silva et al., 2015). It provides the scaffold for the deposition of 
HA crystals during bone mineralisation and also regulates this process (Nudelman et 
al., 2010). Its sub chains Col1a1 and Col1a2 are expressed in the ratio 2:1. The Col1a1 
mutation phenotype has been extensively studied in the brittle-bone disorder 
osteogenesis impecta (Eimar et al., 2016). This mutation is characterised by reduced 
collagen type 1 synthesis, high bone turnover, increased bone material density, poor 
mineralisation and a high incidence of fractures (Willing et al., 1994, Chen et al., 2014, 
Roschger et al., 2014). 
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1.3.2.4 Periostin  
The Postn gene is expressed in osteoblasts and in foetal periosteum, cardiac valves, 
and periodontal ligament of the mouse.  Its loss of function mutation results in les 
than 20% peri-natal mortality, but in adult life, mice show reduced growth with scant 
trabecular bone and periodontal disorders (Rios et al., 2005).  
1.3.3 Osteocytes 
Osteocytes are long-lived (>25 years) bone cells and constitute about 90-95% of all 
bone cells (Franz-Odendaal et al., 2006). Osteocytes are flat cells with dendritic 
cellular processes located deep in the lacunae/canaliculi of the mineralised bone ECM 
(Holmbeck et al., 2005). These dendrites enable the osteocyte to communicate with 
other osteocytes, osteoblasts, osteoclasts and the vasculature by means of their 
interconnecting dendritic gap junctions of the lacunae/canaliculi system (Fig. 1.4). 
Osteocytes are characterised by a reduction in biosynthesis of osteoblast marker 
proteins such as Col1a1, Alpl, Bglap (Sasano et al., 2000, Knothe Tate et al., 2004); but 
upregulation of osteocyte gene markers such as E11, Dmp1, Phex and Sost (Fig. 1.5). 
Osteocytes are involved in mechano-reception and transduction, calcium 
homeostasis, osteoid development and calcification and bone remodelling regulation 
(Zhang et al., 2011, Dallas et al., 2013). The mechano-reception and transduction role 
of osteocytes is a response to form more bone during skeletal loading (walking, 
running) or stimulate bone loss when the body is immobilized for an extended period 
(Bonewald and Johnson, 2008). This function has been validated by dendrite and gap 
junction hemichannels’ response to fluid flow shear stress loading models using 
Chapter 1: Introduction 
17 
 
MLO-A4 osteocyte-like cells (Burra et al., 2010). In addition, osteocyte deletion studies 
have  revealed reduced formation of bone, more bone resorption and lack of response 
to loading (Bonewald, 2006, Tatsumi et al., 2007).  While the precise mechanism for 
this function is still largely unknown, some authors believe the dendrites are the 
mechano-sensing structures of the osteocyte (Han et al., 2004, Adachi et al., 2009), 
whereas others propose that both dendrites and the cell body are required (Nicolella 
et al., 2008).  Furthermore, others have contended that the mechano-sensing role is 
the responsibility of the primary cilia (Xiao et al., 2006, Malone et al., 2007).  
Some authors have also concluded that osteocytes should be categorised as endocrine 
cells because of their production of factors such as FGF-23, RANKL, OPG and 
sclerostin into the vascular system (Quarles, 2008, Dallas et al., 2013, Florencio-Silva 
et al., 2015).  
1.3.3.1 Osteocytogenesis 
Osteocytogenesis, once regarded as a passive process of osteoblast differentiation, is 
now believed to be an active, well-regulated mechanism involving both osteoblast 
and osteocytes in its molecular regulation (Dallas et al., 2013).  As the osteoblast lays 
down osteoid, that is subsequently mineralised, it changes shape from cuboidal to the 
characteristic spindle shaped osteocyte with cytoplasmic processes (dendrites) 
containing fewer organelles and increased nucleus-to-cytoplasm ratio (Palumbo, 
1986). Recruitment of  new osteoblasts committed to this pathway has been reported 
to be influenced by osteocyte secreted molecules like PGE2, insulin growth factor 1 
(IGF-1), NO, and sclerostin which antagonises the pathway (Schaffler et al., 2014). 
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Also the products of the osteocyte genes such as Sost, Dmp1, and  Phex  have been 
reported to be actively involved in bone mineralisation (Fig. 1.5), phosphate 
homeostasis and cytoskeletal organisation (Guo et al., 2010, Dallas et al., 2013).  
1.3.3.2 Dentin matrix protein 1 (Dmp1) 
Dmp1 is a member of the small, integrin-binging ligand, N-linked glycoprotein 
(SIBLING), located in bones and dentin regulating matrix mineralisation amongst 
other functions (Staines et al., 2012). Dmp1 is expressed in embryonic chondroblasts 
and osteoblasts but limited in osteocytes during adult life (Toyosawa et al., 2001). It 
regulates phosphate homeostasis and bone mineralisation as disclosed in the study 
of Dmp1-null mice which have low blood phosphate levels and poor mineralisation 
(Feng et al., 2006).  Similarly in humans DMP1 loss of function mutation has been 
diagnosed in hypophosphatemia rickets (Feng et al., 2006). Dmp1 gain of function 
studies in mice have reported conflicting results; some studies have shown the 
absence of any effect on bone whereas others have reported elevated bone mineral 
density. The mechanism of Dmp1 regulation of bone mineralisation and osteocyte 
differentiation is sequel to its action in maintaining body phosphate homeostasis (Lu 
et al., 2011, Zhang et al., 2011, Bhatia et al., 2012).  
1.3.3.3 Phosphate-regulating gene with homologies to endopeptidases on the X 
chomosome (Phex).  
Phex is expressed by maturing osteocytes and is involved in bone matrix phosphate 
and mineralisation regulation in a similar manner to Dmp1 (Liu et al., 2007). Phex loss 
of function is seen in X-linked hypophosphatemic rickets, a disease characterised by 
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poor growth, deficient bone mineralisation, and hypophosphatemia caused by poor 
phosphate retention in the kidneys (Sabbagh et al., 2003). The effects of Phex on 
phosphate regulation is though moderation of FGF-23, another osteocyte signalling 
factor, that acts like an endocrine factor on the kidneys’ sodium/phosphate 
cotransporters that are crucial for renal phosphate uptake (Larsson et al., 2004, 
Gattineni et al., 2009). Hence, in Phex loss of function mutations, FGF-23 levels 
increase by an unclear mechanism leading to hypophosphatemia (Larsson et al., 
2004). 
1.3.3.4 Sclerostin 
The Sost gene that encodes the protein sclerostin was first identified as a mutation 
manifesting in Sclerostosis and Van Buchem diseases in humans, both of which are 
characterised by high bone mass (Bezooijen et al., 2005). The gene is expressed only 
in mature osteocytes (Brunkow et al., 2001, Winkler et al., 2003). Sclerostin is a 
negative regulator of bone formation and acts via the Wnt/β-catenin pathway (Li et 
al., 2005b). Sost loss of function mutations in mice are characterised by increased bone 
mass and strength, while reduced bone mass is seen in Sost gain of function mutations 
(Winkler et al., 2003, Li et al., 2008b). One function ascribed to osteocytes is their 
ability to regulate bone turnover in response to load bearing. This property is, 
mediated in part by sclerostin expression, which is consistent with the observation 
that loading down-regulates sclerostin expression and thereby promoting bone 
formation. Recently anti-sclerostin monoclonal antibodies (Romosozumab (AMG 
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785)) have undergone clinical trials for the management of bone disorders associated 
with low bone mass such as osteoporosis (Ominsky et al., 2011, Padhi et al., 2011).   
1.4 Podoplanin/E11 
The protein podoplanin/E11 is a mucin type transmembrane glycoprotein of about 
38-42 KDa , encoded by the Pdpn gene (Fig. 1.6; written in this thesis as ‘E11’).  The 
name E11 was first used to describe its expression  in rat osteocytes (Wetterwald et 
al., 1996). Moderately conserved homologues exists in other species which include 
humans, mice, rats, dogs and hamsters (Astarita et al., 2012).   It has several regulatory 
functions that include cell development and differentiation, epithelial-mesenchymal 
transition (EMT), oncogenesis and invasiveness (Thiery, 2002, Wicki and Christofori, 
2007, Martín-Villar et al., 2009, Astarita et al., 2012).  
1.4.1 The structure and expression of E11 
The protein E11 has an extracellular domain (EC), transmembrane Section (TM) and 
a cytoplasmic tail (CT) (Fig. 1.6). The CT has the fewest amino acids and is therefore 
short in relation to the other domains/Sections (Martin-Villar et al., 2005, Kaneko et 
al., 2006). While the EC domain is involved in stimulating platelet aggregation 
(Kaneko et al., 2006) the TM domain has been reported to be a key factor in initiating 
EMT (Fernández-Muñoz et al., 2011) whereas the CT is associated with intercellular 
adhesion stability and is a binding site for ezrin, radixin and moesin (ERM) proteins 
(Astarita et al., 2012). 
In platelets and immune cells, a C-type lectin-like receptor CLEC-2 has been 
described for E11 , where it facilitates platelet clumping on oncogenic cells despite the 
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absence of blood clotting factors (Sawa, 2010). This interaction of E11 with CLEC-2 is 
associated with lymphatic vessel integrity and invasive cancer regulation (Kato et al., 
2005, Bertozzi et al., 2010).  Owing to its expression in several body tissues (Fig. 1.7), 
E11 has several names, which include podoplanin in kidney podocytes; T1α in 
alveolar type 1 epithelial cells; and OTS-8 in osteoblasts following phobol ester 
treatment. It is also called PA2.26 in skin keratinocytes, gp38 in lymphoid organs and 
E11 in lymphatic endothelial cells and bone cells (Farr et al., 1992, Wetterwald et al., 
1996, Breiteneder-Geleff et al., 1997, Scholl et al., 1999, Ramirez et al., 2003). It is highly 
expressed by various cell types in many tissues and in bone; it is expressed highly by 
embedding osteocytes but not osteoblasts.  Specifically, it is highly expressed by the 
both the osteocyte body and its dendritic processes which connect neighbouring 
osteocytes but also surface osteoblasts (Fig. 1.6). The essential expression of E11 in 
lung cells and lymphatics results in E11 global KO mice are non-viable immediately 
after birth due to respiratory failure and generalised lymphoedema (Ramirez et al., 

































Figure 1.4. Graphic representation of an osteocyte embedded in mineralised matrix.  
 
Note the  extending dendrites connected to other osteocytes, osteoblasts and vasculature 
(Dallas et al., 2013). 

























 Phex, Dmp1 
E11 
Sost 
Figure 1.5 Gene markers expressed as osteocytogenesis progresses from 
osteoblast to mature osteocyte.  
 
E11 early osteocyte marker is expressed as dendrites form while sclerostin 
expression indicates attainment of mature osteocyte. Adapted from (Dallas 
and Bonewald, 2010) 
Alp, Col1a1, Bglap 
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1.4.2 The function of E11 in osteocytogenesis  
Plasma membrane shape, stability and re-organisation is the function of the cells 
cytoskeleton. The elements involved in this cytoskeletal/plasma membrane 
interaction include actin and keratin filaments, CD44, ERM proteins, small GTPase 
RhoA, and E11 (Fig. 1.6) (Hirao et al., 1996, Astarita et al., 2012). The ERM family of 
related proteins are associated with having a cross-linker function in their 
relationship with the plasma membrane protein CD44, forming the CD44/ERM 
complex that is enhanced by phosphatidylinositol 4,5-bisphosphate (Hirao et al., 
1996), and RhoA is believed to act as a molecular regulator of this complex (Hirao et 
al., 1996). E11 is a recognised early osteocyte marker associated with the acquisition 
of the dendritic morphology, as enhanced post translational stability of E11 through 
the prevention of its proteosomal degradation extended osteocyte dendrite length 
and promoted osteocytogenesis (Zhang et al., 2006, Gupta et al., 2010, Staines et al., 
2016).  This osteocyte dendritic phenotype which reflects a re-arranged actin 
cytoskeleton, can be linked to the ability of E11 to regulate RhoA as is the case during 
EMT (Sawa, 2010). E11 expression has been reported to be increased by mechanical 
loading and during differentiation and mineralisation of some osteoblast cell lines 






























Figure 1.6 Schematic representation of E11 (PDPN) showing interaction 
with other molecules especially as it regards cytoskeletal reorganisation.  
Note its receptor CLEC-2; relationship with cytoskeletal apparatus 
molecules like CD44, ERM and RhoA (Astarita et al., 2012). 
 

























Figure 1.7 Immunostaining of E11 in various body tissues 
Immunostaining for E11 in various tissues showed positive staining in 
trabecular bone osteocyte (A), cortical bone osteocytes (B), cortical bone 
osteocyte cell body and dendrites are positive, and not the surface 
osteoblasts (C), podocytes of the kidney glomeruli (D), lung type 1 
alveolar cells (E), and (F) the brain choroid plexus.  Insets show negative 
controls (Zhang et al., 2006). 
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1.5 Fibroblast growth factor (FGF) biology 
The FGF family of signalling molecules interact with receptors, co-receptors and 
mediating molecules to play critical roles in vertebrate growth, development, body 
homeostasis, and disease pathogenesis (Powers et al., 2000, Bottcher and Niehrs, 
2005). Members of the family include the ligands, which are the growth factors 
(FGFs); their transmembrane receptors called fibroblast growth factor receptors 
(FGFRs) that are cell surface receptor tyrosine kinases (RTKs). The FGFs are 
transcribed from 10 genes in zebrafish and 22 genes in mice and humans (Table 1.1) 
(Thisse and Thisse, 2005). FGF1-10, FGF16-18, FGF-20 and FGF-22 are secreted ligands 
with paracrine signalling properties and bind to FGFRs in close association with 
heparan sulphate proteoglycan (HSPG) co-factors. In contrast, FGF19, FGF-21 and 
FGF-23 are endocrine molecules that require Klotho proteins to activate FGFRs (Yang 
et al., 2015, Katoh, 2016, Sarabipour and Hristova, 2016) .   
1.5.1 Fibroblast growth factor receptors (FGFRs) 
Central to the activating property of the FGFs are the single-pas transmembrane 
proteins referred to as the FGFRs (Dailey et al., 2005, Sarabipour and Hristova, 2016). 
In mammals, FGFRs are encoded by four specific genes (Fgfr1-4), with 55-72% amino 
acid homology (Givol and Yayon, 1992, Powers et al., 2000, Bottcher and Niehrs, 
2005). Also documented are the generation though splicing of other isoforms like 
FGFR5/FGFRL1 (Rieckmann et al., 2008).  
The importance of FGFR activation or downregulation is not limited to physiological 
growth and development, FGFR mutations and over-expression have been 
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demonstrated in several developmental and post-natal disorders including Crouzon, 
Apert, and Pfeiffer syndromes (Burke et al., 1998, Sarabipour and Hristova, 2016). 
Also these FGFR have been implicated in cancer aetiology e.g. 1) FGFR4 expression  
is increased in terminal stages of mouse pancreatic β-cells cancer but not in the early 
stages of the disease (Olson et al., 1998), 2) FGFR3 is detected in human multiple 
myeloma (Richelda et al., 1997), 3) FGFR2 has been implicated in T-lymphocyte 
metastasis (Hattori et al., 1992) 4) FGFR1 has been reported in human breast cancer 
(Yoshimura et al., 1998), and 5) some myeloproliferative diseases (Popovici et al., 
1998, Reiter et al., 1998).  
Structural analysis of the FGFRs reveals an extracellular (EC) ligand binding 
immunoglobulin-like domain (IgD), a short transmembrane (TM) connecting 
domain, and two intracellular tyrosine kinase (TK) domains.  The latter contains a 
juxtamembrane domain and a kinase domain containing an ATP-binding site and a 
cytoplasmic tail (CT) (Thisse and Thisse, 2005, Gotink and Verheul, 2010). 
FGFR5/FGFRL1 unlike other FGFRs lacks a TK (Ornitz and Itoh, 2015).  The FGFR 
extracellular domain has several IgDs but IgD1, -2, and -3 have been most widely 
studied. While IgD1 is not associated with any specific function, IgD2 has a heparin 
binding site, and the region between IgD2 and IgD3 is the active FGF binding site 
(Thisse and Thisse, 2005). The IgD3 of FGFR1-3 has two main splice variants IgD3b 
and IgD3c.  
Receptor dimerisation occurs with FGF binding and this initiates the cascade of 
events that accumulates in FGFR phosphorylation at its CT. This activates 
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downstream signalling pathway including MAPKs, PI3K/Akt, protein kinase C 
(PKC) and signal transducer and activator of transcription (STAT) (Turner and Grose, 
2010, Su et al., 2014).  
There is evidence that while the biological effects of FGFs can be dose-dependent, 
they can also be stage-dependent following activation of a specific receptor, even 
though redundancy has been reported amongst the FGFRs in the mature skeleton 
(Jackson et al., 2006, Soltanoff et al., 2009). In cartilage, FGFR1 is mostly upregulated 
by mitogens, whereas FGFR3 is upregulated during differentiation and morphogenic 
response (Weksler et al., 1999, Wang et al., 2001, Li et al., 2008a).  In osteoblasts, FGFR1 
is expressed principally during differentiation whereas FGFR2 expression is 
predominantly observed during osteoblast proliferation. Interestingly FGFR3 
expression is observed in during both differentiation and proliferation (Marie, 2003, 
Fakhry et al., 2005, Jackson et al., 2006, Marie, 2012).  
1.5.2  FGF-2 and its downstream signalling molecules 
FGF-2 initially was characterised as a 15kDa  molecule isolated from bovine pituitary 
and brain, with mitogenic capacity on mouse 3T3 fibroblasts (Armelin, 1973, 
Gospodarowicz et al., 1974). It was then named basic FGF (bFGF) to buttres its high 
isoelectric point (Gospodarowicz, 1975, Gospodarowicz et al., 1978). FGF-2 is 
described as the most studied member of the FGFs family (Mundhenke et al., 2002, 
Behr et al., 2010). This almost ubiquitously expressed FGF-2 (Dailey et al., 2005), has 
three isoforms: one low molecular weight isoform of 18kDa that is cytoplasmic 
located. Its secretion is associated with typical FGF-2 effects on bone formation. The 
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other isoforms are two high molecular weight isoforms of 21 and 22kDa  located in 
the nucleus and mostly related to phosphate homeostasis (Xiao et al., 2010a, Su et al., 
2014).  
Basic fibroblast growth factor or FGF-2 is expressed by osteoblasts and stored in the 
ECM (Hurley et al., 2002, Fei et al., 2011). It is a member of the FGF large family of 
polypeptide growth factors involved in several developmental mechanisms 
including skeletal development in several multicellular organisms (Itoh and Ornitz, 
2004, Thisse and Thisse, 2005).  At optimal expression, it is involved in normal bone 
formation, where as its absence in genetically altered knockout mice is associated 
with poor bone formation and mass (Coffin et al., 1995, Montero et al., 2000). In vitro, 
FGF-2 down regulates osteoblast markers such as collagen type 1 and regulates genes 
controlling mineralisation during osteoblast differentiation (Fang et al., 2001, Kyono 
et al., 2012). FGF-2 is also involved in the regulation of bone matrix protection by 
inducing the expression  of tissue inhibitors of metalloproteinases – TIMPs (Varghese 
et al., 1995). It is involved in the catabolic pathways of the bovine intervertebral disc 
(Li et al., 2008a). While redundancy amongst the FGFs is known, the attachment of 
HSPG to the EC domain of the FGFR confers some specificity to the FGF ligand 
including FGF-2 (Ornitz and Marie, 2002, Mundhenke et al., 2002, Debiais et al., 2004). 
The regulatory effects of FGF-2 ligand after attachment to FGFR1-4 is mediated 
though cell signalling pathways such as MAPKs, PI3K/Akt and phospholipase C 
(PLC) ɣ pathways. The MAPKs family (Fig 1.8) include the extracellular signal-related 
kinases (ERK1/2), stress-activated protein kinase/c-Jun N-terminal kinase 
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(SAPK/JKN) and p38 MAPK pathways (Kim et al., 2003, Jackson et al., 2006, Li et al., 
2008a, Eda et al., 2008, Kyono et al., 2012, Fei and Hurley, 2012). MAPK signalling is 
controlled by three-level kinase cascades consisting of MAPK, MAPK kinase (MEK, 
MKK, and MAPKK), and MAPKK kinase or MEK kinase (MAPKKK or MEKK) 
(English et al., 1999, Chang and Karin, 2001, Chaudhary and Hruska, 2001). 
1.5.2.1 Extracellular signal-related kinases (ERK1/2) 
ERK1/2 has been described as the major pathway mediating FGF effects in skeletal 
cells (Murakami et al., 2004, Matsushita et al., 2009b), especially osteoblast and 
chondroblast differentiation (Matsushita et al., 2009a). Studies using the MEK 
(upstream to ERK1/2 in the Ras-MAPK pathway) inhibitor U0126, revealed the 
downregulation of the skeletal cell mineralisation gene Dmp1, and lack of the 
osteocyte dendritic phenotype in MLO-Y4 cells (Kyono et al., 2012). This report 
supports the increasing data on the central role of ERK1/2 molecules in FGF signalling 
during osteocyte differentiation (Murakami et al., 2004). ERK1/2 activation is 
associated with cell proliferation, differentiation, survival, and protection against 




















FGF2–4, 6, 8, 10, 17a, 
17b, 18, 24 FGFR HSPG paracrine 
Xenopus  6 FGF2–4, 8–10  FGFR HSPG paracrine 
Chickens  13 
FGF1–4, 8–10, 12, 13, 
16, 18,20 FGFR HSPG paracrine 
    FGF19 FGFR Klotho endocrine 
Mice 22 FGF1–18,20  FGFR HSPG paracrine 
    21, 23  FGFR Klotho endocrine 
Human 22 FGF1–14, 16–18, 20, 22  FGFR HSPG paracrine 
    FGF19, 21, 23 FGFR Klotho endocrine 
 
Table 1.1 Summary of FGFs biology  
Note the ligand number per species, specific co-receptors and the different signalling 


















Figure 1.8 Schematic of FGF signalling. 
Binding of the FGF to its receptor (FGFR) activates downstream signalling pathways 
including MAPK-mediated pathways. The inhibitors to these pathways are 
highlighted in green oval shapes (MEK inhibitors, PD98059 and U0126; PI3K 
inhibitor, LY294002; p38 MAPK inhibitor, SB203580; and FGFR1/2/3 inhibitor, 
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1.5.2.2. Phosphatidylinositol 3 kinase/Akt (PI3K/Akt) 
Protein kinase B (PKB), also known as Akt, in mammals.  It has three isoforms  
expressed by three genes namely: PKBα/Akt1, PKBβ/Akt2, and PKBɣ/Akt3 (Song et al., 
2005). Generally, Akt phosphorylation is involved in the regulation of tissue size, 
metabolite homeostasis like glucose, new blood vessel formation, cell cycle 
progression, apoptosis, and cell survival (Chaudhary and Hruska, 2001, Suhara et al., 
2002).  In osteoblasts, the activation of the PI3K/Akt pathway after FGF-2 stimulation, 
mediates cell survival including protection from apoptosis signalling (Debiais et al., 
2004). This role of phosphorylated Akt in the inhibition of apoptosis signalling 
involves caspase-3 cleavage, activation of B-cell lymphoma 2 (Bcl-2), Bcl-2 associated 
death promoter (Bad) and blocking of mitochondrial cytochrome C release (Suhara et 
al., 2002, Song et al., 2005). During neuronal differentiation of pheochomocytoma cell 
line (PC12) under the stimulation of nerve growth factor (NGF), Akt is involved in  
cytoskeletal re-organisation leading to neurite formation (Jeon et al., 2010).  
1.5.2.3 p38 MAPK 
This p38 MAPK molecule has four isoforms including  p38α, p38β, p38ɣ, and p38δ 
MAPKs, which are all activated by MEK3/6 of the MAPK pathway (Chang and Karin, 
2001). The isoforms p38α and p38β MAPKs are expressed universally in most tissues; 
p38ɣ MAPK has been localised in the muscle; while p38δ MAPK is limited to kidney 
and lungs (Hu et al., 2003, Cuenda and Rousseau, 2007). Even though p38 MAPK is 
associated with apoptosis, there is a growing body of evidence that it has a critical 
role in embryogenesis, as deletion of one of its isoforms p38α, leads to embryonic  
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death due to inadequate synthesis of erythopoietin (Chang and Karin, 2001). 
Functionally in a number of cells including the osteoblast, it regulates cell growth and 
differentiation, stress and inflammatory response that enhances cell survival (Hu et 
al., 2003, Hong et al., 2015). 
1.5.2.4 Stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK)  
JNK consists of 3 isoforms and was originally characterised by its specific capacity to 
phosphorylate the transcription factor c-Jun at its N-terminal transactivation domain 
(Hibi et al., 1993). These isoforms are JNK1, 2 and 3, which are expressed by 
individual genes, have been localised in most body tissues, with the exception of 
JNK3 that is principally isolated to the brain, testis and heart (Kyriakis and Avruch, 
2001). The molecular weight of these isoforms varies, as JNK1 is 46kDa, whereas JNK2 
and JNK3 are predominantly 56kDa (Matsuguchi et al., 2009). Functional and 
structural similarities, as well as specific differences exist amongst these isoforms. 
JNK1 up-regulates c-Jun-dependent fibroblast proliferation (Sabapathy et al., 2004), 
and TNF-α stimulated apoptosis (Liu et al., 2004).  There is a report of JNK signalling 
being involved in apoptosis regulation in vascular smooth muscle cells (Villunger et 
al., 2000). These isoforms are activated by MEK4/7 in the MAPK cascade signalling 
(Chang and Karin, 2001).  
1.5.2.5 Cell signalling and the use of inhibitors 
Signalling pathways are integrated protein to protein interactions mediating cell 
activities and relationships with other cells (Martin, 2003). Even though they are 
complex networks, they are strictly conserved, with some reports of redundancy 
(McCormick, 2000). Various models have been utilised in exploring the nature and 
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mechanism of action of these signalling pathways. These include the use of 
monoclonal antibodies, siRNA gene silencing, dominant negative mutants and 
chemical inhibitors (Alessi et al., 1995, McCormick, 2000, Gotink and Verheul, 2010). 
Chemical inhibitors are small sized hydrophobic molecules with the ability to pas 
though the cell membrane. This property readily distinguishes them from 
monoclonal antibodies (Imai and Takaoka, 2006). Inside the cell, some of these 
hydrophobic molecules quickly associate with cytoplasmic domain of receptors and 
their downstream signalling molecules especially at their Adenosine Tri-Phosphate 
(ATP) binding site. This association is marked by their competition with ATP, 
denying the receptors or downstream molecules the critical ability to be 
phosphorylated (Fig. 1.9).  This prevents the cascade of such signalling pathways 
(Gotink and Verheul, 2010). This mechanism is observed with type I inhibitors such 
as epidermal growth factor receptor (EGFR) inhibitors PD15870 and ZD1839, FGFR 
inhibitors BGJ398 and AZD4547, PI3K/Akt inhibitor LY294002, and p38 MAPK 
inhibitor SB203580 (Rewcastle et al., 1996, Wakeling et al., 1996, McCormick, 2000, 
Tan et al., 2014, Fisk et al., 2014).  
Another mechanism of action of some kinase inhibitors, which are not direct ATP-
competition dependent, involves the binding to the hydrophobic pocket situated 
adjacent to the ATP-binding site (Fig. 1.9). This induces a conformational change in 
the kinase.  This indirectly prevents kinase activity as the allosteric change stops ATP 
binding. Examples of these are type II inhibitors such as MEK inhibitors PD98059 and 
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U0126 and the VEGFR inhibitor, sorafenib (Alessi et al., 1995, Favata et al., 1998, Wan 
et al., 2004, Fisk et al., 2014). 
Some kinase inhibitors have been classified into type III inhibitors based on their 
ability to form covalent bonds with cysteines at designated locations of the kinase 
(Gotink and Verheul, 2010). They are thus referred to as covalent inhibitors and most 
of their effects are irreversible like the FGFR inhibitors FIIN-2 and FIIN-3 (Tan et al., 
2014).  
On a general note, the ability of these three classes of kinase inhibitors described 
above to prevent the specific action of any target pathway without hindering the 
activation of other pathways in cells have been exploited in their deployment as 
therapeutic agents in some diseases such as cancer (McCormick, 2000, Gotink and 
Verheul, 2010).  
1.6. Osteoarthritis (OA) 
OA is a painful joint disorder and a major world-wide health concern. It has 
significant implications for health budgets and is associated with the loss of 
productive working hours due to attendant morbidity (Funck-Brentano and Cohen-
Solal, 2011, Bouaziz et al., 2015). OA is characterised by articular cartilage (AC) loss, 
subchondral bone (SCB) sclerosis, joint space narrowing, synovitis, thickened fibrous 
capsule, osteophyte formation, cysts and loss of joint function (Funck-Brentano and 
Cohen-Solal, 2011, Blom et al., 2009, Quasnichka et al., 2006). 
 









Figure 1.9 Structure of receptor tyrosine kinase. 
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While OA can develop in any synovial joint, knee, hip, hands and vertebrae remain 
the most prevalent predilection sites. 
OA affects mostly middle aged and older people with older women affected more 
severely due to reduced oestrogen levels in post-menopausal life (Buckwalter and 
Martin, 2006, Roman-Blas et al., 2009). Oestrogen, as a sex steroid, is generally 
protective to both bone and cartilage via activation of an anti-apoptotic pathways in 
osteocytes and upregulates chondrocyte glycosaminoglycan’s expression (Chen et al., 
2005, Maneix et al., 2008).  Although the fundamental cause(s) of OA are unknown, it 
is recognised to be a multifactorial disorder (Lorenzo et al., 2004, Lajeunesse, 2002, 
Jaiprakash et al., 2012). OA has been broadly divided into primary and secondary 
types based on some predisposing factors such as ageing which is associated with 
primary OA, whereas secondary OA is correlated with sporting injury, joint 
malalignment, hereditary, sedentary life and obesity (Blom et al., 2009).  
The initiation and progression of OA remains an issue of controversy to both 
clinicians and researchers alike (Kawcak et al., 2001). Owing to the observable 
cartilage destruction and loss at late stages of OA, it has traditionally been designated 
an AC disorder (Quasnichka et al., 2006). However, changes in the SCB thickness is 
one of the earliest detectable radiographic signs in OA (Jaiprakash et al., 2012). This 
sclerosis physically negatively impacts on AC during repetitive loading or stress 
leading to AC damage, thereby suggesting that the SCB should be targeted to relieve 
the pathogenesis of OA (Radin and Rose, 1986, McIlwraith et al., 2010). Regardless, it 
is clear that OA is a disorder of the entire joint including the AC, SCB, synovium, 
Chapter 1: Introduction 
40 
 
capsular tissues, and ligaments (Kannus and Rvinen, 1989, Lajeunesse, 2002, 
Quasnichka et al., 2006, Goldring and Goldring, 2010, Li et al., 2013).  
1.6.1 Normal synovial joint: structure and function 
A joint simply described is where bones meet and articulate. Structurally, it is 
classified based on the binding tissue into fibrous, cartilaginous and synovial joints.  
Functionally, a joint can also be classified based on the type and gradation of 
movement allowable and in this classification we have synarthodial, amphiarthodial 
and diarthodial joints (van Weeren, 2016a). Of these types, the synovial joint is the 
most abundant in the mammalian body allowing the most movement, hence is also 
referred to as a diarthodial joint. 
Structurally, a typical synovial joint consist of a joint capsule which comprises of an 
outer fibrous membrane continuous with the articulating bone periosteum, and an 
inner synovial membrane secreting the synovial fluid (Pacifici et al., 2005). There is a 
smooth slippery articular cartilage of the hyaline type with no perichondrium (Lorenz 
and Richter, 2006). This AC covers the underlying SCB in articulating bones (Decker 
et al., 2014). The AC is separated into a superficial non-calcified cartilage and a deeper 
calcified cartilage (CC) by a non-fixed borderline referred to as tidemark that appears 
basophilic in routine light microscopy (Li et al., 2013). The CC component is in direct 
contact with the SCB at the osteochondral junction. The SCB consist of two anatomical 
components: the subchondral bone plate and the subchondral trabecular bone 
(Goldring and Goldring, 2010). Other synovial joint structures include articular discs 
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or menisci, articular fat pad, tendon, bursa, and accesory ligaments that maybe 
extracapsular-fibular collateral ligament or intracapsular-cruciate ligament (Pacifici 
et al., 2005). 
Functionally, the synovial joint allows movements such as abduction, adduction, 
extension, flexion and rotation. The joint components such as synovial fluid are 
involved in lubrication, shock absorption, nourishment and metabolic waste removal 
(Lorenz and Richter, 2006). The AC is associated with shock absorption and reduction 
in friction during movement (Kawcak et al., 2001) whereas the SCB is the major load 
absorber  across the joint and it maintains the joint space and nourishes the CC by 
diffusion though its vascular network (Milz and Putz, 1994, Li et al., 2013). The bursa 
develops to reduce mechanical friction between structures like bone and ligaments 
whereas the supportive role of ligaments help resist strains during movements 
dangerous to articulation. In general, the joint components are adapted for support, 
aiding ease of body movements in several directions (Kawcak, 2016). 
Deviations from the normal anatomy and physiology of the synovial joints results in 
painful joint disorders like dislocation, gout, arthritis and sprains. Arthritis is a large 
family of illnesses within the joint disorders, including OA, rheumatoid arthritis, 
septic arthritis, and Still's disease (Wright et al., 2014, Bouaziz et al., 2015, van Weeren, 
2016b). It may occur as a distinct condition, or appear secondary to other diseases.  
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1.6.2 Changes in AC in OA 
Articular cartilage homeostasis involves the maintenance of the components of the 
ECM in a dynamic equilibrium in relation to the chondrocytes. The components of 
the inter-territorial matrix of the ECM include a network of collagen fibres and 
proteoglycans where aggrecan predominates. The collagen fibres present are mostly 
type II, type XI and type IX whereas the pericellular matrix is reported to contain 
mostly type VI collagen fibres (Goldring and Goldring, 2010). 
The AC gradually losses colour, form and function during advancing OA. This 
phenotypic change is driven by increased levels of matrix degrading enzymes such 
as matrix metalloproteinases (MMPs), and aggrecanases (Lorenz and Richter, 2006); 
making the AC les viscoelastic, which are features associated with increased 
production of collagen type I and decreased production of type II collagen (Wenz et 
al., 2000, Lorenz and Richter, 2006). As OA progresses, the catabolic actions of these 
degrading enzymes is enhanced by the downregulation of their inhibitors by 
inflammatory cytokines such as Interleukins (IL) IL-1, IL-17, IL-18 and tumour 
necrosis factor alpha (TNF-α) (Martel-Pelletier, 1998). To compound this catabolic 
state, new cartilage ECM is not commensurately synthesised by the chondrocyte 
anabolic activities. The anabolic activities of healthy articular chondrocytes are 
induced by growth factors which include IGF-1, TGF-β, BMP, and FGFs (Fortier et al., 
2011). This somewhat negative balance in cartilage ECM turnover results in the 
clasical feature of cartilage degradation and loss observed in most late OA 
radiographs (Sharma et al., 2013). This cartilage loss makes for the direct contact 
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between two articulating bones or bones and intact AC aggravating the symptomatic 
excruciating pain associated with late OA.  
There are reports of increased vascularisation of the SCB (Fig. 1.10), which invades 
the CC during OA pathogenesis (Goldring, 2012, Jaiprakash et al., 2012). This vascular 
invasion of CC from SCB causes the establishment of new secondary centres of 
ossification in the CC leading to advancement and duplication of the tidemark 
towards the non-calcified cartilage, hence, thinning and the formation of microcracks 
in the AC and consequent loss due to shear stress (Radin et al., 1995, Goldring, 2012). 
This osteoarthritic CC expresses type X collagen, typical of hypertrophic cartilage in 
secondary centres of ossification providing supportive evidence for the reactivation 
of secondary centres of ossification (Hoyland et al., 1991). At this site of vascular 
invasion and newly established secondary ossification centre, nerve growth factor 
(NGF) and vascular endothelial growth factor (VEGF), are expressed by sensory 
nerve fibres and fibro-vascular tissue respectively (Walsh et al., 2007, Walsh et al., 
2010, Ashraf et al., 2011). 
1.6.3. Changes in the SCB in OA 
The SCB of healthy joints is continuously remodelled which results in changes to its 
shape, architecture, volume, and mechanical properties.  Alterations in  elasticity are 
due to changes in ECM mineralisation (Kawcak et al., 2001). This remodelling is 
suggested to be orchestrated by osteocytes (Section1.3), and it enables the skeleton to 
actively respond to bone injury repair, and adapt to changing mechanical loading in 
the body (Burr, 2004, Martin, 2007, Chan et al., 2011).  
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SCB sclerosis, one of the defining features of OA observed prior to joint space 
narrowing (Jaiprakash et al., 2012), has been described as a product of bone 
remodelling in response to microdamage in the CC and SCB (Sokoloff, 1993, Radin et 
al., 1995).  This sclerosis is characterised at the cellular level by dysregulated 
osteoblasts making more bone as there is a down regulation of sclerostin expression ; 
morphological and phenotypic changes in osteoclasts showing early increased 
resorption rate and later reduction; and decreased osteocyte dendrite number (Fig. 
1.10) (Logar et al., 2007, Sanchez et al., 2008, Jaiprakash et al., 2012). Structurally, it is 
associated with stiffness, poor mineralisation, and poor adaptation to loading (Pool 
and Meagher, 1990). Osteocytes, though their expression  of sclerostin, RANKL and 
OPG, are directly involved in bone remodelling and consequently SCB sclerosis (Li et 
al., 2005b, Nakashima et al., 2011b, Xiong et al., 2011). The down-regulation of 
sclerostin expression in OA may also aid AC degradation, as chondrocyte sclerostin 
expression has been demonstrated to be chondro-protective though its action on 
antagonising the cartilage catabolic protease, aggrecanase - a disintegrin and 
metalloproteinase with thombospondin motifs (ADAMSTS) 4/5  (Chan et al., 2011). 
Also MMP-1, -9, and ADAMTS4/5, which are well known mediators of matrix 










Figure 1.10 Architecture of dysregulated subchondral bone during OA. 
Scanning electron microscopy images of osteocytes in OA showing poor osteocyte 
phenotype, vascular invasion, and dysregulated dendrites are suggestive of active 
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1.6.4. Osteophyte formation 
The development of osteophytes which cause pain and loss of function has been 
described as one of the hallmarks of OA (van der Kraan and van den Berg, 2007). 
They are mostly seen near joint margins, arising in the periosteal covering at the 
osteochondral junction (Menkes and Lane, 2004). Endogenous growth factors such as 
TGF-β, BMP2, and FGF-2 have been associated with their development and growth 
(Blaney Davidson et al., 2007, Kwan Tat et al., 2010). Also altered biomechanical forces 
on the joint have been implicated as drivers of their formation as osteophytes may 
help in the maintenance of joint stability (Menkes and Lane, 2004, Lorenz and Richter, 
2006). This view is not universally accepted however as others have proposed that 
osteophytes may cause joint malalignment (Felson et al., 2005). 
1.6.5. Other features of the OA joint  
Bone marrow oedema or cyst formation is a frequent feature of the SCB in most OA 
patients. First described by Wilson et al., in 1988, it represents localised areas of bone 
marrow lesions of fat necrosis and fibrosis (Wilson et al., 1988, Taljanovic et al., 2008, 
Leydet-Quilici et al., 2010). Their formation are now considered part of the healing 
process for loading induced micro-fractures in SCB. Local ischaemia during SCB 
remodelling also contributes to cyst development (Bancroft et al., 2004, Carrino et al., 
2006, Findlay, 2007). Histological evidence from studies on the role of synovial 
inflammation in OA pathogenesis is very suggestive that lymphocytic infiltration, 
cellular hyperplasia and changes in mediators of inflammation like ILs and TNFα  are 
very common in OA (Benito et al., 2005, Wenham and Conaghan, 2010, Johnson et al., 
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2016), although they are inconsistent between different studies. In a recent scholarly 
review a strong argument was made for the huge impact of synovitis in driving OA 
pathology such as inducing cartilage damage and early SCB thinning (Hügle and 
Geurts, 2017). However,  some earlier reports have indicated absence of correlation 
between inflammation of the synovium and induced collagen destruction in the dog 
AC (Pelletier et al., 1985).   Nevertheless, synovitis is very common in OA and studies 
exploring therapies targeting its inflammatory molecules during OA 
pathophysiology illustrates the importance of synovial health for proper joint 
function (Wenham and Conaghan, 2010).  
1.7. FGF-2 signalling in OA 
The role of FGFR in OA development is still unfolding. What is known now from 
both ligand and receptor knockout/inhibition studies suggest some species and 
developmental stage variation, and to some degree, ligand specificity (Weng et al., 
2012). In human AC stimulated with FGF-2, the most expressed receptor is FGFR1, 
which has a catabolic effect by upregulating MMP-1 and MMP-13 and down-
regulating aggrecan expression  (Yan et al., 2012).  The catabolic effect of FGFR1 
signalling in human AC after FGF-2 stimulation has been corroborated in adult mice 
showing extensive AC degeneration (Weng et al., 2012). However, contrasting reports 
in murine OA cartilage shows that FGFR2 and 4 are the most commonly expressed 
receptors, in addition to the upregulation of FGFR3 may help explain the reported 
anabolic and chondro-protective effects of FGF-2 in this species (Chia et al., 2009, Li 
et al., 2012). However, while this possible explanation subsists, some researchers 
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insist that the specific roles of FGFR2 and 4 remain largely yet to be deciphered 
(Nummenmaa et al., 2015).    
Nevertheless, some researchers have documented evidence associating FGF-2 with 
chondroprotection and delayed onset of OA in surgically destabilised murine joints 
(Chia et al., 2009, Li et al., 2012, Chong et al., 2013). This species variation maybe 
related to the type of FGFR activated by FGF-2 (Li et al., 2012, Nummenmaa et al., 
2015).  
FGF-2 is known to be released from cartilage upon injury and is able to change 
chondrocyte gene expression in vitro. One gene known to be regulated by FGF-2 is 
E11 and this has been found in murine joints following surgical destabilisation (DMM 
model) and cartilage explant injury models. Specifically, E11 expression was found to 
be FGF-2 dependent following injury to cartilage in vitro and to joint tissues in vivo 
(Chong et al., 2013). The importance of FGF-2 in driving gene (and protein) changes 
in the aetiology of OA is further emphasised by the observations that FGF-2 promotes 
both E11 expression in osteoblasts and the osteocyte phenotype (Gupta et al., 2010). 
It is therefore conceivable that whilst the role of E11 in osteocyte differentiation 
remains unclear in OA aetiology, E11 expression and stability is controlled at various 
junctures and this may be key in terminal osteoblast differentiation and the 
acquisition of the osteocyte phenotype. 
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1.8 Aims and strategy  
Cognizant of FGF-2 stimulation of E11 expression in cartilage explants and osteoblast-
like cells, it is likely that FGF-2 will influence bone remodelling via increased 
osteoblast E11 expression and concomitant osteocyte dendrite formation. This in turn 
would therefore protect against the abnormal osteocyte morphology observed in SCB 
sclerosis in OA. Therefore, the aim of this project was to test the hypothesis that: 
FGF-2 regulates E11 mediated osteocytogenesis and that E11 expression in SCB 
osteocytes protects against OA pathophysiology. 
 
To undertake this investigation, the following aims were undertaken.  
1. Examine the potential regulation of E11 expression and osteocyte formation by      
FGF-2. 
The osteoblast-like cell line (MC3T3), and primary osteoblasts (murine) in Chapter 3 
were studied in culture and the relationship between FGF-2 stimulation and (i) E11 
expression  (gene and protein) (ii) the attainment of the osteocyte morphology and 
(iii) the expression  of osteocyte markers like Sost, Dmp1, and Phex, was examined. 
This aim elucidated that FGF-2 upregulates E11 and other osteocyte marker genes in 
both MC3T3 cells and primary osteoblasts; thus promoting osteocytogensis in these 
cells. 
2.  Investigate the signalling pathways and cytoskeletal changes involved in FGF-2 
regulation of E11 expression and dendrite formation in MC3T3 cells using chemical 
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inhibitors. The molecules under investigation were analysed using western blots, RT-
qPCR and GLISA cytoskeleton assay kit.  
The results of these in Chapter 4 indicated that the promotion of the osteocyte 
phenotype by FGF-2 is possibly via Fgfr1 activation and increased E11 expression. 
The signalling pathway(s) involved however, remains unclear but may involve 
phosphorylation of signalling molecules such as ERK1/2, Akt and p38 MAPK. 
3. Examination of E11 expression during OA pathology in Fgf-2 KO mice and canine 
tissues. 
The relative expression of E11 in AC and SCB in normal and OA tissues was 
specifically examine using immunohistochemistry technique (Chapter 5). In 
addition, sclerostin was also examined.  Optimisation of anti-mouse and anti-
human E11 antibodies using various antigen-demasking agents on the SCB 
samples from the ovine, canine, feline and equine tissues were used for 
comparative studies. The canine OA samples showed significant increase in 
E11 immunolabelled SCB osteocytes when compared with the control 
samples.  The SCB from mice and human OA samples showed no difference 
in osteocyte E11 and sclerostin immunolabeling. 
In conclusion, these studies have established that FGF-2 regulates E11 during 
osteocytogenesis (Fig. 1.11), a mechanism that can help in understanding the biology 
of osteocyte during OA pathology. 
 





















Fig. 1.11 Schematic of my project hypothesis. 
This thesis will examine the hypothesis that:  FGF-2 drives increased E11 
expression during osteocytogenesis in MC3T3 osteoblast-like cells and primary 
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2.1. Biochemicals and solutions 
Reagents for this work were obtained from Sigma-Aldrich (Dorset, U.K.) and 
cell/organ culture media and additives were sourced from Thermo Fisher Scientific 
(Paisley, U.K.) unless otherwise stated. 
2.2. Cell and organ culture protocols 
2.2.1. Thawing of cell lines 
Murine MC3T3 osteoblast-like cells (clone 14; American Type Culture Collection 
ATCC, USA) were utilised throughout this thesis. Frozen cryovials of cells were 
thawed quickly from -150°C storage by warming in a beaker of 37°C water (Rosser 
and Bonewald, 2012). Cells were slowly pipetted into a universal and 5ml of warm 
(37°C) culture medium (αMEM supplemented with 10% v/v foetal bovine serum 
(FBS), and 0.05 mg/ml gentamycin) was added drop-wise to prevent osmotic shock 
and rupture of the cells. Cells were centrifuged at 9300 g for 5 min (Eppendorf 
Centrifuge 5415R, Eppendorf UK Limited), and the supernatant discarded. Cells were 
resuspended in 2ml of culture medium, and seeded into a T175 flask containing 23 
ml (total volume) of culture medium in a humidified environment maintained at 37oC 
and 5.0% CO2 for approximately 3 days. When the cells were semi-confluent, the 
media was carefully removed from the flask and cells washed in phosphate buffered 
saline (PBS). Subsequently, 0.25% v/v trypsin-EDTA was added to detach the cells 
from the plastic surface. The detached cells were transferred to a universal, and 8ml 
of culture media was used to wash out the remaining cells in the flask and then 
transferred to the universal to deactivate the trypsin. The universal was centrifuged 
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at 1100g for 5 min. The supernatant was disposed of and the pellet dispersed with 
gentle pipetting in 1 ml of culture medium to enable resuspension of the cells. After 
thorough mixing, a haemocytometer was used to count the cells. The cells were 
subsequently plated down in 6-well plates at a seeding density of 1.0 x 104 cells/cm2.   
2.2.2. Calvarial osteoblast isolation 
Under sterile conditions, the calvaria of 3 days old mice (strain C57BL/6) were 
dissected out and osteoblasts were  isolated according to published literature  (Orriss 
et al., 2012). After a brief wash in a universal containing Hank’s balanced salt solution 
(HBS), they were digested with collagenase type II (1mg/ml) for 10 min at 370C in an 
automatic shaker. The supernatant was discarded. The collagenase digestion was 
repeated and the supernatant retained (fraction 1). The remaining calvaria were 
washed with PBS and the PBS was added to fraction 1. The calvaria were further 
incubated with 4 mM ethylenediaminetetraacetic acid (EDTA) for 10 min at 370C in 
an automatic shaker and the supernatant retained (fraction 2). The calvaria were 
washed with HBS and added to fraction 2. Fractions 1 and 2 were combined into one 
universal, centrifuged at 9300 g for 5 min. Subsequently, the cells were re-suspended 
in 3 ml of αMEM containing 10% v/v FBS and 0.05% v/v gentamycin before dividing 
equally into three T75 flasks containing 11 ml of culture media. Meanwhile, the 
calvaria were subjected to another 30 min collagenase digestion and the resultant 
supernatant was retained as fraction 3. Fraction 3 was centrifuged to pellet the cells 
before resuspending in 3 ml  of culture media and dividing equally (1 ml each) into 
each of the three T75 flasks containing combined fractions 1 and 2. After 3 h 
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incubation in a humidified environment (370C and 5.0% CO2), the media was changed 
and the cells were expanded by maintaining them in culture for 3 days. The cells were 
then washed in PBS, trypsinised, pelleted and seeded in three T175 flasks containing 
15 ml growth media and returned to a humidified incubator maintained at 370C and 
5.0% CO2 for approximately 3 days.  The cells were finally plated down in 6-well 
plates at a seeding density of 1.0 x104 cells/cm2. 
2.2.3. Whole calvarial organ culture  
Calvariae were dissected from 3 days old C57BL/6 wild-type (WT) mice under sterile 
conditions according to published literature (Mohammad et al., 2008, Orriss et al., 
2012). Calvaria were transferred to pre-warmed calvaria culture media (α-MEM 
containing 0.2% w/v bovine serum albumin (BSA) and 0.05 mg/ml gentamycin) in a 
12-well plate. Subsequently, the calvariae were cut mid-sagittal and the two hemi-
Sections were cultured in calvaria culture media for 24 hours prior to 
experimentation. Calvaria hemi-Sections were cultured in a humidified incubator 
maintained at 370C and 5.0% CO2 for up to 2 days. 
2.3. FGF-2 treatments 
 When MC3T3 and calvaria primary osteoblasts were 100% confluent (approx. 72 h) 
the culture media was removed from the wells and the cells washed in PBS.  In the 
initial experiments, media containing variable concentrations (0 – 50 ng/ml) of FGF-2 
(PeproTech -USA) in α-MEM supplemented with 1% v/v FBS and 0.05 mg/ml 
gentamycin was added to each well. The vehicle diluent for the FGF-2 (0.1% w/v BSA 
in PBS) was added to 1% v/v FBS containing media and served as the control culture. 
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After 4 and 24 h FGF-2 incubation, the media was removed and the cells washed with 
sterile ice-cold PBS to remove excess media. The cells were scraped and processed for 
RNA extraction and protein assay (see Sections 2.4.1 and 2.5.2, respectively). For all 
further experiments, FGF-2 was used at 10 ng/ml to treat cells over short and long 
time periods (see results for precise details) and 0.1% w/v BSA in 1% v/v FBS media 
served as the negative control. Each experimental condition was completed in 
triplicate.  For calvaria cultures, FGF-2 at 10 ng/ml concentration (0.1% w/v BSA as 
negative control) was added to appropriate wells.  
2.4. RNA methods 
2.4.1 Isolation of RNA from cells 
Cell monolayers were scraped with 1 ml ice-cold PBS, pelleted by centrifugation and 
stored at -800C freezer. The RNA was later extracted with Qiagen RNeasy Mini kit 
(Qiagen, Manchester, UK), following manufacturer’s instructions and as reported 
previously (Genetos et al., 2011). In summary, this involved homogenising the sample 
in lysing and denaturing buffer. Ethanol (70%) was added for the efficient binding of 
RNA precipitates to the silica-gel-based membrane. Contaminants were removed 
with washing buffers and centrifugation, while DNAse treatment was used to digest 
any DNA present. The RNA was subsequently eluted though the membrane with 
RNase free water. The quantity of RNA in ng/ul was measured with a NanoDrop 
spectrophotometer (ThermoScientific, Paisley, U.K.). The level of purity was 
evaluated by determining the ratio of absorbancies at 260/280 nm wavelengths, and 
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values ~2.0 was taken as optimal. The samples were diluted with RNase free water 
and stored at -800C for later analysis. 
 2.4.2 Isolation of RNA from tissues 
RNA was extracted using a RNeasy mini kit, following the manufacturer’s instruction 
(Qiagen) as previously published (Reno et al., 1997) . The bone and calvaria were 
homogenised in 1 ml Qiazol (Qiagen, Germany) for cell lysis, and left at room 
temperature for 5 min to promote disociation of nucleoprotein complexes. 
Chloroform (200 ul) was added and thoroughly mixed to enhance phase separation, 
which was then undertaken by centrifugation at 9300 g for 15 min at 40C. After 
centrifugation, 3 phases were visible: an upper colourless aqueous phase containing 
RNA; white interphase; and lower red phase containing organic matter. The upper 
colourless phase was carefully aspirated to avoid contamination with the other 
phases. Seventy percent ethanol (600 ul), was added for efficient binding of RNA 
precipitates to the silica-gel-based membrane. Contaminants were removed with 
washing buffers and centrifugation, while DNAse treatment was used to digest any 
DNA present. The RNA was assessed for quantity and purity by 
spectrophotmometry as described above (Section 2.4.1). The RNA was stored at -800C.     
2.4.3. Reverse transcription 
DNA polymerase enzyme - reverse transcriptase was used to convert the diluted 
RNA samples to complementary DNA (cDNA). The RNA was diluted to 5 ng/ul with 
nuclease free water (NFW) and the diluted RNA (10 ul) was incubated with 2 ul of 
random primers (0.05 ug/ul) and loaded onto the Dyad PCR Thermal Cycler (MJ 
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Research, Canada) and incubated at 700C for 10 min.  A master mix of 2 ul 10X PCR 
reaction buffer, 2 ul dithiotheitol (DTT) (0.1 M), 1 ul deoxyribonucleotide 
triphosphate (dNTP) mix (10mM) and 1 ul Superscript II RNase H enzyme was 
prepared and added to each sample. The samples were reverse transcribed to cDNA 
using the following thermal profile in the Dyad PCR thermal cycler: 250C for 10 min; 
420C for 50 min; 70°C for 15 min and held at 40C. The cDNA produced was stored at 
-200C. 
2.4.4. Optimisation of qPCR primers 
Primer efficiency was tested with serial dilutions of cDNA (known to express the gene 
of interest) and a standard line drawn. Primers were considered satisfactory if the 
amplification efficiency was within the range of 93-107%, with an R2 value between 
0.98 and 1.00 indicating a perfect linear correlation, and an amplification curve with 
sigmoid curves at regular intervals along the dilution series. Primer specificity was 
demonstrated by the formation of a single peak in the disociation curve. 
2.4.5. Quantitative polymerase chain reaction (qPCR) 
The cDNA samples were all diluted to 5 ng/ul with NFW. A master mix, consisting 
of 10 ul 2xqPCR master mix with SYBR green (PrimerDesign, UK), 1 ul primer mix 
(detailed in Appendix, Table 1), and NFW (4 ul) was made up. Primers were deigned 
to span an intron to avoid amplifying any contaminating genomic DNA. Fifteen 
microlitres of the master mix was added to 5 ul of diluted cDNA, and loaded into the 
MX3000p Stratagene qPCR machine (Agilent technologies, Santa Clara, USA).  
Amplification of the cDNA was as follows: 10 min at 950C, 45 cycles of 15 s at 950C 
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and 1 min at 60°C, and a final cycle of 1 min at 950C, 30 s at 600C, and 15 s at 950C  and 
30 s at 250C to provide dissociation curves. The cycle threshold (Ct) values for the 
samples were normalised to that of Atp5b in MC3T3 cell lines and  mice primary 
osteoblasts, or Gapdh in whole mice calvaria as previously reported (Kyono et al., 
2012, Huesa et al., 2015, Houston et al., 2016) , and the relative expression  of each 
gene was calculated using the 2ΔCt method (Livak and Schmittgen, 2001). NFW 
instead of cDNA was amplified as a negative control.   
2.5. Protein methods 
2.5.1. Protein isolation 
To enable fast efficient lysis of the cell and protein solubilisation, 100 ul  of 
Radioimmunoprecipitation assay (RIPA) buffer (ThermoScientific, UK) solution 
containing protease inhibitor cocktail (Roche, Germany) was added to the cell 
monolayers. The cells were scraped with a sterile filter tip and an additional 100 ul  of 
RIPA buffer was used to wash the well. Samples were vortexed and lysates in a total 
volume of 200 ul were stored at -200C.  
2.5.2. DC protein assay 
The protein concentration of each sample was determined using a detergent 
compatible (DC) protein assay (Bio-Rad, Watford, UK) based on the Lowry assay 
(Lowry et al., 1951). Protein samples were thawed, vortexed and centrifuged at 9300 
g for 5 min and 5 ul of sample was pipetted in duplicate into a 96-well micro titre 
plate alongside standard dilutions of a protein assay standard (lyophilised bovine 
plasma gamma globulin 0 – 2 mg/ml). To all standards and samples, 25 ul  Bio-Rad 
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DC protein assay  Reagent A (Bio-Rad, Hertfordshire, UK) and 200 ul  of Bio-Rad DC 
protein assay Reagent B (Bio-Rad, Hertfordshire, UK), were added and the plates 
were allowed to incubate for 15 min. Absorbance was analysed using a BioTek 
Synergy microplate reader (Winooski, Vermont, USA), at 690 nm. Protein 
concentration in each sample was determined using the standard curve generated 
from the standard dilutions. 
2.5.3 Western blotting 
Protein lysates were denatured in a pre-heated block at 700C for 10 min. An equal 
quantity of the denatured protein (8-12 ug), was loaded into 10% SDS-polyacrylamide 
gel wells (NuPAGE- Life tech. UK), which were subsequently placed in a 
electrophoresis gel tank (Xcell Surelock, Invitrogen, UK) containing MOPS (3-N-
morpholino propanesulfonic acid) and SDS (sodium dodecyl sulfate). The gel tank 
was connected to a Bio-Rad power pack (Pac300; Bio-Rad). Five percent 
MOPS running buffer (Appendix), in water was poured into the tank chamber, while 
antioxidant (NuPAGE, UK) was added to the inner chamber of the gel tank to 
preserve the reduced proteins. Electrophoresis was completed at 200 V for 50 min at 
room temperature (RT). 
Protein was transferred to a nitrocellulosse (NC) membrane (GE Healthcare, 
Buckinghamshire, U.K.). Briefly, the NC membrane was sandwiched between Tris-
buffered saline (1X TBS) soaked filter paper and sponges creating a wet transfer 
within a transfer module (Invitrogen). Transfer was carried out on ice at 30V for 
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90min. The NC membrane was blocked in appropriate buffer dissolved in 
TBS/Tween-20 (TBS/T) and incubated over night at 40C.  
The NC block solution was washed off the membrane in TBS/T (3 x 10 min) and 
incubated for 1 h at RT with the appropriate primary antibody (see Appendix, Table 
2). After further washing in TBS/T (3 x 10 min) at RT, the NC membrane was 
incubated for 1 h at RT with species appropriate peroxidase labelled secondary 
antibody (see Appendix, Table 3), (Dako, Denmark) diluted in 5% w/v Marvel in 
TBS/T buffer. The NC membrane was finally washed with TBS/T (4 x 10 min), before 
bound antibody was detected with enhanced chemiluminescence (ECL) (GE-
Healthcare) according to the manufacturer’s recommendation.  In brief, the ECL 
mixture was pipetted on to the NC membrane, allowed to stand for 1min and placed 
in an X-ray cassette sandwiched between two transparencies. In the dark room, the 
film was placed in the same cassette for 30 s, removed and loaded into the X-
OGRAPH medical film processor (Konica Minolta, SRX-101A, Banbury, UK) and 
allowed to develop in the dark(Mahmood and Yang, 2012). The films were scanned 
and saved and densitometric analysis of protein expression  was performed using 
Image J (https://imagej.nih.gov/ij/) (Baldari et al., 2015). 
2.5.4. Stripping NC membrane for additional western blotting 
The NC membrane was stripped in Restore Plus western blot stripping buffer 
(Thermo- Scientific), for 30 min at RT, and then washed in 1xTBS/T (3x10 min). The 
NC membrane was blocked in 5% w/v Marvel or 5% w/v BSA in TBS/T and incubated 
overnight at 40C.  Subsequently it was washed in 1xTBS/T (3 x 10 min). For the 
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detection of the loading control, NC membrane was treated with the stripping buffer 
(Appendix) to clear all bands which was confirmed with ECL.  The stripped NC 
membrane was incubated for 1 h at RT with an antibody to peroxidase tagged β-actin 
(Appendix, Table 2). Subsequently the NC membrane was washed in 1xTBS/T (3 x 10 
min) and the peroxidase label was detected with ECL as previously described. The 
films were scanned and saved, while densitometric analysis of protein expression was 
performed using Image J as previously described. 
2.6. Immunofluorescence of cultured cells 
Immunofluorescence localisation of target proteins was carried out as published 
(Anastasiadis et al., 2000), on MC3T3 osteoblast-like cells that had been cultured on 
sterilised glas coverslips at a density of 6.3 x 103 cells/cm2. Following treatment with 
FGF-2 (Section 2.3), the cells were fixed with 4% paraformaldehyde (PFA) for 15 min 
and washed 3 times (5 min each) with 1 ml of PBS. A blocking buffer (1X PBS, 5% v/v 
normal serum from an appropriate animal species (donor of secondary antibody) and 
0.3% v/v Triton X-100) was added to each well and incubated at RT for 1 h. After 
removal of the blocking buffer the primary antibody (Appendix, Table 2) diluted in 
antibody dilution buffer (1X PBS, 0.3% v/v Triton X-100 and 1% w/v BSA), was added 
to each well. The negative control consisted of an identical concentration of IgG from 
the same animal species as the primary antibody. The cells were incubated on a 
shaker, overnight at 4°C after which the primary antibody was discarded and the 
monolayers were washed 3 times with PBS, for 5 min each. AlexaFluor-conjugated 
secondary antibodies (Table 3) diluted in antibody dilution buffer, was added to each 
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well. The cells were incubated for a further 2 h in the dark at RT. The monolayers 
were subsequently rewashed 3 times with PBS after which the cover slips (containing 
the cell monolayers) were carefully turned upside down onto a microscope slide with 
ProLong Gold antifade reagent with DAPI (Life Tech, USA) for nuclei staining. The 
slides were then visualised using a Leica DMRB fluorescence microscope and images 
were taken with a Leica DFC300 digital colour camera (Leica, Milton Keynes, UK).  
2.7. Phalloidin staining of cultured cells 
MC3T3 osteoblast-like cells were stained for filamentous (F)-actin using the 
Phalloidin (Liu et al., 2011). The cells were seeded at 1.0 x104 cells/ cm2 in 6-well plates 
and were maintained in reduced serum medium (Section 2.2.1). Following treatment 
with FGF-2 (Section 2.3), the cells were fixed in 4% PFA for 15 min after which they 
were rinsed 3 X PBS, permeabilised in 0.1% w/v trypsin (Sigma-Aldrich, Poole, UK) 
in PBS for 10 min and then rinsed again with 3 X PBS. The cells were incubated in 
30ul of Alexa Fluor 488-conjugated phalloidin (Life Tech, Oregon, USA) (5 uM in PBS 
with 2% w/v BSA) in the dark at RT for 3 h. They were then rinsed 3 X PBS and imaged 
on a Zeis Axiovert 25s inverted microscope and digital imaging system (Carl Zeis 
Microscopy, LLC, USA). 
2.8. Transfection of MC3T3 cells with E11 siRNA 
E11 small interfering ribonucleic acid (E11 siRNA) and scrambled siRNA stocks were 
obtained from Qiagen, UK, and diluted to 10 nM. MC3T3 osteoblast-like cells were 
expanded, seeded at 8.0 x 103 cells/cm2 in 12 well plates and maintained in reduced 
serum medium (1% v/v FBS). The use of siRNA has been described also in literature 
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to deplete RNA post transcriptionally (Genetos et al., 2011, Garufi et al., 2014). This 
was carried out according to manufacturer’s instruction and involves gentle 
transfection of cells with a mix of 5.4% v/v of 10 nM E11 siRNA or scrambled siRNA 
for study or scrambled groups respectively; 84% v/v of serum free media; and 10.7% 
v/v of HiPerFect transfection agent, which was added drop-wise to the cells as per 
manufacturer’s instructions (Qiagen, UK). Mock cells were transfected gently with a 
mix of 89.3%v/v serum free media and 10.7%v/v HiPerFect transfection reagent. After 
24 h incubation in a 370C/5%CO2 incubator, FGF-2 at 10 ng/ml was added to 
appropriate wells whereas 0.1% w/v BSA served as the negative control. The cells 
were scraped after 24 h of FGF-2 treatment (Section 2.3) for downstream gene and 
protein analysis (Sections 2.4 and 2.5).   
2.9. RhoA activity assay  
MC3T3 cell monolayers were scraped in a G-LISA lysis buffer supplied with the 
GLISA assay kit (Cytoskeleton, Denver, USA), after 4, 6, 24 and 48 h culture with FGF-
2 (Section 2.3). Lysates were immunoblotted for E11 (Section2.5) to ensure FGF-2 
stimulation of E11. Subsequently, using a GLISA assay which precisely identifies 
active GTP-bound RhoA, the quantification of RhoA activation was carried out by 
luminometry and expressed in relative light units (RLU) as per the manufacturer’s 
instructions (Staines et al., 2016).   
2.10 Alamar Blue Cell Viability Assay 
This was carried out according to published literature (White et al., 1996, Nakayama 
et al., 1997). MC3T3 cells were cultured in 6-well plates as described in Section 2.2.1. 
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Cells were treated with FGF-2 (10 ng/ul) and 0.1% w/v BSA as positive control at 
confluency (Section 2.3). After 24 h FGF-2 stimulation, the media was removed and 
700 ul of fresh media added to each well. To each well, 70 ul Alamar Blue reagent was 
added, then the plate was wrapped in aluminium foil to prevent light contact and 
placed in a humidified incubator maintained at 370C and 5.0% CO2 for 3 h. Fresh 
media plus FGF-2 or BSA was used as a negative control. The Alamar blue 
fluorescence were read at 530/25, 590/35 nm on Bioteck plate reader.  
2.11  Lactate Dehydrogenase (LDH) Assay 
MC3T3 cells were cultured in 6-well plates as described in Section 2.2.1. Cells were 
treated with FGF-2 (10 ng/ul) and 0.1% w/v BSA as positive control at confluency 
(Section 2.3). After 24 h FGF-2 stimulation, the media was removed and an LDH assay 
kit used according to the manufacturer’s instructions (Promega, Southampton, UK). 
Briefly, the Assay Buffer was thawed, and 12 ml taken out, wrapped in aluminium 
foil to protect from light and warmed to room temperature. This 12 ml of room 
temperature Assay Buffer was added to a bottle of Substrate Mix to form the 
CytoTox96 Reagent. It was inverted and shaken gently to disolve the substrate. Fifty 
micro litres aliquots from all test and control wells was transferred to a fresh 96-well 
flat clear bottom plate. Fifty microlitres of the CytoTox96 Reagent was added to each 
sample. The plate was covered with foil to protect it from light and incubated for 30 
min at room temperature. Fifty microlitres of Stop Solution was added to each well 
of the 96-well plate. Using Biotek plate reader, absorbance was read at 490 nm within 
1 h after adding the Stop Solution. 
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2.12. Histological Studies 
2.12.1 Paraffin embedded tissue 
The knee joints of Fgf-2 global KO (Zhou et al., 1998) and WT mice (kind gift from 
Prof. Tonia Vincent, The Kennedy Institute of Rheumatology, Oxford University) 
were fixed for 48 h in 10% neutral buffered formalin and preserved subsequently in 
70% ethanol. The joints were decalcified in 10% w/v EDTA at 40C with regular 
changes for approximately 4 weeks. An automated tissue processor (Leica 
microssystems, Wetzlar, Germany) was used to prepare all of the samples. Briefly, 
the samples were passed through an increasing series of ethanol baths until 
dehydrated in 100% ethanol; they were then infiltrated with paraffin wax. The 
samples were then manually placed in paraffin wax blocks. The surface of the paraffin 
wax blocks were cooled with an ice block and 5μm sections were cut using a Leica 
RM 2235 microtome (Leica, Milton Keynes, UK).  The sections were finally mounted 
onto microscope slides coated with poly-l-lysine.  
2.12.2 Immunohistochemistry 
For immunohistochemical analysis of target proteins, the Vectastain ABC kit (Vector 
Laboratories, Peterborough, UK) was used according to the manufacturer’s 
instructions. This was carried out on paraffin embedded Sections (Section 2.12.1). 
Sections were first de-waxed in xylene and rehydrated though a series of graded 
alcohols to distilled H2O. Antigen unmasking was carried out with 0.1% v/v trypsin 
in PBS for 30 min  at 37oC using water bath (Cattoretti et al., 1993). Endogenous 
peroxidase activity was blocked by treatment with 0.03% v/v H2O2 in methanol for 30 
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min at RT.  After 3 x 5 min washes in PBS the sections were blocked in normal 
blocking buffer (1:50 dilution of the appropriate normal serum in PBS) for 20 min at 
RT. The test sections were then incubated in primary antibody (see Appendix 1, Table 
2), while the control sections were incubated in appropriate immunoglobulin G (IgG). 
They were diluted to an appropriate concentration in normal blocking buffer at 40C 
overnight. Unbound primary antibody was removed by 3 x 5 min washes in PBS. The 
sections were subsequently incubated in biotinylated secondary antibody (Appendix, 
Table 3) diluted with normal blocking buffer at RT for 30 min. After 3 x 5 min washes 
in PBS, sections were incubated with Vectastain ABC reagents 2A and 2B (2 drops of 
avidin and 2 drops of biotin complex) in 5ml PBS for 30 minutes at RT. They were 
later washed for 3 x 5 min in PBS. Staining was then developed in diaminobenzidine 
(DAB) solution (0.06% v/v DAB in 0.1% v/v H2O2 in PBS) for about 2 minutes. The 
sections were rinsed in tap water and counterstained with haematoxylin using Leica 
Autostainer XL (Leica, Milton Keynes, UK). Finally, sections were dehydrated though 
graded alcohols, cleared with xylene and mounted in DePeX. Images were captured 
with Nikon Eclipse Ni microscope (Nikon, UK), fitted with Zeis Axiocam 105 colour 
camera (Carl Zeis, UK). 
2.12.3 Frozen tissue  
Tibia from Fgf-2 KO and WT mice were decalcified in 10% w/v EDTA at 40C with 
regular changes for 4 weeks. They were then subjected to increasing concentrations 
of sucrosse from 10% to 30% w/v for cryoprotection and then subsequently coated in 
5% w/v polyvinyl acetate and snap frozen in a cooled hexane bath for 30 s (Bradbeer 
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et al., 1988, Ruan et al., 2013). The tissue was finally stored at -80oC until use. Frozen 
tissue was embedded in optimal cutting temperature (OCT) embedding medium 
(Brights) and attached to a metal chuck. Following trimming of excess OCT, 10 uM 
sections were cut at -300C using a cryostat (OTF500/HS-001, Brights, Huntingdon, UK) 
with the knife blade angle set to 220. The sections were placed in a slide tray, covered 
in aluminium foil, and stored at -80oC. 
2.12.4 Phalloidin staining for cryosections 
The slides (Section 2.10.3) were removed from -80oC freezer and kept on the bench for 
45 min to bring them to RT before the removal of the tin foil. They were subsequently 
washed twice in PBS before incubation in 0.1% v/v triton X-100 in PBS for 30 min  at 
RT. After extensive washing in PBS the sections were incubated in a solution 
containing 0.05% v/v phalloidin/1% w/v BSA/PBS at RT in the dark for one h. The 
slides were then washed 3 x PBS and finally mounted in Dako fluorescence mounting 
medium (Dako, USA). The slides were stored in the dark at RT and subsequently 
imaged on a Zeis Axiovert 25 Phase/Fluorescent microscope fitted with Zeis Axiocam 
503 high resolution colour camera/Zen software, single eGFP semrock filter block + 
multiple bandpas Semrock DAPI/AF488/TRITC (Carl Zeis, UK). 
2.13. Data analysis 
Data are presented as mean ± S.E.M. for n≥3 observations. Using GraphPad Prism 6 
(GraphPad Software, Inc., USA), differences unless otherwise stated were assessed by 
one or two-way analysis of variance (ANOVA) for which Tukey’s post-tests for 
multiple comparisons were conducted. P<0.05 was considered to be significant. Tests 
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for assumptions of ANOVA done included tests on equality or homogeneity of 
variance such as Brown-Forsythe test.    






Regulation of E11 














The protein E11 is a mucin type transmembrane glycoprotein of about 38-42 kDa  with 
several regulatory functions spanning from cell development and differentiation, 
epithelial-mesenchymal transition (EMT), oncogenesis and invasiveness (Thiery, 
2002, Wicki and Christofori, 2007, Martín-Villar et al., 2009, Astarita et al., 2012).  
Fundamental studies by Bonewald and colleagues identified E11, a mucin-type 
transmembrane glycoprotein, as the earliest osteocyte marker protein expressed 
during osteocytogenesis (Zhang et al., 2006). Furthermore, E11 triggers actin 
cytoskeletal dynamics (Staines et al., 2016), which are required for dendrite formation 
and transient E11 knockdown blocks dendrite elongation (Zhang et al., 2006). E11 has 
also been reported to be up-regulated during mechanical loading with associated 
extensions of the osteocyte dendrites in the mineralized matrix, suggesting a possible 
role in aiding biochemical communication amongst osteocytes, and other bone cells 
in their microenvironment (Zhang et al., 2006). Despite this, how E11 expression is 
regulated and the precise mechanisms by which E11 promotes dendrite formation are 
poorly understood. 
Nonetheless, clues from other model systems have indicated that basic fibroblast 
growth factor (bFGF) or FGF-2 is able to change chondrocyte gene expression  in vitro, 
including that of E11 (Chong et al., 2013). Specifically, E11 expression was found to 
be FGF-2 dependent following injury to cartilage in vitro and to joint tissues in vivo 
(Chong et al., 2013).  FGF-2 is a member of the FGF large family of polypeptide growth 
factors involved in several developmental mechanisms, including skeletal 
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development, in several multicellular organisms (Itoh and Ornitz, 2004, Thisse and 
Thisse, 2005).  In addition to chondrocytes, FGF-2 expressed by osteoblasts and stored 
in the extracellular matrix (ECM), where it regulates bone formation via influence on 
progenitor cell lineage commitment and/or osteoblast differentiation (Sabbieti et al., 
1999, Montero et al., 2000, Hurley et al., 2002, Xiao et al., 2010a). FGF-2 is also involved 
in normal bone formation as highlighted by its absence in KO mice being associated 
with poor bone formation and mass (Coffin et al., 1995, Montero et al., 2000). In vitro, 
FGF-2 down regulates osteoblast markers such as collagen type 1 and also regulates 
genes controlling mineralisation during osteoblast differentiation (Fang et al., 2001, 
Kyono et al., 2012). FGF-2 is involved in regulation of bone matrix protection by 
inducing the expression  of tissue inhibitors of metalloproteinases – TIMPs (Varghese 
et al., 1995).   
In view of the published role of FGF-2 in stimulating E11 expression in cartilage 
explants and osteoblast-like cells, it is therefore likely that FGF-2 may have an impact 
on osteoblast expression of E11 and the acquisition of the dendritic osteocyte 
phenotype (Gupta et al., 2010, Chong et al., 2013). Hence, the aim of this Chapter is to 
elucidate the nature of FGF-2 regulation of E11 during osteocytogenesis. 
3.2. Hypothesis 
FGF-2 stimulates the expression of E11 in MC3T3 osteoblast like cell lines and 
primary osteoblasts, promoting the acquisition of the osteocyte phenotype. 
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3.3.  Aims 
I To examine the effect of FGF-2 on E11 expression in MC3T3 osteoblast cell lines and 
primary osteoblasts.  
II To establish the effect of FGF-2 on the attainment of the osteocyte phenotype in 
osteoblast cell lines and primary osteoblasts. 
III  To evaluate the effect of FGF-2 on E11 expression in SCB osteocytes from mice 
deficient in Fgf-2.  
3.4. Materials and methods 
3.4.1 MC3T3 cells 
As outlined in Section 2.2.1, MC3T3 cells were cultured at a density of 6 x 104 cells/cm2 
in a humidified atmosphere (37°C, 5% CO2) for up to 15 days. When confluent, cells 
were initially supplemented with FGF-2 at increasing concentrations from 0 – 50 
ng/ml or 0.1% w/v BSA as negative control. For subsequent experiments, FGF-2 was 
added at 10 ng/ml with 0.1% w/v BSA as negative control. The medium was changed 
every 2-3 days.  
3.4.2 RNA analysis of MC3T3 cells 
RNA was isolated from MC3T3 cells at specific time points using a Qiagen RNeasy 
kit according to the manufacturer’s instructions and cDNA was prepared (Section 
2.4.1). For qPCR analysis, cDNA was used at 5 ng/ul, as detailed in Section 2.4.5. 
Results were normalised to the Atp5b housekeeping gene. Primers used are detailed 
in Appendix I Table 1.  
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3.4.3 Protein extraction from MC3T3 cells and western blotting 
At defined time points, protein was extracted from MC3T3 cells in RIPA buffer as 
detailed in Section 2.5.1. Protein samples were quantified (Section 2.5.1) and 
appropriate quantities were used for western blot analysis (Section 2.5.3). E11 protein 
expression was determined using a goat anti-mouse anti-E11 antibody at a dilution 
of 1:1000 and a HP-labelled rabbit anti-goat secondary antibody (1:3000).  Antibody 
labelling was visualised using the ECL detection kit. Uniform protein loading was 
confirmed by re-probing the membrane with mouse monoclonal HP-labelled anti-β 
actin antibody (1:70000). 
3.4.4. Immunofluorescence 
Immunofluorescence for localisation of E11 after treatment of MC3T3 with FGF-2 at 
10 ng/ml concentration or 0.1% w/v BSA as negative control was as described in 
Section 2.6. E11 protein expression was localised using a goat anti-mouse anti-E11 
antibody at a dilution of 1:900 and a donkey anti-goat AlexaFluor-conjugated 
secondary antibodies HP-labelled rabbit anti-sheep secondary antibody (1:250). The 
slides were subsequently stained with ProLong Gold antifade reagent with DAPI for 
nuclei staining, before imaging with microscope. 
3.4.5 Transfection of MC3T3 cells with E11 siRNA 
Functional studies using E11 siRNA transfection was carried out on MC3T3 cells as 
described in Section 2.8. Two control groups were used, one treated with scrambled 
siRNA while the mock group was treated with only the HiPerFect transfection agent. 
RNA was extracted and reverse transcribed (Sections 2.4.1 and 2.4.3). For qPCR 
Chapter 3: Regulation of E11 expression by FGF-2 
75 
 
analysis, Section2.4.5. Western blotting on extracted protein was done as described in 
Section 2.5.3. Immunofluorescence for localisation of E11 after transfection was as 
described in Section 2.6. E11 protein expression was localised using a goat anti-mouse 
anti-E11 antibody at a dilution of 1:900 and donkey anti-goat AlexaFluor-conjugated 
secondary antibodies (1:250). 
3.4.6 Primary osteoblasts 
Primary osteoblasts were extracted from the calvaria of 3 days old WT mice as 
detailed in Section 2.2.2. Cells were cultured for 2 days at 37oC in cell culture media 
before treatment with FGF-2 at 10 ng/ml concentration or 0.1% w/v BSA as negative 
control in appropriate wells. RNA was extracted and reverse transcribed (Sections 
2.4.1 and 2.4.3 respectively). For qPCR analysis, cDNA was used at 5 ng/ul, as detailed 
in Section 2.4.5. RT-qPCR results were normalised to the Atp5b housekeeping gene. 
Primers used are detailed in Appendix I, Table 1. Proteins were extracted as described 
(Sections 2.5.1), and western blotting was done as described above in Section 3.4.3 
and β-actin served as loading control. 
3.4.7 Whole calvaria 
Whole calvariae were dissected from 3-day-old C57BL/6 wild-type mice as detailed 
in Section 2.2.3. Cavaria hemiSections were incubated in calvaria culture media for 2 
days after treatment with FGF-2 at 10 ng/ml concentration or 0.1% w/v BSA as 
negative control in appropriate wells. After 6, 24 and 48 h of FGF-2 stimulation, RNA 
was extracted and reverse transcribed as described in Section 2.4.2 and 2.4.3 
respectively). For qPCR analysis, cDNA was used at 5 ng/ul, as detailed in Section 
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2.4.5. Results were normalised to the Gapdh housekeeping gene. Primers used are 
detailed in Appendix I Table 1.  
3.4.8 Immunohistochemical staining of the murine tibias  
Tibias of 10-week old Fgf-2 KO and wild type mice (Section 2.10.1) were 
immunostained for E11 and sclerostin as described in Section 2.10.2. 
Immunohistochemical staining of 5 um-thick tibiae paraffin embedded decalcified 
sections was performed using antibodies for E11 (1:500), and sclerostin (1:500), and 
the Vectastain ABC kit, as outlined in Section 2.10.2 and Appendix 1 Table 1. 
Immunohistochemical labelling was visualised using DAB chromogen. Goat IgG 
concentrations at same concentrations were used instead of the primary antibodies as 
negative controls. The labels on the slides were masked by tape to allow blind 
assessment of the staining. For analysis of the percentage of positively stained E11 or 
sclerostin osteocytes, the Grid/Collection Stitching Plugin within Fiji was use to 
merge the several images of the Section afterwards positive staining and total 
osteocytes were counted (Schindelin et al., 2012). 
3.4.9 Measuring osteocyte cell volume and dendrite parameters in mouse tibiae  
Histological Sections of longitudinally cut mouse tibiae were stained with Phalloidin- 
Fluorescein Isothiocyanate to demonstrate F-actin (Section 2.12.4). 
Sections were imaged on a Zeis LSM 710 Laser Scanning Confocal Microscope with 
488nm laser excitation and detection settings from 493 to 634 nm. Z-stacks were 
produced with optimal Nyquist overlap settings using a 63x/1.4 na oil immersion 
lens. Voxel sizes were 0.1x0.1x1.00 um in x,y,z planes respectively. 
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Images were analysed using Bitplane Imaris software as previously published 
(Staines et al., 2017). This essentially involved importing the image stacks into 
Bitplane Imaris 9.2.0 software. Imaris Filament Tracer was used to create algorithms 
to render and measure canalicular processes; while surface rendering was used for 
osteocyte cell body measurements. Algorithm settings were set constant and applied 
to all images (see Appendix Algorithm 1.). Histological sections were blinded to the 
operator/analyst by masking with tape, later  divided into 2 unknown groups (Group 
1 and Group 2) to allow comparisons in the Imaris Vantage software module. Imaging 
and analysis with the Bitplane Imaris software was done by Mr Robert Fleming. 
Statistics were carried out in Minitab 17 software. 
3.5  Results 
3.5.1. Dose-response of FGF-2 on the expression of E11 gene and protein by 
MC3T3 osteoblast-like cells. 
To ascertain the optimum concentration of FGF-2 for use in future experiments, a 
dose-response study was conducted in MC3T3 osteoblast-like cells. Increasing 
concentrations of FGF-2 (1, 10, 25 and 50 ng/ml) were examined for their effects on 
E11 expression. After 4 h of incubation with 1, 10, 25 and 50 ng/ml of FGF-2, there was 
an upward trend of higher E11 gene expression  when compared to control cultures 
(no FGF-2 supplementation) (Fig. 3.1A).  The differences did not reach significance. 
There was also an upward trend in E11 gene expression with   stimulation by FGF-2 
for 24 h at all concentrations studied (Fig. 3.1B). Similarly, after 24 h, the FGF-2 treated 
cells synthesized more E11 protein and this was particularly notable in the 10, 25, and 
50 ng/ml treated cells. This increase in E11 protein expression was not apparent after 
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4 h of FGF-2 treatment (all concentrations tested) (Fig. 3.1C).  Since FGF-2 at 10 ng/ml 
promoted E11 gene, albeit not significantly, and protein expression, this 
concentration was chosen based on optimal induction and cost effectivenesss for 
subsequent studies. 
3.5.2  Effect of FGF-2 10 ng/ml over a short time-course on E11 expression and 
osteocyte/osteoblast gene markers in MC3T3 osteoblast-like cells.  
Cells were stimulated  with FGF-2 at 10 ng/ml for 4, 6, and 24 h. RT-qPCR showed 
that E11 gene expression  was significantly up-regulated after 4 (P<0.001) and 6h 
(P<0.001) exposure to FGF-2 but there was a lessened response after 24 h (P<0.05) 
when compared with untreated control cells (Fig. 3.2A). This confirms the gene 
expression data shown in Figure 3.1. Although in this experiment, statistical 
significance was reached whereas trends were only previously observed.  Further 
confirmation was observed at the protein level where western blotting showed that 
at 4, 6 and 24 h time points, E11 protein expression was increased in FGF-2 stimulated 
cells when compared to control cells (Fig. 3.2B).  
FGF-2 also induced the up-regulation of osteocyte markers Phex and Dmp1 (P<0.01; 
Fig. 3.2C & D) and down regulation of the osteoblast markers Col1a1, Bglap, Alpl, with 
Postn (P<0.01; Fig. 3.2E - H). The down regulation of Col1a1, Bglap and Alp and 
upregulation of E11, Phex and Dmp1 by FGF-2 after 24 h, strongly suggests that FGF-
2 promotes the differentiation of pre-osteoblast/osteoblast to the osteocyte 
phenotype. Sost Ct values were high with almost flat dissociation curve as MC3T3 
cells are not known to expresss Sost especially in early time points. 





Figure 3.1 Temporal expression of E11 by MC3T3 cells cultured in increasing 
concentrations of FGF-2.  
The effects of FGF-2 (0 – 50 ng/ml) on E11 gene (A & B), and protein (C) expression 
after 4 and 24 h incubation was assessed  by RT-qPCR and western blotting, 
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(Previous page)  Figure 3.2 Temporal expression of E11 and osteocyte/osteoblast 
gene markers by MC3T3 cells cultured in FGF-2 10 ng/ml over short time course.  
The effect of FGF-2 on (A) E11 gene and (B), E11 protein expression after 4, 6 and 24 
h stimulation. Note the effect on other osteocyte markers (C) Phex, and (D) Dmp1 gene 
expression; and osteoblast gene markers (E) Col1a1, (F) Bglap (G) Alpl, and (H) Postn 
gene expression after same time points.  Data are presented as mean ± S.E.M (n=3); 
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3.5.3  Effect of FGF-2 over a long time-course on osteocyte gene markers in 
MC3T3 osteoblast-like cells. 
MC3T3 osteoblast-like cells were stimulated with FGF-2 at 10 ng/ml for 2, 5, 9, 12 and 
15 days to evaluate its long term effects on E11 and osteocyte gene markers. At all-
time points studied, E11 expression was not significantly increased by FGF-2 
stimulation (Fig. 3.3A).  Interestingly, western blotting showed that E11 protein 
synthesised by MC3T3 cells from day 9 onwards, was lower in FGF-2 stimulated cells 
when compared with time-matched controls (Fig. 3.3B). There was however a robust 
up-regulation of two late osteocyte marker genes Phex and Dmp1 (P<0.001) by day 15 
(Fig. 3.3C & D). Sost expression was not significantly altered at any time points 













Figure 3.3 Temporal expression of osteocyte gene markers by MC3T3 cells cultured 
in FGF-2 10 ng/ml over long time course.  
The effect of FGF-2 10 ng/ml on (A) E11 gene and (B), E11 protein expression after   2 
– 15 days stimulation. Note the effect on other osteocyte markers (C) Phex, (D) Dmp1, 
and (E) Sost gene expression after same time points. Data are presented as mean ± 
S.E.M (n=3); *p<0.05; **p<0.01; ***p<0.001 compared to control cells.  
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3.5.4  Effect of FGF-2 on the spatial expression of E11 in MC3T3 osteoblast-like 
cells 
The above data has shown that FGF-2 was able to induce E11 expression and other 
markers of the osteocyte phenotype. To extend these data, I investigated the spatial 
expression of E11 in MC3T3 osteoblast-like cells treated with FGF-2 at 10 ng/ml for 6, 
24, 48 and 72 h by phase contrast microscopy and E11 immunostaining. Phase contrast 
microscopy revealed that after 14 days in culture, the control cells were still 
ovoid/cuboidal shape (Fig. 3.4A), while the treated cells had the prominent elongated 
dendrites typical of osteocytes (Fig. 3.4B).  The immunofluorescence microscopy of 
the cells after 6 h FGF-2 treatment showed little alterations to E11 expression  or cell 
morphology (data not shown), whereas FGF-2 treatment for 24 - 72 h  resulted in a 
stark change in cell morphology with the appearance of many dendritic processes 
radiating from the cell membrane when compared to control cells (Figs. 3.4C-H & I-
N). Furthermore, the distribution of intra-cellular E11 expression was also altered by 
FGF-2 treatment. In the control cells, E11 expression  was more generally uniformly 
located within the cytoplasm with a more perinuclear location whereas in the FGF-2 
treated cells E11 was associated with the dendrite projections at the cell membrane 
(Figs. 3.4C-H & I-N). The control, non FGF-2 treated cells also trended towards a 
similar appearance with time in culture, but this accelerated with FGF-2 treatment. 
Together, these data are consistent with altered E11 expression and distribution (in 
response to FGF-2) driving the acquisition of the dendritic phenotype in 
differentiating osteoblasts.  
 





















Figure 3.4 Spatial expression of E11 in MC3T3 osteoblast-like cells cultured in   
FGF-2 
Phase contrast microscopy showing phenotypic change from cuboidal osteoblast 
shape in control (A); to a dendritic osteocyte phenotype in FGF-2 treated cells (B).  
Immunofluorescence microscopy showing E11 expression and distribution in control 
cells (C-H), and FGF-2 stimulated cells (I-N), for 24, 48 and 72 h time points. Note the 
blue arrows pointing at long dendrites, white arrows point to E11 accumulations at 
sites of dendritic projections. Images are representative of three separate experiments. 
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3.5.5  Effect of 24 h FGF-2 treatment on the spatial distribution of F-actin in 
MC3T3 osteoblast-like cells  
Phalloidin staining was used to observe the phenotypic distribution of the 
microfilament F-actin in FGF-2 treated MC3T3 cells (Wulf et al., 1979). This is 
important, as intra-cellular F-actin organisation is associated with the formation of 
dendrite formation during the acquisition of the osteocyte phenotype. Phalloidin 
staining revealed that the control cells had a typical rounded morphology with fewer 
and shorter dendrites (Fig. 3.5A), while FGF-2 treated MC3T3 cells expressed more 
numerous, and longer dendrites, intertwining with one another (Fig. 3.5B).  
3.5.6. Cell Viability Assay and LDH Assay 
The Alamar Blue Cell Viability assay and the LDH assay were carried out according 
to manufacturer’s instruction (Section2.10). This was conducted to validate the 
biological life of the cells under study and to investigate if the treatments were having 
toxic effects on the cells during the study. The results for cell viability showed no 
differences between FGF-2 treated and control MC3T3 cell cultures (Fig. 3.6A); and 
the blue colour of the Alamar Blue dye were all reduced to red in both control and 
treated cultures, thus confirming the cells were viable. The LDH assay revealed that 
FGF-2 treated MC3T3 cells release les LDH than the control cultures, thereby 
indicating les cell death in these cultures (P<0.05, Fig. 3.6B).    
 
 















Figure 3.5. Spatial distribution of F-actin in MC3T3 osteoblast-like cells cultured 
in FGF-2 
The effect of FGF-2 10 ng/ml  on MC3T3 osteoblast-like cell morphology after 
phalloidin staining for F-actin after 24 h in control (A and B), and treated cells (C and 
D). Note the white arrows pointing at the dendrites F-actin in the treated cells. Images 
are representative of three separate experiments.  Scale bar (A and C) = 200 um; (B 



















Figure 3.6. Cell Viability and Lactate Dehydrogenase (LDH) profile of MC3T3 cells 
cultured in FGF-2 10 ng/ml for 24 h. 
(A) Alamar Blue cell viability assay showing no difference between the FGF-2 treated 
and control cultures. (B) LDH release from FGF-2 treated cultures was significantly 
lower than the control cultures. Data are presented as mean ± S.E.M (n=3); *p<0.05; ns 
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3.5.7 Effect of E11siRNA transfection on FGF-2 stimulation of E11 expression and 
F-actin distribution by MC3T3 cells 
To investigate if the effects of FGF-2 on MC3T3 osteoblast-osteocyte differentiation is 
mediated by E11, the cells were transfected with E11siRNA and incubated for 24 h by 
FGF-2. E11 gene (77% knockdown vs. mock control, 70% knockdown vs. scrambled 
control; P<0.05; Fig. 3.7A) and protein (Fig. 3.7B) expression were silenced 
successfully by E11 siRNA transfection. After 24 h of FGF-2 treatment, FGF-2 
stimulated E11 gene expression in scrambled and mock treated groups but not in the 
E11 siRNA transfected cells (Fig. 3.7A).  Gene expression analysis of the other 
osteocytes makers showed the significant up-regulation of Phex (P<0.01; Fig. 3.7C) 
and Dmp1 (P<0.001; Fig. 3.7D), in the FGF-2 treated cells when compared to the 
control samples of E11siRNA, scrambled and mock groups. Immunofluorescence 
intensity of E11 expression in siRNA treated cells (Fig. 3.8A & B) was less than that 
observed in the scrambled (Fig. 3.8C & D) and mock (Fig. 3.8E & F) treated cells. 
Moreover, whilst FGF-2 promoted dendrite formation in all groups of cells, their 
number appeared les in those pre-treated with E11siRNA (Fig. 3.7A & B) when 
compared to the scrambled (Fig. 3.8 & D) and mock (Fig. 3.8E & F) treated cells. F-
actin distribution after 24 h FGF-2 stimulation showed similar trend with shorter 
dendrites seen in the E11siRNA pre-treated cells with retained osteoblast cuboidal 
shape (Fig. 3.8G & H), when compared to scrambled (Fig.3.8I & J), and mock (Fig.3.8K 
& L) that showed more spindle osteocyte like shape in the FGF-2 stimulated cells. 
 














Figure 3.7 Temporal expression of E11, Phex and Dmp1 by FGF-2 stimulated  
MC3T3 cells after E11 siRNA transfection  
The effect of E11siRNA transfection on FGF-2 10 ng/ml  stimulation of (A) E11 gene 
and (B), E11 protein expression  after 24 h stimulation. Note the effect on other 
osteocyte markers (C) Phex, and (D) Dmp1 gene expression after same time point. 
Results are normalised to the Atp5b housekeeping gene. Data are presented as mean 
± S.E.M (n=3); *p<0.05; **p<0.01; ***p<0.001 compared to control cells; #p<0.05 of 
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Figure 3.8 Spatial expression of E11 and F-actin distribution by MC3T3 cells 
cultured in FGF-2 after E11siRNA transfection  
Immunofluorescence of E11 localisation (A-F) revealed loss of dendrite formation in 
the E11siRNA groups (A & B ) when compared to the scrambled (C & D) and mock 
(E & F). Phalloidin staining for F-actin (G-L) showing similar trend as seen E11siRNA 
groups (G & H), when compared to the scrambled (I & J) and mock (K & L). Note 
longer and prominent dendrites in FGF-2 treated scrambled and mock cultures (white 
arrow), and retained flattened shaped cell (red arrow) in E11siRNA phalloidin 
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3.5.8  The effect of FGF-2 on the expression of E11 gene and protein expression 
by primary calvarial osteoblasts 
Primary osteoblasts isolated from the calvaria of 3-day old wild type mice were used. 
An FGF-2 concentration-response experiment was first completed to optimise further 
studies with primary osteoblasts and therefore the temporal analysis of E11 gene 
expression in the presence of a range of FGF-2 concentrations was carried out as 
previously described in MC3T3 osteoblast-like cells (Fig 3.1). After 4 h treatment with 
FGF-2 at 1, 10, 25 and 50 ng/ml, there was a small but consistent trend of higher E11 
gene expression when compared to control cells (Fig. 3.9A). This up regulation of E11 
protein expression was more marked after 24 h FGF-2 treatment (Fig. 3.9B).  Analysis 
of E11 protein expression revealed that E11 expression was higher in control cells (no 
FGF-2 treatment) cultured for 24 h than in cells cultured for 4 h (Fig. 3.9C).  This 
suggests that prolonged culture length induced E11 expression. After 4 h, the FGF-2 
treated cells expressed more E11 protein and this was particularly notable in the 25, 
and 50 ng/ml treated cells (Fig. 3.9C).   
Similarly, after 24 h, the FGF-2 treated cells expressed more E11 protein and this was 
most noticeable in the 10, 25, and 50 ng/ml treated cells (Fig. 3.8C). A 10 ng/ml 
concentration of FGF-2 was chosen for future experiments to reflect optimum 
expression and cost effectiveness. 
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3.5.9 Effect of FGF-2 10 ng/ml over a short time-course on (1) E11 expression and (2) 
osteocyte/osteoblast gene markers in primary osteoblasts 
E11 expression was significantly up-regulated after 6 (P<0.05) and 24 h (P<0.001) 
exposure to FGF-2 when compared with untreated control cells (Fig. 3.10A). Western 
blotting also indicated that FGF-2 induced E11 protein expression and this was 
particularly evident after 24 h FGF-2 exposure (Fig. 3.10B). FGF-2 at 10 ng/ml also 
induced the up-regulation of osteocyte markers Phex (P<0.001, Fig. 3.10C) and Dmp1 
(P<0.01, Fig. 3.10D) whilst down regulating osteoblast markers, Col1a1, Bglap, Alpl, 
Postn (Fig. 3.10E - H). The down regulation of Col1a1, Alp, Postn and Bglap and 
upregulation of E11, Phex and Dmp1 by FGF-2 after 24 h, indicates that FGF-2 is 














Figure 3.9 Temporal expression of E11 by primary osteoblasts cultured in 
increasing concentrations of FGF-2.  
Temporal gene expression of E11 by primary osteoblasts cultured in increasing 
concentrations of FGF-2. The effects of FGF-2 (0 - 50 ng/ml) on E11 gene expression  
at (A) 4 h and (B) 24 h. (C) E11 protein expression  was also examined after FGF-2 
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(Previous page) Figure 3.10 Temporal expression of E11 and osteocyte/osteoblast 
gene markers by primary osteoblasts cultured in FGF-2 10 ng/ml.  
The effect of FGF-2 10 ng/ml on (A) E11 gene and (B), E11 protein expression after 4, 
6 and 24 h stimulation. Note the effect on other osteocyte markers (C) Phex, and (D) 
Dmp1 gene expression; and osteoblast gene markers (E) Col1a1, (F) Bglap (G) Alpl, and 
(H) Postn gene expression after same time points.  Data are presented as mean ± S.E.M 
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3.5.10  Effect of FGF-2 on the osteocyte phenotypic appearance of primary 
osteoblasts 
The previous data using immunofluorescence microscopy indicated that FGF-2 was 
able to increase E11 expression and promote greater dendritic cytoplasmic projects in 
MC3T3 cells.  In this present study, primary osteoblasts were similarly investigated 
to ases the cellular distribution of E11 during the osteocytogenesis.   The control cells 
showed a similar cuboidal shape at all stages of differentiation with little evidence of 
dendritic formation at the membrane surface (Fig. 3.11A-F).  After treatment with 
FGF-2, there was clear evidence for the formation of dendrites from the primary cells 
at all-time points (Fig. 3.11G-L).  
3.5.11  Effect of FGF-2 10 ng/ml E11 expression and osteocyte/osteoblast gene 
markers in cultured whole calvaria. 
To investigate if FGF-2 drives E11 expression in more physiological condition i.e. 
compared with cultured cells as done previously, an ex-vivo study was completed on 
whole calvaria. This model will replicate possible interactions between the ECM and 
both E11 and FGF-2, which was absent in both the cell line and the primary osteoblast 
models used previously.  Changes in gene expression in this model were limited.  
There was however a small but significant increase in E11 (P<0.05, Fig. 3.12A) and 
Dmp1 (P<0.001, Fig. 3.12B) expression by FGF-2 after at 6h but not at the other time 
points.  No changes in the expression of osteoblast marker genes (Phex (Fig. 3.12C), 
Alp (Fig. 3.12D), Bglap (Fig. 3.12E), and Postn (Fig. 3.12F)) by FGF-2 were noted at any 
of the time points studied.  














Figure 3.11 Spatial expression of E11 in primary osteoblasts cultured in the 
presence of FGF-2. 
The effect of FGF-2 10 ng/ml on E11 expression and distribution in primary cells 
assessed by immunofluorescence microscopy of control cells (A); and cells treated by 
FGF-2 (B) at 24, 48 and 72 h time points. Note the arrows pointing at the dendrites. 
Images are representative of three separate experiments. Scale bar, A-C & G-I = 200 
























Figure 3.12 Temporal expression of E11 and osteocyte/osteoblast gene markers in 
whole calvaria cultured in the presence of FGF-2 10 ng/ml.  
Temporal gene expression of whole calvaria cultured with FGF-2 10 ng/ml 6- 48 h. 
RT-qPCR assessed expression of (A) E11 (B) Dmp1 (C) Phex (D) Alp, (E) Bglap, and (F) 
Postn. Data are presented as mean ± S.E.M for n=3 observations; *p<0.05; ***p<0.001. 
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3.5.12. Investigating if deletion of Fgf-2 in vivo affect E11 and Sclerostin expression 
in osteocytes. 
Having shown the up-regulation of E11 expression  by FGF-2 in MC3T3 osteoblast-
like cell line, primary osteoblasts and whole calvaria, the next study was designed to 
investigate the relationship between FGF-2 and both E11 and sclerostin expression  in 
vivo. Immunohistochemistry was employed to examine whether bones from Fgf-2 KO 
mice exhibited altered E11 and sclerostin expression. Osteocytes of subchondral, 
trabecular and cortical bone from Fgf-2 KO stained positively for E11, and this 
osteocyte staining appeared larger and stronger when compared to the same in 
osteocytes from WT mice (Figs. 3.13, 3.14, and 3.15).  However, the quantification of 
the number of E11 positive cells in all three bone regions was similar in samples from 
both Fgf-2 KO and WT mice (Fig. 3.15E). Sclerostin osteocyte immunostaining was 
similar in cortical, trabecular and subchondral bone of Fgf-2 KO and WT mice as was 
the quantification of the number of sclerostin positive osteocytes in all three  bone 
regions (Figs. 3.16, 3.17, and 3.18). Hypertrophic chondrocytes of the articular 
cartilage stained positive to sclerostin immunostaining (Fig. 3.16A & B). IgG control 
Sections were negative (Fig. 3.19). 
3.5.13. Investigating if deletion of Fgf-2 in vivo affects osteocyte dimension in mice. 
Having observed larger osteocytes in Fgf-2 KO mice relative to those in WT mice 
(Figs. 3.14A & C), osteocyte phalloidin staining was performed in the cortical bone of 
Fgf-2 KO and WT mice (Fig. 3.20A & B) to confirm this. There was a significant 
increase in cell body volume (P<0.05, Fig. 3.20C), but no differences in cell sphericity 
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were observed (Fig. 3.20D). In addition, the total number of dendrites (Fig. 3.20E) and 
dendrite volume (Fig. 3.20F) were unchanged between Fgf-2 KO and WT mice. There 
was, however, a significant decrease in average dendrite volume in Fgf-2 KO mice 







































Figure 3.13 E11 immunostaining of tibial subchondral bone osteocytes 


















































Sections of subchondral bone osteocytes (black arrow) in both Fgf-2 KO (A 
& C) and WT (B & F) showing E11 localisation to osteocytes and their 
dendritic processes., Quantification of E11 positive osteocytes  was similar 
in both WT and Fgf-2 KO subchondral bone (E). Data are presented as 
mean ± S.E.M for n=3 observations, NS= not statistically significant. Scale 
Bar (A & B) =150 um; (C & D) =100 um   




















Figure 3.14 E11 immunostaining of tibial trabecular bone osteocytes from Fgf-
2 KO and WT mice.  
Section of trabecular bone osteocytes (black arrow) in both Fgf-2 KO (A & C) and 
WT (B & F) showing E11 localisation to osteocytes and their dendritic processes., 
Quantification of E11 positive osteocytes  was similar in both WT and Fgf-2 KO 
trabecular bone (E). Note the larger osteocytes in the Fgf-2 KO (A & C). Data are 
presented as mean ± S.E.M for n=3 observations, NS= not statistically significant. 
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Figure 3.15 E11 immunostaining of tibial cortical bone osteocytes of Fgf-2 KO and WT 
mice  
Section of cortical bone osteocytes (black arrow) in both Fgf-2 KO (A & B) and WT (C & 
D), showing E11 localisation to osteocytes and their dendritic processes., Quantification 
of E11 positive osteocytes  was similar in both WT and Fgf-2 KO cortical bone (E). Note 
the bone marrow, BM. Data are presented as mean ± S.E.M for n=3 observations, NS = 
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Figure 3.16 Sclerostin immunostained Fgf-2 KO and WT mice tibial articular 
cartilage and subchondral bone. 
Section of subchondral bone osteocytes (black arrow) in both Fgf-2 KO (A & B) 
and WT (C & D), showing no difference in Sost immunostaining, as was also 
shown from quantification of sclerostin positive osteocytes (E). Note the positive 
staining of hypertrophic chondrocytes of the articular cartilage (red arrow). Data 
are presented as mean ± S.E.M for n=3 observations. NS= not statistically 
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Figure 3.17 Sclerostin immunostained Fgf-2 KO and WT mice tibial trabecular 
bone osteocytes 
Section of trabecular bone osteocytes (black arrow) in both Fgf-2 KO (A & C) and 
WT (B & F) showing no difference in sclerostin immunostaining, as was also shown 
from quantification of sclerostin positive osteocytes (E). Data are presented as mean 
± S.E.M for n=3 observations, NS = not statistically significant. Scale Bar (A & B) 
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Figure 3.18 Sclerostin immunostained Fgf-2 KO and WT mice tibial cortical 
bone osteocytes 
Section of cortical bone osteocytes (black arrow) in both Fgf-2 KO (A & C) and WT 
(B & F) showing no difference in sclerostin immunostaining, as was also shown 
from quantification of sclerostin positive osteocytes (E). Note the bone marrow, 
BM. Data are presented as mean ± S.E.M for n=3 observations, NS = not 


































Figure 3.19 IgG control sections of tibial trabecular bone osteocytes of Fgf-2 
KO and WT mice.  
Section of trabecular bone osteocytes (black arrow) in both Fgf-2 KO    (A & B) 
and WT (C & D) showing no positive staining in the absence of the primary 
antibodies.  This confirms the specificity to the sclerostin and E11 antibodies.  
Scale bar=300 um  
A B 
C D 
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Figure 3.20 Phalloidin stained Fgf-2 KO and WT mice tibial cortical bone 
osteocytes 
Section of cortical bone osteocytes in both Fgf-2 KO (A) with larger cell body 
volume than the WT (B) as was confirmed by quantification (C), but same cell 
spherical shape (D). While the total dendrite number and volume (E & F), were 
same, the average length of the WT was longer than the Fgf-2 KO (G). Note the 
dendrites (pink arrow) emerging from the osteocyte cell body. Data are 
presented as mean ± S.E.M for n=3 observations; *p<0.05, **p<0.01. Scale bar = 7 
um. 










The transmembrane glycoprotein E11, has long been recognised to be an early driver 
of the osteoblast to osteocyte transition and the acquisition of the dendritic 
appearance (Zhang et al., 2006, Gupta et al., 2010).  Consistent with this, the data in 
this study, which used a number of osteoblast and organ culture models, showed that 
FGF-2 is able to increase E11 expression and that this is likely to lead to the observed 
increase in osteocyte dendrite formation.   
A previous brief report has shown that FGF-2 treatment of osteoblast-like cells was 
able to induce an increase in E11 expression  and the appearance of the osteocyte 
phenotype (Gupta et al., 2010, Miyagawa et al., 2014),  this present study, has  
confirmed these observations in both MC3T3 and primary osteoblasts. The significant 
up-regulation of E11, Phex and Dmp1 and down-regulation of Col1, Bglap, Alp and 
Postn in the FGF-2 treated cultures suggests that FGF-2 is inducing the differentiation 
of the osteoblast to the osteocyte phenotype. This was demonstrated further by the 
lack of difference in E11 expression after prolonged treatment with FGF-2, suggesting 
that the osteocyte had differentiated beyond this early gene marker threshold. This 
study has also extended these observations to show that E11 is an early osteocyte 
marker, is also regulated by FGF-2 at the protein level, just like the 
osteoblast/osteocyte gene markers (Paic et al., 2009, Gupta et al., 2010, Stern et al., 
2012). The similar stimulatory effect of FGF-2 on E11 expression in both cell types, 
especially the primary osteoblasts, suggests the possibility of a similar effect in vivo, 
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as down-regulation of E11 has been reported in Fgf-2 KO mice in an injured joint 
model study (Chong et al., 2013).  
The whole calvaria study was aimed at providing an ex vivo environment to extend 
the understanding on FGF-2-E11 interactions, having established a positive 
stimulatory effect on E11 expression by FGF-2 in MC3T3 osteoblast like cells and 
primary osteoblasts. This system replicates a near physiological environment, 
maintaining cell plurality and ECM interactions (Mohammad et al., 2008, Kyono et 
al., 2012), hence it is commonly used to investigate the regulatory mechanisms of bone 
formation (Mohammad et al., 2008, Dallas et al., 2013).  FGF-2 up-regulated E11 gene 
expression, as well as known osteocyte marker gene Dmp1, in the early time points. 
This stimulatory effect was abolished in the later time points. This loss in stimulation 
may be due to the differentiated state of the cells after prolonged culture. It is possible 
that following attainment of the osteocyte phenotype, these cells do not respond to 
further FGF-2 stimulation as the requirement for E11 to promote dendrite formation 
is past.  Other explanations may also exist and include the degradation rate of FGF-2 
where it possesses a half-life of 7.6 h in vivo (Beenken and Mohammadi, 2009). It is 
also possible that as FGF-2 saturates the ECM and its pro-differentiating effects were 
diminished as different cell types in the calvaria such as mesenchymal cells and  
fibroblasts responded to it stimulation. Worthy of note is that the concentration of 10 
ng/ml may be too low to maintain physiological adequacy as 1-10 ng/ul has been 
reported to induce bone formation and maturation in mice study (Nakamura et al., 
2005). The up-regulation of early osteocyte genes in the whole calvaria model here 
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corroborates with the data from the cell line and primary osteoblasts, strongly 
supporting a role for FGF-2 in the stimulation of E11 expression in normal 
physiological conditions.     
Fluorescence microscopy also disclosed altered E11 expression and localisation 
within the differentiating osteoblasts.  E11 was found to be concentrated at the base 
of the dendritic spikes of the osteocytes after 24-72 h of FGF-2 treatment and it is likely 
that this redistribution of E11 within the cell is necessary for the transformation of the 
osteoblast from a cuboidal shape to the osteocytic phenotype characterised by a 
stellate-like cell with long dendritic processes (Zhang et al., 2006). The presence of 
more E11 in the cytoplasm than the plasma membrane projections of control cells 
suggests that FGF-2 not only stimulates up-regulation of E11, but also facilitates the 
translocation of the E11 towards the cell membrane. This ability of FGF-2 to alter 
subcellular protein distribution is supported by a previous finding in mesenchymal 
stem cells (MSCs), in relation to the expression  of Twist and Spry4 proteins from peri-
nuclear to nucleus as regards Twist,  but Spry4 was translocated to the cytoplasmic 
surface of the plasma membrane (Lai et al., 2011). While fluorescence microscopy 
revealed increase in length and number of dendrites, this was not readily appreciated 
by phase contrast microscopy, a feature that may be associated with higher cell 
density and low colour resolution. Further evaluation with quantification tools like 
Imaris software should be done to ascertain if this increased dendricity in the FGF-2 
treated cells is of a significant size compared to control cultures.  
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The intracellular signalling mechanisms by which FGF-2 promotes E11 cytoplasmic 
redistribution and dendrite formation is likely to involve interactions with the cell 
cytoskeleton. Cytoskeletal actin reorganisation is associated with aiding cell 
movement and serves as a sensory cell membrane projection (Lamouille et al., 2014). 
The use of phalloidin staining to detect F-actin, confirmed that this microfilament, is 
an abundant member of the osteoblast cytoskeleton and is involved in FGF-2 
mediated cell shape changes.  Further studies are warranted, however to investigate 
if the distribution of other cytoskeletal proteins such as microtubules and 
intermediate filaments are also modified by FGF-2 treatment (Fletcher and Mullins, 
2010). The F-actin filaments concentrated at the dendritic spikes may serve as a 
sensory function. This view is supported by published work where the dendrites 
served as mechanoreceptors in osteocytes during a loading experiment (Zhang et al., 
2006). Some actin-rich cell projections reported include filopodia, lamelliopodia and 
invadopodia (Ridley, 2011, McNiven, 2013).  The observed E11 immunofluorescence 
localisation at osteocyte dendritic spikes has been reported previously in MLO-Y4 
osteocyte-like cells and primary osteocytes isolated from long bones (Stern et al., 
2012).  
Here the utilisation of E11 siRNA to firstly successfully knock down E11 expression 
in MC3T3 cells, and secondly to examine the effects of FGF-2 on osteoblast to 
osteocyte transition in the absence of E11. The resultant data revealed that the E11 
siRNA cells had fewer and shorter dendrites after treatment with FGF-2. These data 
when combined with the immunofluoresence and phalloidin data support the 
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growing model of evidence that E11 is very important in the acquisition of the 
dendritic morphology of osteocytes though actin, thus very suggestive that E11 plays 
a crucial role in the early events of osteocytogenesis (Zhang et al., 2006). A notable 
finding with the E11 siRNA knockdown was the ability of FGF-2 to still upregulate 
Phex and Dmp1 expression. This suggests that the effects of FGF-2 on osteoblasts are 
not all mediated via E11 expression. 
The in vitro studies herein have shown FGF-2 promotes E11 expression in osteoblast 
like-cell line (MC3T3), murine primary osteoblasts and calvaria.  It was therefore quite 
surprising to observe that E11 and sclerostin protein expression by osteocytes was 
similar in Sections of bone (cortical, trabecular and subchondral) from Fgf-2 deficient 
and WT mice. This observation differs from published data that reported the down-
regulation of E11 in these Fgf-2 KO mice chondrocytes as assessed by mRNA 
quantification (Chong et al., 2013). This difference in E11 expression may be due to 
different tissue types or the effect of surgery (DMM) stress in the earlier report while 
the tissue used in this study were from out on naïve mice.  Additionally, the age of 
the mice studied may have had a bearing on the E11 expression data. Young mice ( 6 
weeks-old) were used in this study, whereas a study with adult mice revealed skeletal 
abnormalities in the bone of Fgf-2 deficient mice including abnormal osteoblast 
differentiation and bone volume loss associated with decreased bone formation and 
mineralization (Montero et al., 2000, Fei et al., 2011). This suggests that the loss of 
FGF-2 signalling was not compensated for in older mice by other members of the FGF 
family of polypeptides, as redundancy between them has been previously reported 
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(Kan et al., 1999, Behr et al., 2010). In contrast, another study has shown no obvious 
skeletal developmental abnormality in Fgf-2 KO adult mice, a result attributed to 
effect of redundancy in the FGF family (Ortega et al., 1998, Su et al., 2014).  
The similar E11 and sclerostin protein expression by osteocytes from Fgf-2 deficient 
and WT mice maybe a consequence of the significantly increased cell body volume 
observed in Fgf-2 KO osteocytes as revealed by phalloidin staining. Indeed FGF-2 has 
been reported to decrease chondrocyte hypertrophy in a murine metatarsal organ 
culture model and as such, may play a similar role in the formation of the osteocyte 
(Mancilla et al., 1998). Also the phalloidin staining revealed a significant decrease in 
average dendrite length in Fgf-2 KO mice compared to WT mice; a phenotype that 
has been previously reported in bone specific E11 conditional knockout mice (Staines 
et al., 2017). This therefore suggests that lack of FGF-2 in vivo results in dysregulated 
osteocytogenesis.   
In conclusion, in this Chapter, has shown that FGF-2 promotes E11 expression and 
redistribution within the differentiating osteoblast (Fig. 3.21), but further studies are 
required to show the signalling mechanism underlying this FGF-2 induced increased 


























Fig. 3.21 Schematic of Chapter 3 results 
In this chapter, I have revealed that FGF-2 increases E11 expression and this 
influences the F-actin cytoskeleton to promote osteocyte dendrite formation.   
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In Chapter 3 it was revealed that FGF-2 stimulates E11 mRNA expression in MC3T3 
osteoblast-like cells, primary osteoblasts and whole calvaria. This increased E11 
expression was associated with increased expression of osteocyte marker genes (Phex 
and Dmp1), downregulation of osteoblast marker genes (Col1a1, Bglap and Alpl), 
promotion of E11 protein synthesis and the acquisition of the osteocytic dendritic 
morphology. To better understand the mechanistic role of FGF-2 in mediating 
osteocytogenesis, it is necessary to understand the signalling events that are up- and 
down-stream of raised E11 expression in response to FGF-2. 
The FGF-2 signalling cascade is activated after the ligand FGF-2 binds to the 
appropriate FGF receptor (FGFR), a Receptor Tyrosine Kinase (RTK), for which there 
are four well documented different types (FGFR 1-4). After FGF induced dimerisation 
of the FGFR, upstream molecules such as the adaptor proteins phospholipase C-ɣ 
(PLC-ɣ), and FGF receptor substrate 2 (FRS-2), are phosphorylated (see Fig. 1.7) 
(Turner and Grose, 2010). The PLC-ɣ downstream cascade involves hydrolysis of 
phosphatidylinositol-4,5-diphosphate to inositol-1,4,5-triphophate and 
diacylglycerol; and subsequent activation of protein kinase C (PKC) by 
diacylyglycerol (Bottcher and Niehrs, 2005). FGF-2 activation of PKC is involved in 
the upregulation of N-cadherin expression, differentiation, early apoptosis and 
sodium-dependent phosphate transport in human and murine osteoblasts (Suzuki et 
al., 2000, Debiais et al., 2001, Marie et al., 2002).   
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FRS-2 phosphorylation is central to a series of signalling complexes that involve Shp2, 
Grb2, GAB1, Ras (Jackson et al., 2006), which together promote various downstream 
signalling pathways including mitogen activated protein kinase (MAPK), 
signal transducer and activator of transcription (STAT), phosphatidylinositol 3-
kinase/Protein Kinase B (PI3K/Akt), and canonical WNT (Kevin and Stuart, 1997, Yao 
et al., 2015). The Ras/MAPK is the major signalling pathway activated upon FGFR 
dimerisation (Thisse and Thisse, 2005). There is evidence that while its effects can be 
dose dependent, it can also be stage dependent following activation of a specific 
receptor, even though promiscuity has been reported amongst the FGFRs in the 
mature skeleton (Jackson et al., 2006, Soltanoff et al., 2009). 
During the FGF signalling cascade, MAPK family members phosphorylate nuclear 
transcription factors such as E26 transformation-specific (Ets), activator protein 1 (AP-
1), and Activating transcription factor/cAMP response element-binding proteins for 
appropriate gene regulation (Dailey et al., 2005, Thisse and Thisse, 2005, Marie, 2012). 
The members of the MAPK family include ERK1/2, p38 MAPK and JNK (Matsuguchi 
et al., 2009). There is a fourth member of the family referred to as ERK5 (Chang and 
Karin, 2001).  The activation of this MAPK family of molecules is associated with cell 
proliferation, cell survival and protection from apoptosis, differentiation and cell 
cycle arrest (Kevin and Stuart, 1997, Matsuguchi et al., 2009).  
Whilst the role of these downstream signalling pathways in the proliferation and 
differentiation of some cells have been documented, their role in mediating FGF-2 
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driven osteocytogenesis though increased E11 expression  is largely unknown. 
Similarly, how E11 modifies cytoskeletal re-organisation is not clear. Evidence from 
other cell types suggests that E11 associates with the ezrin, radixin and meosin (ERM) 
family of proteins to induce cytoskeletal re-organisation via activation of the small 
GTPase RhoA (Martín-Villar et al., 2006). However whether FGF-2 mediates this 
process is unclear. Therefore, the aim of this Chapter was to decipher the signalling 
molecules and the nature of their actions associated with FGF-2 mediated 
osteocytogenesis.  
4.2 Hypothesis 
FGF-2 regulates E11 expression principally though MAPKs signalling pathways and 
influences cytoskeletal re-organisation though ERM. 
4.3 Aims 
I Decipher the intracellular signalling molecules activated in MC3T3 osteoblast-
like cells by FGF-2 treatment. 
II Determine the importance of these signalling molecules for the promotion of 
E11 expression after FGF-2 stimulation of MC3T3 
III Examine the role of ERM and the small GTPase RhoA in FGF-2 mediated 
osteocytogenesis. 
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4.4 Materials and Methods 
4.4.1 MC3T3 osteoblast-like cells 
As outlined in Section 2.2.1, MC3T3 cells were cultured at a density of 6 x 104 cells/cm2 
in a humidified atmosphere (37°C, 5% CO2) for up to 15 days. When confluent, cells 
were supplemented with FGF-2 at a concentration of 10 ng/ml, or 0.1% BSA as 
negative control. The culture medium was changed every 2-3 days.  
4.4.2 Signalling inhibitors 
MC3T3 cells were incubated for with appropriate concentrations (specific details in 
results) of the MEK inhibitors, PD98059 (Millipore, Hertfordshire, UK) and U0126 
(InvivoGen, Toulouse, France); PI3K inhibitor, LY294002 (InvivoGen, Toulouse, 
France); p38 MAPK inhibitor, SB203580 (Cell Guidance System, UK); and FGFR1/2/3 
inhibitor, AZD4547 (Stratech Scientific Ltd, Suffolk, UK). These inhibitors have been 
reported to be selective for these molecules (Hotokezaka et al., 2002, Macrae et al., 
2007, Choi et al., 2008, Shimada et al., 2016). Control cultures were incubated with the 
inhibitor vehicle (0.1% DMSO) only. After a pre-incubation with the inhibitors for 1 h 
except AZD4547 which was 3 h, the cells were subsequently treated with FGF-2 at 10 
ng/ml concentration, or 0.1% BSA. These experiments were carried out in triplicates 
and three independent experiments unless otherwise stated.  
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4.4.3 RNA analysis of MC3T3 cells 
RNA was isolated from MC3T3 cells at specific time points using a Qiagen RNeasy 
kit according to the manufacturer’s instructions and cDNA was prepared (Section 
2.4.1). For qPCR analysis, cDNA was used at 5 ng/ul, as detailed in Section 2.4.5. 
Results were normalised to the Atp5b housekeeping gene and the relative gene 
expression  level was calculated using the ΔΔCt method (Livak and Schmittgen, 
2001). Primers used are detailed in Appendix I, Table 1. The housekeeping gene 
Atp5b was stable  
4.4.4 Protein extraction from MC3T3 cells and western blotting 
At defined time points, protein was extracted from MC3T3 cells in RIPA buffer as 
detailed in Section 2.5.1. Protein samples were quantified (Section 2.5.1) and 
subsequently were used for western blot analysis (Section 2.5.3). Protein expression 
was determined using appropriate primary and HP-linked secondary antibodies 
(Appendix, Tables 2 & 3). Antibody labelling was visualised using ECL detection. 
Equal protein loading was confirmed by probing the membrane with mouse 
monoclonal HP-labelled anti-β actin antibody (1:70000). Densitometry analysis of 
protein was performed using Image J (https://imagej.nih.gov/ij/) (Baldari et al., 2015). 
4.4.5  RhoA activity assay  
MC3T3 cell monolayers were scraped in a G-LISA lysis buffer supplied with the 
GLISA assay kit (Cytoskeleton, Denver, USA), after 4, 6, 24 and 48 h culture with FGF-
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2 (Section 2.3). Lysates were immunoblotted for E11 (Section 2.5) to confirm FGF-2 
stimulation of E11. Subsequently, using a G-LISA assay which precisely identifies 
active GTP-bound RhoA, the quantification of RhoA activation was carried out by 
luminometry and expressed in relative light units (RLU) as per the manufacturer’s 
instructions (Staines et al., 2016).   
4.5. Results 
4.5.1  Evaluation of FGFR expression by MC3T3 cells following FGF-2 
stimulation.  
To undertake receptor profiling in MC3T3 cells following FGF-2 stimulation, mRNA 
from treated and control cultures were analysed by RT-qPCR at 0.25, 4 and 24 h after 
FGF-2 stimulation. The results revealed no significant change in Fgfr1 expression at 
all-time points studied (Fig. 4.1A). However, the expression of Fgfr2 and Fgfr3 were 
both similarly affected by FGF-2 treatment, with a decrease in their expression noted 
after 4 and 24 h stimulation (Fig. 4.1B &C). Fgfr4 was not found to be expressed by 
MC3T3 cells using several primer pairs from the published literature and primer 
banks. The expression  levels of Fgfr1 were however 12-fold higher over a 24 h time 
period, while the expression  levels of Fgfr2 and Fgfr3 presented a significant decrease 
especially in the treated cultures over same time period. Therefore, one can speculate 
on a more prominent involvement of FGFR1 in mediating the FGF-2 mediated 
transition from osteoblast to osteocyte.  
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Figure 4.1 Temporal Fgfr gene expression of MC3T3 cells cultured with FGF-2 for 
15 min, 4 h and 24 h.  
RT-qPCR assessed expression of (A) Fgfr1 (B) Fgfr2 (C) Fgfr3 after FGF-2 stimulation. 
After several attempts with different Fgfr4 primer sequences obtained from primer 
banks and published papers no amplified product was obtained suggesting that 
MC3T3 cells do not express Fgfr4. Data are presented as mean ± S.E.M for n=3 
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4.5.2.  Identification of the downstream intracellular signalling pathways driving 
FGF-2 stimulation of E11 expression in MC3T3 osteoblast-like cell 
FGF-2 stimulation resulted in increased phosphorylated ERK1/2 (ERK1/2), Akt and 
p38 MAPK when compared to BSA treated control cells (Fig. 4.2A). Densitometry 
quantification revealed a significant increase in phosphorylated ERK1/2 (P<0.001, Fig. 
4.2B); p38 MAPK (P<0.05, Fig. 4.2C); and Akt (P<0.01. Fig 4.2D) in FGF-2 treated 
samples compared to BSA controls. No significant increase in JNK activity was seen 
in samples treated with FGF-2 (Fig. 4.2A & E).  
4.5.3.  Temporal effects of FGF-2 on ERK1/2 activation in MC3T3 cells  
The duration and intensity of ERK1/2 signalling can be used to evaluate if a growth 
factor is driving cellular proliferation or differentiation (Murphy et al., 2003, Chen et 
al., 2005, Pellegrino and Stork, 2006). In this experiment, ERK1/2 signalling was 
examined after treating cells with FGF-2 for 5 min, 15 min, 30 min , 1 h, 4 h, 8h, 24 h, 
and 48 h. Cells treated with 1% BSA for the same duration served as a negative 
control. Western blotting showed clear and sustained activation of phosphorylated 
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Figure 4.2 Investigating the downstream signalling pathways involved in FGF-2 
stimulation of E11 expression in MC3T3 cells. 
Western blotting analysis of MC3T3 cells for phosphorylated and total ERK1/2, Akt, 
p38 MAPK, and JNK (A). Densitometry analysis of Western blotting revealed 
significant upregulation of (B) activated ERK1/2, (C) Akt, and (D) p38 MAPK in 
MC3T3 cells treated with FGF-2 when compared to control cells. There was no 
significant increase in (E) JNK expression. Samples were normalised to β-actin for 
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Figure 4.3 ERK1/2 signalling in MC3T3 cells stimulated  with FGF-2 for variable 
amounts of time  
Western blotting analysis of MC3T3 cells for phosphorylated and total ERK1/2, in 
MC3T3 cells treated with FGF-2 when compared to control cells. Note the increase in 
phosphorylated ERK1/2 in the treated cells at all-time points studied. Total ERK1/2 
and β-actin were similar at all-time points and treatments suggesting consistent 
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4.5.4.  Investigating the effect of ERK1/2 inhibition on the promotion of E11 
protein expression by FGF-2 in MC3T3 cells  
From the previous study (Section 4.5.1), ERK1/2 was identified as the signalling 
molecule that was most highly activated by FGF-2 suggesting that its activation may 
be central to FGF-2’s ability to stimulate E11 expression. Therefore, the effect of 
inhibiting ERK1/2 phosphorylation on E11 expression  was carried out using PD98059 
a highly selective inhibitor of MEK, which is an upstream activating kinase of ERK1/2 
(Kevin and Stuart, 1997). Consistent with previous data (Fig 4.2), FGF-2 stimulation 
for 15 min promoted ERK1/2 activation (P<0.001, Fig. 4.4A & B), and subsequently 
increased E11 mRNA/protein expression after both 4 and 24 hours (P<0.001, Fig. 4.4C-
E). However, western blotting also revealed that 1 h pre-incubation with the inhibitor 
PD98059 (10 uM) a concentration chosen from previous studies (Macrae et al., 2007), 
it did not reduce ERK1/2 activation in the presence of FGF-2 and the stimulation of 
E11 mRNA/protein expression  by FGF-2 was not consistently reduced by PD98059 
treatment (Fig. 4.4A-E). This suggests that the effect of the inhibitor may be time 
dependent as the inhibition of E11 mRNA expression seen at 4 h were abolished after 
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Fig. 4.4. Effect of PD98059 (10 uM) inhibition on ERK1/2 signalling and E11 gene 
expression  on MC3T3 cells stimulated with FGF-2.   
Western blots result for (A), ERK1/2 expression after 15 min of FGF-2 stimulation; and 
(B), densitometry analysis showing the significant upregulation of ERK1/2. RT-qPCR 
analysis of E11 expression from cells stimulated with FGF-2 for (C) 4 h, and (D) 24 h 
in the presence or absence of the inhibitor PD98059. (E), western blots for E11 protein 
expression. Samples were normalised to Atp5b for RT-qPCR. β-actin was used for 
western blotting loading control. Data are represented as mean ± S.E.M for n=3. 
**p<0.01; ***p<0.001; ns = not significant.  
β-actin 
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In light of this result, an increased concentration of PD98059 (25 uM) was tried in an 
attempt to confirm the importance of ERK1/2 activation to mediate FGF-2’s ability to 
enhance E11 expression. However, the incubation for 1 h with PD98059 (25 uM) did 
not reduce FGF-2’s ability to enhance ERK1/2 activation and E11 protein expression                     
(Figs. 4.5A -C).   
4.5.5  Examining the effects of an alternative MEK inhibitor (U0126) on E11 
expression  in MC3T3 cells 
From the previous studies, the MEK inhibitor PD98509 did not significantly reduce 
ERK1/2 phosphorylation and therefore U0126 another commonly used MEK inhibitor 
was used in further studies (Hotokezaka et al., 2002, Macrae et al., 2007). Increasing 
concentrations of U0126 were pre-incubated with MC3T3 cells for 1 h, after which the 
cells were treated with FGF-2 or BSA for 0.25, 4 and 24 h. Consistent with previous 
data (Figs 4.4A & 4.5A), FGF-2 stimulated a significant increase in ERK1/2 
phosphorylation after 15 min (P<0.001, Figs. 4.6A & B), and E11 gene and protein 
expression  after 4 h (P<0.01, Figs. 4.6C & E) and 24 h (P<0.01, Fig. 4.6D & E) treatment. 
U0126 at 10 uM however did not blunt ERK1/2 activation (Figs. 4.6A & B) or alter E11 
expression (Figs 4.6C-E) and therefore further studies using a higher concentration of 
U0126 (25 uM) were warranted.  This was the highest concentration tested as off-
target effects and toxicity have been reported in studies employing higher 
concentrations of U0126 (Dokladda et al., 2005, Wauson et al., 2013). 
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Figure 4.5 Effect of PD98059 (25 uM) on FGF-2 stimulation of ERK1/2 activation and 
E11 gene and protein expression in MC3T3 cells. 
Western blots result for (A), ERK1/2 expression; and (B), densitometry analysis of gel 
showing the stimulation of ERK1/2 phosphorylation in the presence or absence of 
PD98059. (C), Western blot analysis of E11 protein expression. Samples were 
normalised to β-actin in western blots for loading control. Data are represented as 
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Figure 4.6 Effect of U0126 (10 uM) on FGF-2 stimulation of ERK1/2 phosphorylation 
and E11 gene expression and protein expression in MC3T3 cells. 
Western blots result for (A), ERK1/2 expression ; and (B), densitometry analysis 
showing the significant upregulation of ERK1/2 phosphorylation by FGF-2 in the 
presence or absence of U0126 RT-qPCR and Western analysis of E11 expression  by 
cells stimulated with FGF-2 for (C,E) 4 h, and (D,E) 24 h in the presence or absence of 
the inhibitor. Samples were normalised to Atp5b in RT-qPCR, while in western blots, 
β-actin was used for loading control.   Data are represented as mean ± S.E.M for n=3. 
*p<0.05;**p<0.01; ***p<0.001; ns = not significant.  
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At this higher inhibitor concentration, U0126 did partially blunt FGF-2s ability to 
phosphorylate ERK1/2 (P<0.001) but despite this the resultant ERK1/2 activation 
remained significantly higher than control cells (P<0.001, Figs. 4.7A & B).  The 
stimulation of E11 gene and protein expression by FGF-2 was unaffected by 25 um 
U0126 (Figs 4.7C-E). 
4.5.6  Investigating the effects of U0126 (25 uM) ERK1/2 inhibitor on p38 MAPK 
and Akt signalling 
Due to the sustained promotion of E11 expression even when ERK1/2 
phosphorylation was slightly inhibited (Figs 4.7A & B) by the ERK1/2 inhibitor U0126 
(25 um), it is possible that other compensatory signalling pathways are activated to 
overcome this reduction in ERK1/2 activation.  As reported earlier, FGF-2 also 
promoted p38 MAPK and Akt phosphorylation in MC3T3 cells (Section4.5.2) and 
therefore it was of interest to note if the addition of U0126 could alter FGF-2 effect on 
these signalling molecules. 
 FGF-2 stimulated p38 MAPK phosphorylation which is in agreement with previous 
results (Fig. 4.2D) but this increased phosphorylation was not influenced by the pre-
treatment with U0126 (Figs 4.8A & B).  FGF-2 also increased Akt phosphorylation 
which is in agreement with previous experiments (Fig.4.2C), however unlike p38 
MAPK the addition of U0126 resulted in an increase in Akt activation by FGF-2 (Fig. 
4.8 C & D)  
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Figure 4.7 Effect of U0126 (25 uM) on FGF-2 stimulation of ERK1/2 phosphorylation 
and E11 gene and protein expression  in MC3T3 cells. 
Western blots result for (A), active ERK1/2; and (B), densitometry analysis showing 
the significant upregulation of ERK1/2 phosphorylation by FGF-2 in the presence or 
absence of U0126.   RT-qPCR and Western blot analysis of E11 expression by cells 
stimulated with FGF-2 for 4 h, and 24 h (C - E) in the presence or absence of the 
inhibitor. Samples were normalised to Atp5b in RT-qPCR, while in western blots, β-
actin was used for loading control. Data are represented as mean ± S.E.M for n=3. 
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Figure 4.8 Effect of U0126 (25 uM) on p38 MAPK and Akt phosphorylation after 
FGF-2 stimulation in MC3T3 
Western blot showing p38 MAPK phosphorylation in the presence and absence of 
FGF-2 and U0126 (A), and densitometry analysis showing its significant increase in 
the FGF-2 treated cultures in the presence of inhibitor U0126 (B). Western blot 
showing FGF-2 driven increased P-Akt expression in the presence of the U0126 
inhibitor (C), which was significantly upregulated as assessed by densitometry 
analysis (D). Samples were normalised to β-actin for loading control. Data are 
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4.5.7  Investigating the combined effects of U0126 (25 uM) ERK1/2 inhibitor and 
LY294002 Akt inhibitor on E11 expression  
As a result of the above study suggesting a possible Akt signalling compensation 
mechanism following ERK1/2 inhibition the next approach was to pre-treat cells with 
both LY294002 (10 uM) and U0126 (25 uM) to potentially inhibit Akt and ERK1/2 
phosphorylation, respectively.  The effects on ERK1/2 and Akt phosphorylation and 
E11 expression would then be determined.  Prior to this, however, a range of 
LY294002 concentrations at 1 h incubation were tested to determine the optimum 
inhibitor concentration for these proposed experiments. All LY294002 concentrations 
tested (10 - 100 uM) resulted in the complete inhibition of Akt activation (Fig. 4.9). 
From this result, 10 uM was chosen as the optimum concentration, as it was the lowest 
inhibitor concentration to get maximum inhibition of Akt phosphorylation and 
thereby reducing the potential toxic off target effects on the cells. Thereafter the cells 
were subjected to a 1 h pre-incubation with the inhibitors, followed by treatment with 
FGF-2 (or 0.1% BSA for control cultures) for 15 min, 4 and 24 h.  
After 15 min of FGF-2 stimulation, phosphorylated ERK1/2 levels were significantly 
increased from control levels but were not influenced by the presence of both U0126 
and LY294002 (Figs. 4.10A, B). FGF-2 caused a small but non-significant increase in 
Akt phosphorylation and whilst the addition of U0126 and LY294002 caused a 
reduction (non-significant) in basal Akt activation levels, the effect of both inhibitors 
together resulted in increased Akt activation in response to FGF-2 (P<0.001).  This 
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response was also higher than the equivalent Akt activation levels seen with FGF-2 
in the absence of both inhibitors (P<0.05; Figs. 4.10A& C).   E11 expression in response 
to FGF-2 at the gene and protein level was relatively unaffected by the addition of 







Figure 4.9 Effect of various concentrations of the inhibitor LY294002 on 
phosphorylated Akt expression.  
Western blotting for p-Akt and total Akt in MC3T3 cells treated with increasing 
concentrations of the Akt inhibitor LY294002 for 15 min. Note that all concentrations 
used were effective in inhibiting Akt activation. Samples were normalised to β-actin 
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(Previous page) Figure 4.10 Effect of both U0126 and LY294002 on FGF-2 induced 
phosphorylation of ERK1/2, Akt, and E11 gene and protein expression in MC3T3 
cells.  
FGF-2 stimulated both ERK1/2 (A & B) and Akt (A & C) phosphorylation.  ERK1/2 
activation by FGF-2 was not influenced by the presence of both U0126 and LY294002 
(B) whereas Akt activation was increased when both U0126 and LY294002 were 
present (C).  Gene (D & E) and protein (F) expression of E11 was not influenced by 
the presence of both U0126 and LY294002.  Samples were normalised to β-actin for 
loading control. Data are represented as mean ± S.E.M for n=3. *p<0.05; ***p<0.001; ns 
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4.5.8 Examination of the possible cross-talk between ERK1/2 and Akt activation 
during FGF-2 stimulated E11 expression and MC3T3 differentiation  
As the stimulation of E11 expression by FGF-2 was maintained despite with the 
presence of both U0126 (25 uM) and LY294004 (10 uM) (Figs. 4.10D, E & F); the 
singular effect of LY294002 (10 uM) was investigated for the existence of possible 
cross-talk between phosphorylated ERK1/2 and Akt molecules after FGF-2 
stimulation. This was important as earlier results (see Figs. 4.8C & D) revealed that 
phosphorylated Akt was significantly upregulated in the presence of U0126 (25 uM). 
After a 1 h pre-incubation in LY294002 (10 uM), the cells were stimulated with FGF-2 
for 15 min, 4 and 24 h. After 15 min in the presence of the inhibitor, FGF-2 was not, as 
expected, able to promote the phosphorylation of Akt as observed in the cultures with 
FGF-2 alone (P<0.001; Figs. 4.11A & B). In contrast, LY294002 (10 uM) was unable to 
stop the activation of ERK1/2 by FGF-2 (Figs. 4.11A & C). E11 expression  at the gene 
and protein level were increased by FGF-2 after 4 and 24 h, which was unaffected in 
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(Previous page) Figure 4.11 Examination of the cross-talk between ERK1/2 and 
Akt activation during FGF-2 stimulated E11 expression in MC3T3 cells.  
Western blot result disclosing the effect of the PI3K inhibitor LY294002 (10 uM) on 
FGF-2 stimulation of Akt and ERK1/2 phosphorylation (A). Densitometry showed 
that in the presence of the inhibitor, FGF-2 did not upregulate P-Akt activation (B) 
but there was no effect of the inhibitor on P-ERK1/2 activation by FGF-2 (C). RT-qPCR 
and Western blot analysis of E11 expression from cells stimulated with FGF-2 were 
unaffected by the presence of LY294002 (D-F). Samples were normalised to Atp5b in 
RT-qPCR and β-actin served as a loading control in western blot. Data are represented 
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4.5.9.  Investigating the effect of p38 MAPK inhibition on E11 protein expression 
in MC3T3 cells  
Having determined that E11 expression was still stimulated by FGF-2 in the presence 
of ERK1/2 and Akt phosphorylation inhibitors (Section 4.5.9), the next study was 
designed to determine whether inhibition of p38 MAPK phosphorylation (one of the 
MAPKs upregulated by FGF-2; Section4.5.2) blunted FGF-2s ability to promote E11 
expression. The compound SB203580 is a known p38 MAPK inhibitor (Jarnicki et al., 
2008, Ferreiro et al., 2010). This inhibitor SB203580 at 10 uM for 1 h pre-incubation 
(Lali et al., 2000), was used to ases the effect of p38 MAPK signalling on E11 
expression  in both treated and control cells. E11 expression at the gene and protein 
level was increased by FGF-2 after 4 and 24 h but expression levels were unaffected 
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Figure 4.12 Effect of SB203580 (10 uM) on FGF-2 induced E11 expression in MC3T3 
cells 
RT-qPCR and Western blot analysis of E11 expression by MC3T3 cells stimulated 
with FGF-2. Expression was unaffected by the presence of SB203580 at 10 uM (A-C). 
Samples were normalised to Atp5b in RT-qPCR, and β-actin served as a loading 
control in western blot. Data are represented as mean ± S.E.M for n=3. *p<0.5; **p<0.01; 
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4.5.10.  Effect of FGF receptor inhibition on FGF-2 mediated ERK1/2 activation and 
E11 expression in MC3T3 cells.  
Having previously detailed the expression of Fgfr1/2/3 in MC3T3 cells, the effect of 
inhibiting FGF function on FGF-2’s ability to stimulate ERK1/2 activation and E11 
expression was next studied. AZD4547 (0-1 uM), a recognised FGFR1/2/3 inhibitor 
(Yao et al., 2015, Zhang et al., 2015, Shimada et al., 2016), was incubated with the cells 
for 3 h prior to treatment with FGF-2 for an additional 15 min to determine the desired 
concentration of AZD4547 for further studies. In these pilot experiments, the read-out 
used was ERK1/2 phosphorylation. The result of the ERK1/2 western blots showed a 
dose response relationship with increasing concentrations of AZD4547, inhibiting 
ERK1/2 activation which was completely inhibited at 1 uM (Fig. 4.13A).  Further 
experiments used this concentration of AZD4547 but also a lower concentration (100 
nM) which was also effective in blocking FGF-2 signalling but would potentially have 
less off-target effects on the cells. 
In a subsequent more long-term experiment (15 min – 24 h), both inhibitor 
concentrations blocked ERK1/2 activation but less effect on inhibiting E11 expression 
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Figure 4.13 Effects of the FGFR1/2/3 inhibitor AZD4547 on the ability of FGF-2 to 
promote ERK1/2 activation and E11 expression in MC3T3 cells.  
Note the dose inhibitory response of AZD4547 on ERK1/2 activation after 15 min FGF-
2 treatment (A).  Both 0.1 uM and 1 uM concentrations of AZD4547 were used to block 
FGF-2 signalling and the effects on ERK1/2 activation (B), and E11 expression  (C), 
were examined over an extended period (15 min – 24 h). Samples were normalised to 
β-actin for loading control. 
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4.5.11  Effect of FGF-2 treatment on activation of RhoA in MC3T3 cells 
To investigate further the mechanism by which FGF-2 is able to drive changes 
towards the acquisition of the osteocytic morphology and increased dendrite 
formation via cytoskeletal re-organisation (as seen previously in Figs. 3.4B & D), the 
ability of FGF-2 to activate the small GTPase RhoA was next investigated. After 4, 6, 
24, and 48 h of FGF-2 treatment, the expression  of the E11 protein was, as expected, 
increased in the treated cultures which was most notable at the 24 h time point (Fig. 
4.14A).  This rise in E11 expression by FGF-2 was not however associated with any 
significant difference in RhoA activation at the time points that FGF-2 promoted E11 
expression (Fig. 4.14B).     
4.5.12  Effect of FGF-2 treatment on activation of ERM in MC3T3 cells 
Having observed no significant differences in the activation of RhoA by FGF-2 a 
further study was carried out to ascertain if FGF-2 was able to influence the activation 
of the ERM family of proteins, which in other cell types can alter cytoskeletal re-
organisation via activation of RhoA.  Consistent with the Rho A data the western 
analysis of ERM phosphorylation showed no differences in phosphorylation of ERM 
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Figure 4.14 Activation of RhoA in FGF-2 treated MC3T3 cultures 
(A) Western blot analysis of E11 expression after treatment of cells with FGF-2 for 4, 
6, 24 and 48 h.  The increase in E11 expression was most obvious after 24 h of FGF-2 
treatment. Samples were normalised to β-actin for loading control. (B), RhoA 
activation levels were similar between the FGF-2 treated and control cultures at all-
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Figure 4.15 Activation of ERM proteins in FGF-2 treated MC3T3 cultures  
Western blot analysis of ERM phosphorylation by FGF-2 treatment for 4, 6, 24 and    
48 h showing no difference in phosphorylated ERM proteins at all-time points 
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The intracellular molecules that mediate FGF-2’s intracellular effects are activated 
upon FGF-2 binding to its RTK receptors - the FGFRs. The downstream signalling 
molecules include ERK1/2, p38 MAPK, Akt and PKC (Turner and Grose, 2010).  In 
this study, activation of the ERK1/2 signalling pathway appeared to be the principal 
pathway activated by FGF-2 in osteoblast-like cells.  This finding of dominant ERK1/2 
signalling is in agreement with an earlier report where FGF-2 was shown to drive the 
upregulation of an osteocyte expression gene Dmp1 in MLO-Y4 osteocyte-like cells 
(Kyono et al., 2012). Phosphorylation of ERK1/2 has also been shown to mediate cell 
proliferation, differentiation, and matrix mineralisation in human osteoblast culture 
(Lai et al., 2001, Marie et al., 2012). These results taken together highlight the 
importance of ERK1/2 signalling in mediating FGF-2s effects in osteoblasts including 
osteocytogenesis.  
ERK1/2 signalling duration and strength are linked to its precise function in 
determining cell fate during growth and development (Murphy et al., 2003, 
Pellegrino and Stork, 2006). Sustained phosphorylated ERK1/2 signalling for 24 h or 
more following treatment with a growth factor is associated with cell differentiation, 
whereas reversal of phosphorylated ERK1/2 to baseline levels after 30 min post-
treatment, which is referred to as transient signalling, is characteristic of a role in 
promoting cell proliferation (Chen et al., 2005, Pellegrino and Stork, 2006). In this 
study, the sustained activation of ERK1/2 by osteoblasts over long time periods (>24 
h) was associated with an up-regulation of osteocyte markers and a down-regulation 
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osteoblast markers, as was shown in Chapter 3, thereby confirming its central role in 
osteoblast terminal differentiation under FGF-2 stimulation. Others have also 
reported the importance of ERK1/2 signalling in osteoblast initiation and commitment 
to the differentiation process (Lai et al., 2001).  
An explanation for the various differentiation and proliferation responses of cells to 
sustained or transient ERK1/2 activation is unclear. However, this may be due to the 
different cell types and growth factors studied, the subcellular localisation of the 
phosphorylated ERK1/2 and the activation of different transcription factors, which 
are reported to serve as duration sensors (Murphy et al., 2002, Murphy et al., 2003, 
Chen et al., 2005, Pellegrino and Stork, 2006). Another explanation may involve the 
induction of various ‘immediate early genes of which E11 will be the prime 
immediate early gene candidate to be induced by FGF-2 for the terminal 
differentiation of osteoblasts to the osteocyte.  
In addition to ERK1/2 activation by FGF-2 in osteoblast-like cells, there was 
significant activation of p38 MAPK and Akt by FGF-2. Activation of p38 MAPK has 
been reported by others to be involved in osteoblast differentiation in an ERK1/2 
independent manner (Hu et al., 2003) whereas Akt activation has been reported to 
stimulate the proliferation of bone marrow derived osteoprogenitor cells, as well as 
osteoblast differentiation in synergy with ERK1/2 pathway (Choi et al., 2008).   
Establishing which specific signalling molecules mediates the increased E11 
expression after FGF-2 stimulation can be achieved by strategies that involve 
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inhibition of the selected signalling pathway. The use of chemical inhibitors in 
pathway elucidation has become popular because  they are commercially available, 
inexpensive,  extensively validated and can be used  in mammalian models  in vivo, 
hence the growing promise of optimising them for therapeutic uses (Alessi et al., 
1995). PD98059 is a known inhibitor of MEK1/2 (Kevin and Stuart, 1997), which is an 
upstream activator to ERK1/2 (Pang et al., 1995). PD98059 treatment of cells to inhibit 
ERK1/2 phosphorylation in this study had little effect on E11 gene or protein 
expression  and this may be due to the inability of PD98059 (at the concentrations 
used in this study) to ablate ERK1/2 activation in the osteoblast-like cells. Indeed, in 
other studies PD98059 has been shown to be ineffective in blocking the activities of 
MEK1/2 which is itself activated by c-Raf (Alessi et al., 1995). Furthermore it has been 
reported in previous studies using NIH3T3 cells that PD98059 only reduced MEK1/2 
activation by 50-80% (Kevin and Stuart, 1997). This disadvantage of using PD98050 
has also been reported with Swiss 3T3 cells, where ERK1/2 was still activated in these 
cells incubated with high concentrations (50 uM) of the inhibitor. Trying higher 
concentration of PD98059 was not considered for this study because apart from 
possible off target effects, it has poor solubility in aqueous media and it may also 
activate c-Raf which lies directly upstream of MEK1/2 (Alessi et al., 1995).  
Due to these disappointing results using PD98059, another MEK1/2 inhibitor, U0126  
(Fukazawa et al., 2002), which has about 100 fold greater affinity for MEK1/2 than 
PD98059, was used to enhance understanding of the role ERK1/2 activation in 
mediating the effects of FGF-2 on E11 expression  (Favata et al., 1998). Similar to the 
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PD98059 experiments, little inhibition of ERK1/2 phosphorylation was observed with 
the concentrations of U0126 used (10 and 25 uM) although at the latter concentration 
the stimulation of ERK1/2 phosphorylation was dampened a little.  This may possibly 
help to explain the lack of effect of U0126 on FGF-2 induced E11 gene and protein 
expression. Despite the significant decrease in ERK1/2 activation by U0126 (25 uM), 
it is likely that the level of activation remained above threshold levels to stimulate 
normal amounts of E11 expression. However, another possibility is that 
compensatory pathways exist to up-regulate E11 expression, since the inhibition of 
ERK1/2, Akt and p38 MAPK had no effect on E11 expression. Cross talk between 
ERK1/2 and other MAPK signalling molecules has been reported e.g. the upregulation 
of p38 MAPK phosphorylation in the presence of U0126 (Hotokezaka et al., 2002). It 
is also possible that the inhibitors used in this study, PD98059 and U0126 may be 
inducing off target effects on cell proliferation and cellular homeostasis (Hotokezaka 
et al., 2002).  Also SB203580 has been shown to induce the upregulation of ERK1/2 at 
high concentrations (Birkenkamp et al., 2000). Therefore, the interpretation of the 
results obtained from the use of these inhibitors should be treated with caution 
(Dokladda et al., 2005, Wauson et al., 2013). In addition, to be noted is the possibility 
of beta actin changing with dendricity during FGF-2 driven osteocytogenesis, but the 
uniform bands of total proteins in these experiments validates the observed changes 
seen after FGF-2 stimulation. 
FGF-2 mediated downstream effects are activated by its attachment to the FGFR 
receptor tyrosine kinase, which in turn induces receptor dimerisation.  In this study, 
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FGF-2 stimulation of E11 expression  by osteoblast-like cells is possibly mediated 
though Fgfr1 because its level of expression  is over ten-fold higher in the 24 h time 
period, while  a significant decrease was seen in the expression  of  Fgfr2/3 in the 
treated cultures. The relative importance of Fgfr1 has been documented to drive 
osteoblast differentiation (Iseki et al., 1999), as a fivefold difference between Fgfr1 
expression  and Fgfr2/3/4 in MC3T3 osteoblast-like cells has been reported (Niger et 
al., 2012). It is of interest to note, however that the expression  levels of Fgfr1 
expression  were not altered in the presence of its ligand whereas prolonged 
incubation with FGF-2 caused a significant decrease in the expression  of Fgfr2/3, a 
feature that is associated with switch from proliferation to differentiation in calvarial 
osteoblasts (Cowan et al., 2003).  The relevance of these observations are unclear for 
FGF-2s ability to stimulate E11 expression , however it has been reported that FGF-2 
treatment of` cells results in an increase in Fgfr1 expression , and down regulation of 
Fgfr2 and Fgfr3 expression  during calvarial suture development, where Fgfr1 
stimulates osteoprogenitor differentiation and suture union, while Fgfr2/3 induces 
proliferation (Teven et al., 2014). Nonetheless, it is important that further 
confirmatory tests like receptor dimerisation activity or cellular localisation of Fgfr1 
be completed to confirm the role of Fgfr1 in this study. 
The importance of the relatively high levels of Fgfr1 expression after 24 h by MC3T3 
osteoblast-like cells, is underscored by published works reporting that FGFR1 
mediates specific stages of osteogenesis and bone mass regulation (Zhang et al., 2014).  
It also induces mature osteoblast to differentiate upon stimulation with FGF-2 a 
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function that is central to driving increased osteocytogenesis (Jacob et al., 2006).  In 
addition, FGFR1  has been shown to be the most important FGF-1 receptor during 
induction of neurite outgrowth of PC12 cells (Lin et al., 1996), a phenotypic switch 
that is key in the adoption of the osteocyte dendritic phenotype.  
It is interesting to note that Fgfr4 was not found to be expressed in these cells despite 
the use of several primer pairs from primer banks, published literature and 
commercial companies. This is consistent with a previous study in which calvaria 
bone has been reported not to express Fgfr4 (Partanen et al., 1991).  
The use of AZD4547 for the inhibition of FGFR kinase has also been well reported 
(Zhang et al., 2012, Gavine et al., 2012, Xie et al., 2013). Its action attenuates the 
activation effects of FGFR1/2/3 on FRS-2 and subsequent down-regulation of the 
downstream signalling pathways such as the MAPKs and PI3K/Akt (Yao et al., 2015, 
Katoh, 2016). The relative level of phosphorylated ERK1/2 expression was employed 
to measure the degree of FGFR activation by FGF-2 after incubation with AZD4547. 
This approach has also been carried out in previous published studies using non-
small-cell lung cancer cells (Marek et al., 2009).  In this study, AZD4547 decreased the 
expression of ERK1/2 activation in a dose dependent manner. This effect has been 
seen in FGFR-expressing colorectal cancer cells (Yao et al., 2015). In this study, the 
inhibitor AZD4547 blunted FGF-2s ability to stimulate ERK1/2 expression, but had 
little effect on blocking E11 protein expression. It may reflect time dependent ability 
of the inhibitor AZD4547 to effectively prevent receptor dimerisation, hence 
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molecules upstream like ERK1/2 were blunted out but more studies should be done, 
as FGF-2 appears to be having little effect on E11 expression.   
One of the functions of the E11 protein in modulating the early events of 
osteocytogenesis includes the acquisition of the osteocyte (dendritic) morphology. 
This feature was detailed in FGF-2 treated MC3T3 cell lines and primary osteoblasts 
in Chapter 3. A potential mechanism underlying this function of E11 protein in 
modifying cell shape is via the up-regulation of RhoA activation (Staines et al., 2016). 
RhoA is associated with regulating the ERM/CD44 complex, which is important in 
plasma membrane shape modification, cell migration and invasiveness (Hirao et al., 
1996, Scholl et al., 1999, Martín-Villar et al., 2006). In this study, FGF-2 treated cells 
showed no RhoA activation. This may be due to the upregulation of other members 
of the Rho family of small GTPases such as Rac1 or Cdc42, which have been reported 
to also serve as molecular linkers during cytoskeletal protein activation and plasma 
membrane modification into structural extension such as filipodia (Nakamura et al., 
2000, Jeon et al., 2010). The lack of activation of RhoA as seen in this study is 
supported by previous published work where E11 induced filipodia-like processes in 
MCF7 carcinoma cells formed despite inactivation of RhoA (Orriss et al., 2014).  
Nevertheless, this result is at variance with reported up-regulation of RhoA activation 
by E11 in MLO-A5 late osteoblast-like cells and MDCK type-II epithelial cells (Martín-
Villar et al., 2006, Staines et al., 2016). This observed difference in the ability of E11 to 
induce cell morphology changes towards including the adoption of cell membrane 
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extensions or processes with or without activation of RhoA may be due to cell type, 
stage of cellular differentiation or even species variation (Martín-Villar et al., 2006).  
Despite the lack of RhoA activation, the data presented in Chapter 3 supports the 
growing body of evidence that E11 is critical for the acquisition of the dendritic 
morphology characteristic of osteocytes (Zhang et al., 2006).   
In addition to the RhoA data, the amount of phosphorylated ERM proteins were 
unaffected by FGF-2 stimulation, which may suggest the existence of another 
pathway to induce cell shape and dendrite formation that is independent of ERM 
proteins (Nakamura et al., 2000).  
In conclusion, the results of this Chapter has indicated that the promotion of the 
osteocyte phenotype by FGF-2 is possibly via Fgfr1 activation and increased E11 
expression (Fig. 4.16). The signalling pathway(s) involved however, remains unclear 
but may involve phosphorylation of signalling molecules such as ERK1/2, Akt and 
p38 MAPK. With this knowledge, further studies will enable the determination of the 
significance of FGF-2/E11 interactions in subchondral bone thickening in the 
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Fig. 4.16 Schematic of Chapter 4 results 
This chapter has revealed that FGF-2 increases E11 expression possibly through ERK1/2 
activation and compensatory Akt signalling, and this influences the actin cytoskeleton to 
promote osteocyte dendrite formation.   
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Osteoarthritis (OA) is a degenerative and painful joint disease, and a worldwide 
healthcare burden in animals and man. OA is a disease of the whole joint and, perhaps 
rightly, research has largely sought to target the articular cartilage (AC) as this tissue 
undergoes severe deterioration (Goldring and Goldring, 2010, Sharma et al., 2013, 
Poulet and Staines, 2016). Subchondral bone (SCB) thickening in OA joints –although 
often considered secondary – is however one of the earliest detectable changes which 
many now consider to be a potential trigger for subsequent AC degeneration and OA 
progression (Li et al., 2013). There remains much speculation regarding the 
mechanism underpinning this modified SCB:AC relationship in OA, with cellular 
cross-talk and modified SCB stiffness proposed to exert a vital role (Goldring and 
Goldring, 2010, Sharma et al., 2013). Indeed, reports of altered SCB mineralisation and 
stiffness in OA have led to proposals that joint loading engenders greater AC 
deformation and OA degeneration (Findlay and Atkins, 2014, Im and Kim, 2014). 
Whilst the role of SCB in OA pathogenesis is unclear, it is undeniable that its modified 
remodelling contributes to sclerosis – a further OA defining feature. Despite this, the 
cellular/molecular mechanisms are not fully understood and therefore current clinical 
strategies remain limited.  
Like cortical and trabecular bone, the SCB contains an abundance of osteocytes which 
are essential to its structure and function. In OA, the osteocytes of the SCB have an 
abnormal morphology, with both fewer and disorganised dendritic processes 
(Jaiprakash et al., 2012). In addition, there are many reports of disrupted expression 
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of the mature osteocyte marker sclerostin in OA SCB (Albisetti et al., 2013, Wu et al., 
2016). This therefore suggests that the osteocyte may play a central role in the 
pathogenesis of the SCB in OA. Furthermore, the dendritic morphology of the 
osteocyte may be essential for maintaining healthy SCB. Published data and data 
reported in this thesis has shown that osteocyte dendrite formation is one of the early 
key events of osteocytogenesis and is associated with the expression of the osteocyte 
early marker gene E11 (Zhang et al., 2006). Increased whole joint E11 expression  has 
been reported in OA mice following surgical destabilisation of the medial meniscus 
(DMM), and in an in vitro cartilage injury assay using RT-qPCR (Burleigh et al., 2012, 
Chong et al., 2013). Despite these observations, the biological importance of altered 
E11 expression in OA has not been progressed further but it may be related to its 
known function in osteocyte biology.  
Various animal models have been established to enable temporal studies on the 
pathogenesis of OA in the joint. The availability of these models help overcome the 
constraint of OA diagnosis and study on human patients, which often present at late 
stages of OA when pain and radiographic features become very apparent (Lorenz and 
Richter, 2006). These models have become an integral part of the armoury in the 
evaluation of either disease modifying therapy or studies towards understanding the 
cellular and molecular mechanisms underlying OA pathogenesis (Goldring and 
Goldring, 2010). The animal species reportedly used in OA studies include mice, rat, 
rabbit, guinea pig, goat, sheep, dog, cat and horses (Radin et al., 1995, Burleigh et al., 
2012, Gregory et al., 2012, McCoy, 2015).  
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DMM, an OA instability model, is one of the most commonly used OA models. DMM 
involves transecting the anterior attachment of the medial meniscus to the tibial 
plateau, releasing a small portion of the medial meniscal anterior horn, hence the OA 
is induced by increased loading on the tibia. While the sham operated control mouse 
undergoes similar surgery the meniscus is not cut; the non-operated mouse control 
undergoes no surgery (Inglis et al., 2008, Botter et al., 2009, Malfait et al., 2010).  This 
model of OA has the advantage of the gradual development over a long time, which 
replicates the human condition. Importantly, it allows the study of OA 
pathophysiology from the early to late stages (Inglis et al., 2008, Botter et al., 2009, Li 
et al., 2012). It also simulates human OA as the mouse develops OA features like SCB 
sclerosis after surgery, joint damage and degeneration long before any evidence of 
pain (Kamekura et al., 2005, Inglis et al., 2008, Malfait et al., 2010). However, there is 
discontent on the presence of SCB thickening observed in both the ipsilateral knee 
(ascribed to the OA process), and the control contralateral knee (ascribed to 
overloading with lamenes) (Loeser et al., 2013, Fang and Beier, 2014). In addition, 
DMM is an invasive procedure, which in itself may be associated with additional 
inflammation and cartilage damage (Fang and Beier, 2014, Miller et al., 2015).  
Previously in this thesis, it was shown that FGF-2 upregulates E11 expression and 
increases osteocyte dendrite formation. Hence, extending my study for clinical 
relevance, this Chapter will help to elucidate the nature of E11 expression in SCB 
osteocytes of OA samples using WT and Fgf-2 KO mice after DMM and sham 
surgeries. In addition, expression of E11 in a number of animal species and human 
OA samples will were also completed for comparative studies.  




E11 protein is differentially expressed in SCB osteocytes in comparative animal and 
human OA samples. The absence of FGF-2 decreases the expression of E11 protein in 
SCB osteocytes of OA samples.  
5.3.  Aims 
I Quantify E11 protein expression in SCB osteocytes of WT mice with DMM 
induced OA.  
II Examine E11 protein expression in SCB osteocytes of Fgf-2 KO mice with 
DMM induced OA samples.  
III  Evaluate E11 protein expression in SCB osteocytes of OA samples from 
human and domestic animals.  
5.4. Materials and methods 
5.4.1 Human and animal samples 
The human SCB samples were obtained from patients undergoing total knee 
replacement of two females and one male aged 63-75 year OA patients. Mr Amish 
Amin (University of Edinburgh) based on clinical and radiographic OA features 
diagnosed OA. Samples are obtained with patient consent and all procedures with 
ethical approval by NHS Lothian in collaboration with Mr. Anish Amin. The 
collection, storage, and subsequent use of human tissues are regulated in Scotland by 
The Human Tissue Act (Scotland) 2006. The study of these tissues was in compliance 
with all necessary UK licenses and ethical approvals.  
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The OA samples from SCB of domestic animals were kindly donated by Dr Dylan 
Clements, while Dr Katherine Staines donated the WT DMM samples. The samples 
were residual tissues collected from pets undergoing surgical for the treatment of 
disease with informed consent (OA samples), or which had died of unrelated disease 
(feline samples, ovine samples and equine samples and healthy canine samples) 
consent for use was obtained from the animal owners, and ethical approval  for their 
collection and use given by the Veterinary Ethical Review Committee of the 
University of Edinburgh (VERC; approval 23/12 (canine), 23/12 (ovine), 7/5/09 (feline). 
The canine and feline samples were from elbow joints, the ovine samples from hip 
joints and the equine samples from the proximal metatarsal joint. In all cases, the 
joints were macroscopically evaluated for signs of disease as OA samples, while the 
healthy joints will be referred to as control in this thesis. The DMM and sham tibias 
of 14 weeks old Fgf-2 KO and WT mice were donated by Prof. Tonia Vincent, were 
sampled 4 weeks post-surgery. 
5.4.2 Toluidine Blue/Fast Green staining of the murine tibias  
Toluidine blue dye is used extensively in cartilage staining as it binds to the 
negatively charged proteoglycans (Appleyard et al., 1999, Schmitz et al., 2010). The    
5 uM thick tibiae paraffin embedded decalcified Sections were first de-waxed in 
xylene and rehydrated though a series of graded alcohols to distilled H2O. They were 
incubated in 0.4% Toluidine Blue dissolved in sodium acetate buffer (see Appendix 
I). After washing in distilled H2O, they were counterstained in 0.02% Fast Green in 
distilled H2O. They were subsequently rinsed in distilled H2O, blot dried and quickly 
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mounted. Images were captured with a Nikon Eclipse Ni microscope (Nikon, UK), 
fitted with Zeis Axiocam 105-colour camera (Carl Zeis, UK). 
5.4.3. E11 and sclerostin protein sequencing alignment  
Species-specific amino acid sequences for E11 and sclerostin were obtained from 
NCBI protein database (https://www.ncbi.nlm.nih.gov/guide/proteins/) while 
Clustal Omega was used to perform alignment and comparison of the species 
sequences under study including mouse, human, sheep, dog, cat, and horse (Sievers 
et al., 2011, McWilliam et al., 2013). The sequences were then uploaded into the online 
Clustal Omega alignment tool hosted on EMBL-EBI website 
(https://www.ebi.ac.uk/Tools/msa/clustalo/) to perform alignment and compute 
sequence similarity/identity between the different species. The level of homology 
between amino acid sequences for two different species was expressed as mean 
percent identity, which was calculated by dividing the degree of identity matching in 
the sequence alignment (pairs of identical letters) by the span of the alignment, where 
gaps are regarded as mismatches (Spalding and Lammers, 2004). 
5.4.4 Immunohistochemical staining of the murine tibias  
Murine tibias of same reference points from DMM and sham groups (Section 2.12.1) 
were immunostained for E11 and sclerostin as described in Section 2.12.2.  
Immunohistochemical staining of 5 um thick tibiae paraffin embedded decalcified 
sections was performed using E11 and sclerostin primary antibodies at (1:500) 
dilution, while secondary antibody was at (1:200) dilution using Vectastain ABC kit 
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as outlined in Section 2.12.2 and Appendix I Table 1. Immunohistochemical labelling 
was visualised using DAB chromogen. For control Sections, goat IgG at the same 
concentrations as primary antibody (1:500) was used instead of the primary 
antibodies. The percentage of positively stained E11 or sclerostin osteocytes was 
calculated (Section 3.4.8). 
5.4.5 Immunohistochemical staining of comparative human and animal studies 
with anti-mouse E11 and sclerostin antibodies.  
Sections of SCB from mouse, human, dog, cat, sheep and horse joints were 
immunostained with anti-mouse E11 and sclerostin antibodies as described in Section 
5.4.1. Quantification was by means of counting sclerostin positively immunostained 
osteocytes across all microscopic fields and expressed as a percentage of the total 
number of osteocytes present.  
5.4.6 Immunohistochemical staining of comparative human and animal studies 
with anti-human E11 antibodies.  
Sections of SCB from mouse, human, dog, cat, sheep and horse joints were first de-
waxed in xylene, and rehydrated though a series of graded alcohols to distilled H2O. 
Antigen unmasking was carried out with 0.1% trypsin in PBS for 30 min  at 37oC using 
a water bath (Cattoretti et al., 1993). Endogenous peroxidase activity was blocked by 
treatment with 0.03% H2O2 in methanol for 30 minutes at RT.  After 3 x 5 min washes 
in PBS the sections were blocked in normal donkey serum buffer (1:5 dilution of the 
appropriate normal serum in PBS) for 20 min at RT. The Sections were then incubated 
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in sheep anti-human E11 primary antibody (1:100 in PBS) at 40C overnight. Sheep IgG 
(1:200 in PBS) was used instead of the primary antibodies as a negative control. 
Unbound primary antibody was removed by 3 x 5 min washes in PBS. The Sections 
were subsequently incubated in donkey anti-sheep secondary antibody (1:200 in PBS) 
at RT for 1 h. They were later washed for 3 x 5 min in PBS. Staining was then 
developed in DAB solution for about 2 minutes. The Sections were rinsed in tap water 
and counterstained with haematoxylin using a Leica Autostainer XL (Leica, Milton 
Keynes, UK). Finally, Sections were dehydrated though graded alcohols, cleared with 
xylene and mounted in DePeX. Images were captured with Nikon Eclipse Ni 
microscope (Nikon, UK), fitted with Zeis Axiocam 105 colour camera (Carl Zeis, UK). 
Quantification triplicates per group was by means of counting E11 positively 
immunostained osteocytes across all microscopic field and expressed as a percentage 
of the total number of osteocytes present as done in Section 3.4.8.  
5.4.7 Immunohistochemical staining of Human OA samples 
Human OA samples were immunostained for E11 protein with anti-human E11 
antibody (Section 5.4.6), and sclerostin protein with anti-mouse sclerostin antibody 
(Section 5.4.4). 
5.4.8. Optimising anti-human E11 antibodies for immunostaining canine SCB 
samples. 
Dog SCB samples were immunostained as described in Section 5.4.4 providing 
encouraging results.  However, for full optimisation a range of antigenic epitope 
retrieval buffers were used. They include EDTA (1 mM at pH of 8.0), Tris/EDTA         
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(10 mM/1m M at pH of 9.0) and citrate buffer (10 mM at pH of 6.0) for 90min at 70oC 
using a water bath. In addition, the concentrations of the primary antibody was 
varied 1:100; 1:50; 1:20; while secondary was varied to include 1:100 and 1:200 
dilutions. 
5.4.9. Measuring SCB thickness in tissue Sections via a histological tool (2D)  
The thickness of the mice SCB was measured using the Fiji program (Schindelin et al., 
2012). Bright field microscopic images of the Sections were sequentially captured with 
a Nikon Eclipse Ni2 microscope (Nikon, UK), fitted with Zeis Axiocam 105 colour 
camera (Carl Zeis, UK), and analysed on Zen Imaging software. Using a Fiji program, 
the images were fused to form a composite picture, while a calibrated rule measured 
SCB length distally from the SCB plate to the dorsal border of the nearest bone 
marrow. This measurement was completed at five points uniformly across the SCB of 











5.5.1 Investigating E11 and sclerostin expression in DMM induced OA samples 
from tibias of WT mice 
The expression of E11 and sclerostin in tibial SCB osteocytes of the DMM and sham 
operated WT mice was assessed by immunostaining. Despite there being an upward 
trend in the percentage of E11 positively stained osteocytes the results revealed the 
absence of a significant difference between sham and DMM groups in both the lateral 
and medial aspects of the tibia, (Figs. 5.1A - F). In addition, the percentage of 
sclerostin positively stained osteocytes were similar in both tibial condyles from the 
two groups (Figs. 5.2A-F).   
5.5.2 Analyses of SCB sclerosis in WT mouse tibias after DMM surgery  
Having observed no differences in the number of E11 and sclerostin positively stained 
osteocytes in the SCB of DMM mouse knee joints, there was a need to investigate the 
development of the SCB sclerotic phenotype to try and explain these unexpected 
results. This becomes imperative as no AC loss was noticed in both sham and DMM 
samples (Fig. 5.3A & B).  2D measurements of SCB thickness in sham and DMM 
samples (Figs. 5.3A & B), showed no overt differences in the thickness of the SCB (Fig. 
5.3C). This lack of SCB sclerosis may therefore explain the unaltered E11 and 
sclerostin expression in this model.  
 








































Figure 5. 1 E11 immunostained WT DMM and SHAM mice tibial subchondral 
bone osteocytes 
Section of WT subchondral bone osteocytes (black arrow) in both SHAM (A & C) 
and DMM (B & D) no difference in E11 immunostaining in both groups was 
shown from quantification of E11 positive osteocytes in both lateral (E), and 
medial (F) sections of the DMM and SHAM groups. Data are presented as mean 
± S.E.M (n=6); ns = not significant. Scale Bar =300 um.   
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Figure 5. 2 Sclerostin immunostained WT DMM and SHAM mice tibial subchondral bone 
osteocytes 
Section of WT subchondral bone osteocytes (black arrow) in both SHAM (A & C) and DMM (B 
& D) showing no difference in sclerostin immunostaining in both groups, as was shown from 
quantification of sclerostin positive osteocytes in both lateral (E), and medial (F) sections of the 
DMM and SHAM groups. Note the positive staining of hypertrophic chondrocytes of the articular 
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C 
Figure 5. 3 Measuring tibial SCB  thickness of WT mice after DMM using 
histological (2D) tool 
Section of WT subchondral bone thickness  (red lines)  measured at 5 points 
distally from the subchondral plate to the dorsal border of the nearest bone 
marrow in both SHAM (A) and DMM (B), showing no difference in between 
them, as was shown from quantification (C). Data are presented as mean ± 
S.E.M (n=3); ns = not significant. Scale Bar = 300 um.   
 Lateral    Lateral 
Chapter 5: Investigating the expression of E11 in OA pathogenesis 
173 
 
5.5.3 E11 and Sclerostin expression in SCB of human tibia OA samples 
The percentage of E11 positive osteocytes in OA and control samples of human tibial 
SCB were quantified. There was no difference in the percentage of E11 positive and 
total osteocytes between the control and OA samples (Figs. 5.4 A –F). Anti-mouse 
sclerostin antibody was used to immunostain human tibial SCB Sections from OA 
and control patients (Figs. 5.5A-D). The percentage sclerostin positive- and total- 
osteocytes showed no difference and were similar in OA and control samples (Figs. 




































Figure 5.4  E11 immunostained OA and control human tibial SCB 
osteocytes 
Section of human tibial SCB osteocytes (black arrow) in both Con (A & C) and OA 
(B & D) samples. Quantification of percentage E11 positive osteocytes and total 
osteocytes indicated no differences between control and OA samples (E & F). Data 
are presented as mean ± S.E.M (n=3). Scale Bar (A & B) =300 um; (C & D) = 150 um. 
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Figure 5.5 Anti-mouse sclerostin immunostained human tibial SCB sections 
from OA and control patients 
Sclerostin localisation to human tibial SCB osteocytes (black arrow) in both Con (A 
& C) and OA (B & D) samples. Quantification of percentage sclerostin positive 
osteocytes and total osteocytes indicated no differences between control and OA 
samples (E & F). Data are presented as mean ± S.E.M (n=3 for OA; n=2 for con). Scale 
Bar (A & B) =300 um; (C & D) = 150 um. 
F 
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5.5.4 E11 and sclerostin comparative protein sequence homology  
As antibodies for dog, cat, horse and sheep E11 and sclerostin are not commercially 
available, E11 and sclerostin protein sequence homology in these species was 
completed using clustal omega programme (Sievers et al., 2011),  as a guide to gauge 
potential cross-reactivity with mouse or human antibody.. The E11 protein of human, 
mouse, dog, horse, sheep and cat showed variable amino (N)-terminal homology, but 
increased homology was found at the carboxyl (C)-terminal (Fig. 5.6). The percent 
identity matrix between all species is shown in Table 5.1. The sclerostin protein of 
human, mouse, dog, horse, sheep and cat showed strongest sequence homology at 
the N terminal (Fig. 5.7). The percent identity matrix between all species is shown in  






























Figure 5.6 E11 protein sequence homology by Clustal Omega programme  
E11 protein sequence homology of man, domestic and lab animals showed 
poor homology at the N-terminal.  Homology was stronger at conserved C-
terminal.  This is illustrated by the relative number of asterix (*) below each 
sequence alignment.  





















Table 5.1 Percent Identity Matrix (E11) - created by Clustal 2.1  
  
  Mouse   Human    Dog       Cat     Horse     Sheep 
     1: Mouse        100.00    47.53    53.70   48.77    47.22    42.76 
     2: Human         47.53   100.00    64.81  57.76    58.39    53.95 
     3: Dog           53.70   64.81   100.00  67.86   61.49    49.68 
     4: Cat        48.77   57.76   67.86   100.00  55.41    41.03 
     5: Horse       47.22   58.39   61.49  55.41   100.00  45.14 
     6: Sheep      42.76  53.95   49.68   41.03  45.14   100.00 
  





















Figure 5.7 Sclerostin protein sequence homology by Clustal Omega programme  
Sclerostin protein sequence homology of man, domestic and lab animals showed well 
conserved N-terminal and poor homology in the C-terminal as was expressed in the 
relative number of asterix (*) below each sequence alignment.  





















Table 5.2 Percent Identity Matrix (Sclerostin) - created by Clustal 2.1  
    
    Mouse    Human    Dog      Horse   Sheep     Cat 
     1: Mouse       100.00     88.15         91.00    65.77     60.87      69.57 
     2: Human      88.15      100.00       95.77     74.17     66.35      74.64 
     3: Dog            91.00       95.77        100.00   74.17     66.35      76.08 
     4: Horse        65.77       74.17         74.17    100.00   55.48      68.71 
     5: Sheep        60.87       66.35         66.35     55.48    100.00    58.94 
     6: Cat           69.57       74.64          76.08    68.71     58.94     100.00 
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5.5.5 Optimisation of antibodies for immunohistochemistry (IHC) protocol in 
domestic animals using anti-mouse and anti-human E11 antibodies 
Taking into account the protein sequence homology data (Section 5.5.4), 
immunostaining with anti-mouse E11 antibodies was carried out on select animals 
including dog, cat, sheep, and horse. The results showed positive E11 staining in 
“positive control” mouse samples (Fig. 5.8A), but no cross reactivity in the Sections 
from the various animals tested (Figs. 5.8C, E & Figs. 5.9A, C, E). The results of anti-
human E11 antibodies showed similar positive E11 immunostaining in human SCB 
osteocytes (Fig. 5.10A), and lack of cross reactivity in most of the other animals (Figs. 
5.10C, E & Figs. 5.11C, E). However, in the canine Sections, which showed the highest 
percent identity homology with human (64.81%, Table 5.1), osteocyte cell bodies (but 
not dendrites) were detected although this was accompanied with strong non-specific 
background staining (Fig. 5.11A). These results were promising, hence the need to 
optimise anti-human E11 antibodies for use in further staining of the canine samples.  
Subsequently, different epitope retrieval buffers were trialled with the anti-human 
E11 antibody on canine samples (Section 5.4.6). However, this revealed that the use 
of these new three buffers did not enhance the identification of E11 in canine SCB 



























 Fig. 5.8. Immunostaining of mouse, sheep and human SCB osteocytes with anti-
mouse E11 antibodies 
Subchondral bone sections of mouse, sheep and human SCB incubated with anti-
mouse E11 antibodies (test) or appropriate IgG control (con); A -test &  B –control 
of mouse knee joints; C -test & D –control of sheep samples; E -test, and F -control 
of human samples. Note, red arrows indicate positive E11 stained osteocytes in the 
mouse test samples whereas black arrows indicate non-stained osteocytes. Scale bar 








































Fig. 5.9. Immunostaining of dog, cat, and horse SCB with anti-mouse E11 antibodies 
Subchondral bone sections of dog, cat and horse reacted with anti-mouse E11 
antibodies; A -test, B -control of dog samples; C -test and D -control of cat samples; E-
test, and F-control of horse samples. Note, black arrows indicate non-stained 









































Fig. 5.10. Immunostaining of human, sheep and mouse SCB with anti-human E11 
antibodies 
Subchondral bone sections of human, sheep and mouse reacted with anti- human 
E11antibodies; A -test & B –control are human samples; C-test & D -control, are 
sheep samples; E -test, and F -control are mouse samples. Note red arrows indicate 
osteocyte positive to anti-human E11 whereas black arrows indicate non-stained 





































Fig. 5.11. Immunostaining of dog, cat and horse SCB with anti-human E11 
antibody 
 Normal subchondral bone sections of dog, cat and horse reacted with anti-human 
E11 antibodies; A -test, B -control are dog samples; C -test and D -control are cat 
samples; E-test, and F-control are horse samples. Note, dog osteocytes look 
positively stained (red arrows), whereas black arrows indicate non-stained 










































Figure 5.12 Optimisation of anti-human E11 immunostaining of canine SCB 
sections using different antigen retrieval buffers. 
Subchondral bone sections of human (A-C), and canine (D-F) immunostained 
with anti-human E11 antibodies after pre-treatment with antigen retrieval buffers 
including citrate buffer (A & D); EDTA (B & E); and TRIS/EDTA (C & F). Note 
red arrows indicate osteocyte positive cells whereas black arrows indicate non-
stained osteocytes. Scale bar = 150 um. 
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5.5.6 E11 expression in canine OA samples using anti-human E11 antibody 
E11 expression in canine tibial SCB osteocytes from OA, and healthy samples that will 
be referred to as control samples was investigated using a anti-human E11 antibody 
after trypsin antigen retrieval. The percentage of E11 positive osteocytes was 
significantly greater (Fig. 513E; P<0.01) in OA canine samples (Figs. 5.13B & D), in 
comparison to non-OA samples (Figs. 5.13A & C).  It also appeared that the dendrites 
radiating from the stained osteocyte bodies were more obvious in the OA samples. 
5.5.7. Optimisation of anti-mouse sclerostin antibody protocol for IHC staining of 
SCB Sections from domestic animals 
The osteocytes within SCB Sections from sheep, dog, cat and horse were also reacted 
with anti-mouse sclerostin antibody to test for potential cross reactivity. As expected, 
positive sclerostin immunostaining was observed in mouse and human SCB samples 
(Figs. 5.14A & C), but no cross reactivity in the other animals tested (Figs. 5.14E & 
Figs 5.15 A, C, E). It is worthy to note that in the horse, there were some osteocytes 


































Figure 5.13 Control and OA canine tibial SCB osteocytes immunostained 
with anti-human E11 antibodies. 
Section of canine tibial SCB showing E11 expression in osteocytes (black arrow) in both 
Con (A & C) and OA (B & D) samples. Quantification of E11 positive osteocytes 
indicated a significantly greater number in the OA samples compared with control 
samples (E). Data are presented as mean ± S.E.M (n=3); **p<0.01. Scale Bar (A & B) =  
300 um; (C & D) = 150 um. 























 Fig. 5.14. Immunostaining of mouse, human and sheep SCB with anti-mouse 
sclerostin antibodies 
Subchondral bone sections of mouse and human all stained with anti-mouse 
sclerostin antibodies; A -test & B –control are mouse samples; C -test & D -control 
are human samples; E -test, and F -control are sheep samples. Note red arrows 
indicate positive osteocyte staining in the mouse and human test samples, while 








































Fig. 5.15. Immunostaining of dog, cat, and horse SCB with anti-mouse sclerostin 
antibodies 
Subchondral bone sections from dog, cat and horse, all reacted with anti-mouse 
sclerostin antibodies; A -test, B -control are dog samples; C -test and D –control are 
cat samples; E-test, and F-control are horse samples. Note black arrows indicating 
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5.5.8 E11 and sclerostin expression in OA (DMM induced) and control samples 
from tibias of  Fgf-2 KO and WT mice 
To extend this project to understand the role of FGF-2 in regulating E11 and sclerostin 
expression during OA pathology, DMM and sham (control) mice from Fgf-2 KO and 
WT samples were investigated. The use of toluidine blue staining showed normal AC 
in the control samples (Figs. 5.16A & B), while the DMM samples (Figs. 5.16C & D) 
confirmed focal AC loss and development of OA in both WT and Fgf-2 KO groups as 
previously reported (Chia et al., 2009). 
E11 immnunostaining on the lateral condyle of the tibia (Figs. 5.17A-D), showed an 
increase in the number of E11 positively stained osteocytes in the Fgf-2 KO mice 
compared with their respective controls  (p<0.05; Fig. 5.17E). However, the number 
of E11 positively stained osteocytes was not affected by the presence of DMM induced 
OA (Fig. 5.17E).  In the medial tibia condyle, (Figs. 5.18A-D), a significant increase in 
the number of E11 positively stained osteocytes was noted in the Fgf-2 KO sham joints 
when compared with WT control mice (p<0.01; Fig. 5.18E). However, as noted with 
the lateral condyle, the number of E11 positively stained osteocytes was not affected 
by the presence of DMM induced OA (Fig. 5.18E).  
Sclerostin immunolabelling revealed no difference in the number of sclerostin 
positively stained osteocytes between genotypes and OA induction in either the 
lateral (Figs. 5.19A-E), or medial (Figs. 5.20A-E) aspect of the tibia. 
 





















Figure 5.16 Histological assessment of DMM induced OA in Fgf-2 KO and WT 
mice tibia using Toluidine blue staining  
Section of tibial SCB showing normal AC (black arrow) in control (non-operated) 
in both WT (A) and Fgf-2 KO (B).  Note OA signs of AC lesion (red arrow) and SCB 
thickening with reduced bone marrow (*) in both WT (C) and Fgf-2 KO (D). Scale 
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Figure 5.17 E11 immunostained Fgf-2 KO/WT DMM and CON (non-
operated) mice. Lateral tibial subchondral bone osteocytes 
Sections of lateral tibial SCB osteocytes (black arrow) in both WT control and 
DMM (A & C), and Fgf-2 KO control and DMM (B & D). Quantification of E11 
positive osteocyte number showed an increase in E11 positive osteocytes in the 
Fgf-2 KO DMM when compared to WT DMM (E). This increase in the number of 
E11 positive osteocytes was also noted in controls of Fgf-2 KO Con when 
compared to WT Con (E). Data are presented as mean ± S.E.M (n=4); *p<0.05; ns 
= not significant. Scale bar = 150 um.   




























Figure 5.18 E11 immunostained Fgf-2 KO/WT DMM and CON (non-
operated) mice. Medial tibial subchondral bone osteocytes 
Sections of medial tibial SCB osteocytes (black arrow) in both WT control and 
DMM (A & C), and Fgf-2 KO control and DMM (B & D). Note, increase in the 
number of E11 positive osteocytes in Fgf-2 KO controls when compared to WT 
Con samples (E). Data are presented as mean ± S.E.M (n=4); *p<0.05; **p<0.01; ns 
= not significant. Scale bar = 150 um.   




























Figure 5. 19 Sclerostin immunostained Fgf-2 KO/WT DMM and CON 
(non-operated) mice. Lateral tibial SCB osteocytes 
Sections of lateral tibial SCB osteocytes (black arrow) in both WT control and 
DMM (A & C), and Fgf-2 KO control and DMM (B & D). Quantification of the 
number of sclerostin positive osteocytes showed no difference in the DMM 
tibias of both WT and Fgf-2 KO groups (E). Data are presented as mean ± S.E.M 

































Figure 5. 20 Sclerostin immunostained Fgf-2 KO/WT DMM and CON (non-
operated) mice. Medial tibial subchondral bone osteocytes 
Sections of medial tibial SCB osteocytes (black arrow) in both WT control and 
DMM (A & C), and Fgf-2 KO control and DMM (B & D). Quantification of the 
number of sclerostin positive osteocytes showed no difference in the DMM tibias 
of both WT and Fgf-2 KO groups (E). Data are presented as mean ± S.E.M (n=4); ns 









Bone remodelling is an integral process to bone health, but is dysregulated during 
OA pathophysiology (Burr and Gallant, 2012, Baker-LePain and Lane, 2012). In OA, 
it varies temporally from early bone resorption, to late stage-associated increased 
bone formation and subsequent sclerosis. Spatially, differences also occur in the 
medial and lateral Sections of the joint (Findlay, 2013). In addition, some osteocyte-
expressed molecules including E11, Phex, Dmp1, and sclerostin that are involved in 
bone remodelling are dysregulated during OA pathology (Appleton et al., 2007, 
Jaiprakash et al., 2012, Chong et al., 2013, Bouaziz et al., 2015). In this Chapter, two 
osteocyte markers, E11 and sclerostin were immunohistochemically localised to SCB 
osteocytes in a number of OA samples. The first investigation compared WT mice 
after sham and DMM surgery and no differences in both E11 and sclerostin 
immunostaining between the DMM and sham control mice was noted. This may be 
due to the absence of obvious OA pathology such as AC loss and absence of SCB 
sclerosis. This was unexpected but there is a need to confirm these data in the 3D 
context by micro computed tomography (micro-CT) analysis as 2D results are highly 
inconsistent mostly due to Sectioning protocols of angle and region (Jia et al., 2017).  
Histological studies of human OA samples are mostly limited to tissues obtained via 
joint replacement therapy and cadaver specimens (Lorenzo et al., 2004, Wallace et al., 
2017). While these sources may present a wide pool of tissues, it has a major limitation 
of representing mostly late stage OA (Lorenzo et al., 2004). In this Chapter, OA 
samples were sourced from patients undergoing total knee replacement, and they 
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showed no obvious differences in osteocyte E11 and sclerostin immunostaining 
compared with control samples. This may reflect that the number of osteocytes 
expressing E11 and sclerostin were not altered during this stage of OA, or that the 
sample size was not big enough to reflect any variation. Another suggestion may be 
the effect of differences in loading on specific sections of the bone. In addition, the 
fact that both samples are from the same disease joint may reflect this similar E11 
expression. Nevertheless, a significant decrease in the number SCB osteocyte 
positively immunolabelled for sclerostin in human OA samples has been reported 
and it was related to the observed sclerosis (Jaiprakash et al., 2012).  
In our domestic animals, the burden of naturally occurring OA is also a major concern 
as documented in sheep, horses, cats and dogs (Clarke et al., 2005, Clements et al., 
2009, Robin et al., 2013, Vandeweerd et al., 2013). Hence, an insight into the molecular 
profile of the SCB during OA pathology of these animals will be very relevant for 
their therapeutic management. This becomes important as there is variation in gene 
expression between human and dogs during OA pathology including the tissue 
inhibitor of matrix metalloproteinase -2 (Kevorkian et al., 2004, Stoker et al., 2006, 
Clements et al., 2009). In this Chapter, the increased number of E11 stained SCB 
osteocytes in the canine OA samples relative to the control samples was a novel result 
and may be attributed to newly formed osteocytes in the sclerotic bone; a cardinal 
feature of OA.  
Protein sequence similarity searching has become an integral aspect of determining 
homologous sequence of new proteins (Pearson, 2013). This process widely employs 
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programs like BLAST, FASTA, PSI-BLAST, HMMER3, SEARCH, CLUSTAL OMEGA 
and PEARSON (Smith and Waterman, 1981, Pearson and Lipman, 1988, Pearson, 
1991, Altschul et al., 1997, Sievers et al., 2011). The resulting information enables 
correlation of structures, function and common ancestry for highly similar sequences. 
Applying the 30% identity rule as the minimum for two sequences to be accepted as 
homologous (Pearson, 2013), the results from E11 sequence alignment analysis 
suggest that the E11 gene from mouse, human, cat, dog, sheep and horse can  be 
described as homologous. This agrees with other authors that have reported the E11 
gene to be highly conserved between species (Astarita et al., 2012).  
Nevertheless, with exception of dog samples, the SCB osteocytes of the species under 
study did not cross-react with anti-mouse or anti-human E11 antibodies. This might 
reflect the specific nature of the E11 epitope that the antibody was raised against 
(Kaneko et al., 2016). It may also reflect low reliability and accuracy of the percent 
identity analysis in sequence homology determination (Pearson, 2013); and the use of 
sequence homology as a tool in predicting antibody cross-reactivity (Sankian et al., 
2005).  
Sclerostin sequence alignment analysis also suggested that the sclerostin gene from 
mouse, human, cat, dog, sheep and horse could be described as homologous 
However, only the SCB osteocytes from human Sections with 88% identity cross-
reacted with anti-mouse sclerostin. This may be due to poor alignment of the 
antigenic epitopes specific to this antibody, as dog sclerostin was >90% identical to 
the mouse sequence and did not cross react. Also some authors have suggested that 
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antibody cross-reactivity potential can be influenced by factors like sequence 
similarity, analogous antigenic determinants, and structural compatibility like 
charges and shape (McClain, 2017). 
Tissue processing activities such as formalin fixation, EDTA decalcification, paraffin 
embedding and even Sectioning has been suggested to deleterious affect the quality 
of immunostaining (Hadjiargyrou et al., 2001). These processes especially formalin 
fixation cause tissue structure modification like protein cross-linking that have the 
tendency to massk antigenic epitopes. In addition to using proteolytic enzymes such 
as trypsin to break formalin induces bonds, several aqueous salts or known protein 
denaturing agents such as Tris-HCl, EDTA-NaOH and citrate buffer can also be used 
at high temperatures (Morgan et al., 1994, Pileri et al., 1997). In this Chapter, trypsin, 
EDTA, Tris EDTA and citrate buffers were used in an attempt to unmassk epitope 
site on canine SCB Sections for optimising anti-human E11 antibodies.  Only trypsin 
treated SCB Sections resulted in osteocytes that were positively immunostained.   
Earlier in this thesis (Chapter 3), FGF-2 showed capacity to regulate E11 in MC3T3 
osteoblast-like cells in vitro, but this correlation was not observed in the in vivo studies 
using Fgf-2 KO mice.  Redundancy amongst other members of the FGF family of 
growth factors was suggested as being responsible for this lack of FGF-2 effect. 
Extending the study further to determine if FGF-2 regulates osteocyte, E11 expression 
during OA was carried out on Fgf-2 KO mice using the DMM model.  Joint instability 
models of OA induction such as DMM has become a widely recognised procedure as 
it produces focal AC lesions, SCB sclerosis, osteophyte formation and pain (Inglis et 
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al., 2008, Little et al., 2009, Zhang et al., 2016).  In this project, the DMM samples from 
Fgf-2 KO and WT mice showed robust AC lesion; while the WT SCB showed sclerosis 
and reduced bone marrow, thus establishing that these samples indeed developed 
OA as has been previously published (Chia et al., 2009). The number of E11 positive 
osteocytes within SCB osteocytes was however not altered after DMM in the Fgf-2 KO 
mice. This result is not consistent with earlier findings of E11 gene down-regulation 
as measured by RT-PCR in the AC of Fgf-2 KO mice after DMM surgery (Chong et 
al., 2013). This may reflect differences method of calculating E11 expression as 
positive cells were counted here while Chong et al measured mRNA.  In addition, the 
differences in tissue types, as studies by Chong et al., involved the AC, rather than 
the SCB. While the possibility of AC contamination with some SCB tissue may be the 
source of E11 in the Chong et al study, as chondrocytes are not show not cytoplasmic 
extension such as dendrites or invadopodia that is a classical function of E11, but 
some authors have also E11 expression in foetal chondrocytes(Smith and Melrose, 
2011). 
It is worthy to note the significant increase in the number of E11 positive osteocytes 
within the SCB of Fgf-2 KO mice compared to the WT mice observed in the control 
joints. In Chapter 3, no differences in the number of E11 positive osteocytes between 
naïve Fgf-2 KO and WT mice was noted. This discrepancy may reflect an adjustment 
to loading on the contralateral knee in the non-operated knee joints. This raises the 
concern on the appropriateness of using the sham surgery or non-operated 
contralateral limb as a control during studies on DMM induced OA models in mice. 
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Specifically, the SCB sclerosis phenotype has been reported in both experimental and 
control limbs in the DMM model (Loeser et al., 2012, Fang and Beier, 2014, Miller et 
al., 2015). 
In this Chapter, whilst WT mice displayed SCB sclerosis after DMM, little sclerosis 
was observed in the Fgf-2 KO mice.  The absence of sclerosis in the Fgf-2 KO is 
consistent with a previous finding of reduced bone formation and fewer trabeculae 
with increased inter-trabeculae space in mice with Fgf-2 loss of function mutation 
(Montero et al., 2000). The authors attributed this structural feature to an imbalance 
in bone resorption than formation. Sclerostin is a well-recognised inhibitor of bone 
formation and acts via of the Wnt canonical pathway.  Sclerostin expression by 
osteocytes is down-regulated during loading which is likely to contribute to the bone 
anabolic response (Robling et al., 2008). During OA pathology, sclerostin expression 
is also down-regulated leading to the clasical SCB sclerosis (Jaiprakash et al., 2012). 
In this present, work the number of sclerostin positive osteocytes in the SCB 
osteocytes of WT and Fgf-2 KO mice after DMM surgery was similar. This lack of 
differential sclerostin expression in the WT mice after DMM on both lateral and 
medial sides has however also been previously noted in a study on SCB osteocyte 
during OA pathology (Jia et al., 2017). In the unoperated group, the lack of any 
difference in the sclerostin positive SCB osteocytes was quite intriguing and further 
studies are required to allow for quantification sclerostin positive SCB osteocytes in 
chronic OA samples. 
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In conclusion, the results of this Chapter have shown that E11 and sclerostin proteins 
from dog, cat, horse, sheep, man and mouse can be considered homologous. E11 
expression was altered during OA.  Specifically, the number of osteocytes expressing 
E11 was increased in the contralateral knee after DMM in Fgf-2 KO mice. This may 
reflect increased loading in the limb due to gait adjustment post-surgery.  In canine 
SCB osteocytes, an increased number of osteocytes positive for E11 suggests a role for 
this bone inhibitory protein in OA disease progression and this aspect is worthy of 
further examination.   






















6.1 General discussion  
The osteocyte is emerging as an important bone cell, with vital roles in regulating 
skeletal function both mechanically and biochemically (Bonewald, 2011, Plotkin and 
Bellido, 2016). Recent evidence has confirmed that bone is an endocrine organ 
regulating phosphate homeostasis (Karsenty and Ferron, 2012, Dallas et al., 2013). 
This emerging function of bone is also attributed to the osteocyte and its lacuna-
canaliculi dendrite network that enables the osteocytes to communicate with itself, 
osteoblasts, osteoclasts and other body organs, though secreted factors such as 
sclerostin, RANKL/OPG and FGF-23 (Bonewald, 2011, Compton and Lee, 2014, Guo 
and Yuan, 2015).  The development of this dendrite network is regulated by E11, an 
early osteocyte marker gene and the focus of this thesis (Zhang et al., 2006, Bonewald, 
2008). 
Whilst the stability of this dendrite linked lacuna-canaliculi network ensures effective 
bone homeostasis; its disruption is associated with adverse effects on bone 
architecture and skeletal health (Dallas et al., 2013, van Dijk et al., 2013, Staines et al., 
2017). High bone material quality has been correlated with dense dendrite networks, 
while the reverse is observed in loose networks (Kerschnitzki et al., 2013). Indeed 
there are a number of disorders associated with disrupted osteocyte dendrites 
including; osteoporosis presenting poorly oriented dendrites towards the vasculature 
with reduced interconnectivity; osteomalacia with an elevated number of dendrites 
that are hyper-connected; and osteoarthritis in which the dendrites are characterised 
by decreased number and morphology (Knothe Tate et al., 2004, Bonewald, 2004, 




Bonewald, 2008, Jaiprakash et al., 2012). The data gathered in this thesis, will add to 
the body of knowledge in designing therapies related to dysregulated osteocyte 
communication networks in pathology.  
One of the predisposing factors to fracture is reduced bone quality and structural alteration 
(Rachner et al., 2011). Recent studies have revealed the relative importance of dendrites as 
regards to osteocyte viability, as a significant reduction in dendrite number is observed prior 
to decreases in cell density during ageing (Tiede-Lewis et al., 2017).  Moreover, a positive 
correlation has been established between the absence of dendrite development and bone 
fragility (Plotkin and Bellido, 2016). Ageing osteoporotic bones are characterised by reduced 
cortical thickness with enlarged diameter, elevated cortical porosity, and reduced trabecular 
bone volume to total volume (Kerschnitzki et al., 2013, Tiede-Lewis et al., 2017). This poor 
quality bone architecture is related to the reduced osteocyte dendritic network, which would 
reduce the bone’s mechanosensing ability and impair its response to loading (Noble et al., 
2003, Tatsumi et al., 2007, Adachi et al., 2009, Staines et al., 2017). From the work of this thesis, 
it can be speculated that the upregulation of E11 expression may reverse the osteocyte 
dendrite reduction in the ageing population - especially in female osteoporosis patients who 
are more at risk of bone fractures (Seeman, 2013, Black and Rosen, 2016, Tiede-Lewis et al., 
2017). This suggestion builds on the emerging function of osteocyte being the master 
regulator of bone remodelling and imbalances lead to diseases such as osteoporosis 
and OA. 
The osteocyte is able to regulate bone mineral homeostasis though its expression of 
FGF-23, a growth factor that has conferred on bone being ascribed the function as an 
endocrine organ (Teti and Zallone, 2009, Bonewald, 2011, Dallas et al., 2013, Plotkin 




and Bellido, 2016). FGF-23 regulates phosphate reabsorption in the kidney tubules 
(Razzaque, 2009). Another mechanism central to whole body mineral regulation is 
the phenomenon of perilacunar remodelling, also referred to as osteocytic osteolysis 
(Bélanger et al., 1967, Teti and Zallone, 2009, Dallas et al., 2013). In this process, the 
osteocyte expresses known osteoclast makers like TRAP and cathepsin K, and 
dissolves mineral deposits in its lacuna (Wergedal and Baylink, 1969, Nakano et al., 
2004, Qing et al., 2012). This action releases minerals such as calcium into the 
circulation during lactation that is associated with high calcium demand (Kwiecinski 
et al., 1987, Qing et al., 2012). What is very remarkable about this mechanism is the 
ability of the osteocyte to exploit its huge surface area to have access to a large mineral 
deposit in the bone matrix (Kerschnitzki et al., 2013). Hence, the maintenance of the 
abundant dendrite network is key in the osteocyte regulation of body mineral 
balance; and the results from this thesis suggest that increased E11 expression may 
play a vital role in this.  
FGF-2 is one of the many growth factors described to be important for skeletal health 
where it has mitogenic potential in several types of mesenchymal cells (Rifkin and 
Moscatelli, 1989). In addition, FGF-2 plays a key role in the differentiation of skeletal 
cells such as osteoblasts during growth and development (Kyono et al., 2012). 
Therapeutically, the use of recombinant FGF-2 to manage traumatic bone injuries like 
fractures has provided a glimmer of hope for its use in other skeletal disorders 
(Einhorn and Gerstenfeld, 2015). In this thesis, FGF-2 upregulation of E11 expression 
and osteocytogenesis is suggestive of a possible physiological application for the 




therapeutic use of FGF-2 in disorders of the osteocyte dendritic network previously 
discussed. This thesis speculatively revealed a strong influence of FGFR1 on FGF-2 
induced osteocytogenesis (Chapter 4), despite the published literature indicating a  
lack of consensus as to which FGFR is the most appropriate receptor to FGF-2 (Yang, 
2013). The implication of this is that it may be difficult to identify an appropriate 
target receptor for therapeutic evaluation in loss or gain of FGFR function with FGF-
2 signalling. It may also portend an advantage for using exogenous FGF-2, as more 
emphasis may be on the downstream signalling pathway to target when evaluating 
outcomes. This suggested emphasis on the downstream molecules may help 
circumvent the cautious opinion of some investigators on the potential difficulties of 
FGF-2 in biological therapeutics due to intricacy in receptor action profiles (Li et al., 
2012).  However, studies in human OA articular chondrocytes have made convincing 
arguments for the use of FGFR1 antagonist in designing OA therapeutic drugs. This 
suggestion was supported by findings that FGFR1 was the most expressed FGFR; and 
was associated with severe catabolic actions in the human OA articular cartilage 
when stimulated by both endogenous and exogenous FGF-2 (Yan et al., 2011, 
Nummenmaa et al., 2015). The discrepancy between my suggestion and the authors’ 
on therapeutic potential for FGFR1 may be related to difference in species, cell types 
and health status of the cells.  
The role of the SCB in the pathophysiology of OA is becoming more widely accepted 
(Kwan Tat et al., 2010). This may be a reflection of better tools for 
investigation/detection such as magnetic resonance imaging, microCT, and more 




advanced animal models (Kwan Tat et al., 2010, Fang and Beier, 2014). Animal models 
have enabled the simulation of various human OA phenotypes for detailed 
investigation including spontaneously occurring, trauma induced, loading induced, 
and genetic manipulation. In OA pathology, SCB sclerosis is underpinned by 
dysregulated bone remodelling, potentially due to altered osteocytogenesis. In early 
OA, excessive remodelling results in a shift towards more bone resorption, however 
in late OA a switch to increased bone formation is seen, therefore resulting in SCB 
sclerosis (Bettica et al., 2002, Bouaziz et al., 2015).  
Sclerostin, a late osteocyte marker protein and Wnt signalling inhibitor, is down 
regulated during mechanical loading and OA pathophysiology (Poole et al., 2005, 
Bezooijen et al., 2005, Robling et al., 2008, Chan et al., 2011, Albisetti et al., 2013, Wu 
et al., 2016, Zarei et al., 2017). In view of the established role of the Wnt canonical 
pathway in regulating osteoblast differentiation and bone remodelling (Macsai et al., 
2008, Jin et al., 2015), it can be postulated that sclerostin modulation of Wnt signalling 
pathway in early OA may be a good target in reducing the development of sclerosis 
associated with late OA. The need for this approach has also been highlighted by 
other researchers including the possible use of recombinant sclerostin protein (Baker-
LePain and Lane, 2012, Wu et al., 2016). This becomes imperative as encouraging 
results are emerging from the use of sclerostin neutralising antibody in reversing 
bone loss (Eddleston et al., 2009, Li et al., 2009). 
Similarly, this thesis examined the possibility of E11 as a target for the prevention of 
OA pathology. Currently, the expression  of E11 in OA is largely unknown. As a 




reduced number of osteocyte dendrites has been observed, it is plausible that the 
expression of E11 may be decreased (Jaiprakash et al., 2012). This reduction may 
dampen the bone’s response to loading during OA due to the known role of the 
osteocyte in this physiological process (Zhang et al., 2006). One can therefore 
speculate on the use of recombinant FGF-2 to induce increased dendrite number, with 
a possible focal reprogramming to normal osteocytogenesis in early OA. Whilst no 
differences were observed in E11 expression in the mouse and human samples, E11 
was significantly increased in canine OA samples in this thesis (Chapter 5). This 
therefore highlights the need to extend the study to ascertain if species differences or 
sample size (human), or methods of OA induction (mouse), and other variables such 
as stage of disease, inflammatory response, sex, age, and sample anatomic location in 
the joint may all be contributing to these contrasting observations. 
In conclusion, this thesis has identified FGF-2 as a regulator of increased E11 
expression and osteocytogenesis speculatively though FGFR1. While the increased 
expression of E11 upregulated osteocyte dendrite formation was established in this 
thesis and corroborated by previous workers, the data on FGFR1 speculatively 
mediating this expression has added to the ongoing debate on the precise FGF-2 
receptor. Nevertheless, the upregulation of some downstream molecules like ERK1/2, 
Akt and p38 MAPK during this process of osteocytogenesis, confers on FGF-2 the 
ability to play a crucial role in the maintenance of the osteocyte network. However, 
some questions remain largely unanswered including if a specific downstream 
molecule like ERK1/2, Akt and p38 MAPK or combination mediates this effect on 




increased E11 expression  and increased dendrite formation. Also unresolved is the 
actual nature of E11 expression  during OA pathology.  The findings of this thesis 
adds to our body of knowledge on the potential of recombinant FGF-2 as a therapeutic 
agent targeting osteocyte network related bone disorders such as osteoporosis and 
osteoarthritis. 
6.2 Directions for future research  
The results presented in this thesis have identified a role for FGF-2 in regulating 
osteocytogenesis. They have pinpointed this functional role to be mediated though 
the expression of E11. However, further work is necessary to fully elucidate the 
signalling mechanisms underpinning this, and the functional role, which this may 
play in OA. 
Certainly, the investigation of other FGF-2 responsive signalling pathways in 
osteoblasts would be of great benefit in furthering our understanding of FGF-2 
mediated osteocytogenesis. The activation of Runx2 in response to FGF-2 stimulation 
of MC3T3 osteoblast-like cells is associated with upregulation of the gap junction 
protein connexion 43 that activates ERK1/2 and PKC δ pathways. PKC signalling, 
which is also associated with RhoA/ERM, has been seen to regulate cell membrane 
protrusion and eventual cell motility (Revenu et al., 2004). This makes a case for 
further studies investigating PKC δ ability to mediate FGF-2 stimulation of E11 
expression and osteocytogenesis (Lima et al., 2009, Hebert and Stains, 2013, Capulli 
et al., 2014). In this thesis, Fgfr1 had over a 10-fold increase in expression after 




stimulation with FGF-2 in comparison with other receptors. Therefore, more studies 
using specific Fgfr1 inhibitors will help decipher its relative importance. In addition, 
primary osteoblasts from Fgfr1 loss of function mutation could be stimulated with   
FGF-2 to observe its effect on E11 expression and dendrite formation.  
Previous studies have shown that FGF-2 upregulates Dmp1 though ERK1/2 (Kyono 
et al., 2012). This may help explain the upregulation of Dmp1 by FGF-2 in this thesis 
despite E11 knock down using E11 siRNA (Chapter 3), as the two genes are possibly 
stimulated though the same ERK1/2 pathway (Kyono et al., 2012). In addition, it is 
possible that residual expression  of E11 is enough to drive the up-regulation of other 
osteocyte markers (Staines et al., 2017). To help establish further the role of E11 in 
osteoblast to osteocyte transition in vitro, the use of gene editing tools like Clustered 
Regularly Interspersed Palindromic Repeats (CRISPR)/ CRISPR-associated protein-9 
nuclease (Cas9), generally referred to as CRISPR/Cas9, may be of immense benefit 
(Sander and Joung, 2014). Also, it will important to induce OA in E11 conditional 
knock out (E11 cKO) mice  as the results from our study using the hypomorphic 
conditional deletion of E11 in bone revealed a reduction in osteocyte dendrite volume, 
length, and response to loading (Staines et al., 2017).  
As reported in this thesis, the induction of OA with the use of the DMM model as 
showed no differences in SCB osteocyte immunolabelling of E11 and sclerostin in Fgf-
2 KO and WT mice. However, the results from E11 immunolabelling showed 
contrasting results in the WT mice in Chapters 3 & 5; E11 was increased in the WT 
versus Fgf-2 KO sham mice in the DMM study, while the naïve mice showed no 




difference. This discrepancy may reflect an adjustment to loading on the contralateral 
knee in the unoperated knee joints. It would therefore be interesting to adopt a 
loading method in the Fgf-2 KO mice to examine the effects of Fgf-2 deletion on the 
bones response to loading, and loading induced OA. This may then also provide key 
insights into the role of E11 in these processes.  
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Reagents for this work were obtained from Sigma-Aldrich (Dorset, U.K.) and 
cell/organ culture media and additives were sourced from Thermo Fisher Scientific 
(Paisley, U.K.) unless otherwise stated. 
Cell culture 
Culture media  
(αMEM supplemented with 10% v/ FBS, and 0.05 mg/ml gentamycin)  
Calvariae Culture media  
(αMEM containing 0.2% w/v BSA and 0.05 mg/ml gentamycin) 
Treatment media 
(αMEM supplemented with 1% v/v FBS), and 0.05 mg/ml gentamycin) 
 
Histology  
10 mM Citric acid buffer pH 6.0 
1.92 g citric acid /1000 ml dH2O   
Tris/EDTA (TE) Buffer (pH 9.0)  
10 mM Tris-HCl and 1 mM EDTA in dH2O. 
1 mM EDTA (pH 8.0)  
 
0.292g EDTA /1000 ml dH2O  
Sodium acetate buffer (Store at 4oC) 
Disolve 13.6 g in 1 L dH2O. Stir well 




1X PBS / 5% v/v normal serum / 0.3% v/v Triton X-100 
Antibody Dilution Buffer  
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Western Blotting  
LDS Sample reducing agent  
40% glycerol, 4% LDS, 4% Ficoll*-400, 0.8 M triethanolamine-Cl pH 7.6, 0.025% 
phenol red, 0.025% coomassie G250, 2 mM EDTA disodium 
10X Transfer buffer 
29.3 mg/ml glycine, 58mg/ml Tris Base (trismethylamine), 18.8ul/ml 20% v/vSDS in 
dH2O  
1X Transfer buffer 
100 ml 10X transfer buffer, 200 ml 98% Ethanol, 700 ml dH2O.  
TBS/T 
Tris-buffered saline/Tween-20 consisting of 50 mM Tris-HCl, 300 mM NaCl, 0.1% 
v/v Tween-20 
1X TBS/T 
100 ml TBS/T, 900 ml water, 1 ml Tween 20 
MOPS running buffer  
50 mM MOPS pH 7.7, 50 mM Tris, 0.1% v/v SDS, 1 mM EDTA  
5% Marvel  
5 g of skimmed milk powder (Oxoid ltd, UK), in 100 ml of 1X TBS/T,  
Stripping buffer 
25 mM glycine, 1% v/v SDS and pH2 
Bio-Rad DC protein assay   Reagent A  
1 ml Bio-Rad DC protein assay   Reagent A (Bio-Rad, Hertfordshire, UK) 







Appendix 1  
244 
 
Table 1. Primers used for RT-qPCR analysis.  
 













F Not disclosed 





















Alpl   Sigma F GGGACGAATCTCAGGGTACA 
R AGTAACTGGGGTCTCTCTC 
Fgfr1 Qiagen F Not disclosed 
R Not disclosed 
Fgfr2 Sigma F CCTGCGGAGACAGGTAACAG 
R CGCGTTGTTATCCTCACCA 
Fgfr3 Qiagen F Not disclosed 
R Not disclosed 
Gapdh Primer 
Design 
F Not disclosed 
R Not disclosed 
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Appendix Table 2. Primary antibodies 
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Table 3. Secondary antibodies  
Antibody Source Use Dilution 
Rabbit anti-goat Dako Western Blotting 1:3000 
Goat anti-rabbit Dako Western Blotting 1:3000 
Donkey anti-goat Abcam Immunofluorescence 1:250 
Donkey anti-rabbit Abcam Immunofluorescence 1:250 
Rabbit anti-goat Vector Lab Immunohistochemistry 1:200 
Goat anti-rabbit Vector Lab Immunohistochemistry 1:200 
 
 
Algorithm 1.  
[IMARIS 8.4 Algorithm] 
Enable Region of Interest = false 
Enable Region Growing = false 
Enable Tracking = false 
[Source Channel] 
Source Channel Index = 1 
Enable Smooth = true 
Surface Grain Size = 0.300 um 
Enable Eliminate Background = false 
Diameter of Largest Sphere = 0.713 um 
[Threshold] 
Enable Automatic Threshold = false 
Manual Threshold Value = 685.082 
Active Threshold = true 
Enable Automatic Threshold B = true 
Manual Threshold Value B = 4073.13 
Active Threshold B = false 
[Classify Surfaces] 
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E11/podoplanin is critical in the early stages of osteoblast-to-osteocyte transitions
(osteocytogenesis), however, the upstream events which regulate E11 expression are
unknown. The aim of this study was to examine the effects of FGF-2 on E11-mediated
osteocytogenesis and to reveal the nature of the underlying signaling pathways
regulating this process. Exposure of MC3T3 osteoblast-like cells and murine primary
osteoblasts to FGF-2 (10 ng/ml) increased E11mRNAandprotein expression (p < 0.05)
after 4, 6, and 24 hr. FGF-2 induced changes in E11 expressionwere also accompanied
by significant (p < 0.01) increases inPhex andDmp1 (osteocytemarkers) expression and
decreases in Col1a1, Postn, Bglap, and Alpl (osteoblast markers) expression.
Immunofluorescent microscopy revealed that FGF-2 stimulated E11 expression,
facilitated the translocation of E11 toward the cell membrane, and subsequently
promoted the formation of osteocyte-like dendrites in MC3T3 and primary
osteoblasts. siRNA knock down of E11 expression achieved >70% reduction of basal
E11 mRNA expression (p < 0.05) and effectively abrogated FGF-2-related changes in
E11 expression and dendrite formation. FGF-2 strongly activated the ERK signaling
pathway inosteoblast-like cells but inhibitionof this pathwaydidnot block the ability of
FGF-2 to enhance E11 expression or to promote acquisition of the osteocyte
phenotype. The results of this study highlight a novel mechanism by which FGF-2 can
regulate osteoblast differentiation and osteocyte formation. Specifically, the data
suggests that FGF-2 promotes osteocytogenesis through increased E11 expression
and further studies will identify if this regulatory pathway is essential for bone
development and maintenance in health and disease.
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1 | INTRODUCTION
Osteocytes are derived from osteoblasts and are the most abundant
cells, residing inmineralized bone of the adult skeleton. It has long been
accepted that osteocytes are formed by the passive entrapment of
redundant osteoblasts by osteoid synthesized by their close neighbors
(Palumbo, Ferretti, & Marotti, 2004; Skerry, Bitensky, Chayen, &
Lanyon, 1989). The transition from the cuboidal-like osteoblastic
morphology to a dendritic shape characteristic of an osteocyte is,
however, a more active and tightly regulated process than originally
recognized (for reviews see Dallas & Bonewald, 2010; Franz-
Odendaal, Hall, & Witten, 2006).
The mechanisms which govern this osteoblast to osteocyte
transition (osteocytogenesis) are generally unknown but fundamen-
tal studies by Bonewald and coworkers identified E11/podoplanin, a
mucin-type transmembrane glycoprotein, as the earliest osteocyte
marker protein expressed during osteocytogenesis (Zhang et al.,
2006). Furthermore, E11 triggers actin cytoskeletal dynamics
(Staines et al., 2016), which are required for dendrite formation
and transient E11 knockdown blocks dendrite elongation (Zhang
et al., 2006). E11 glycoprotein is not unique to bone and is
ubiquitously expressed by many tissues in which it has a range of
regulatory functions including cell development, differentiation and
invasiveness, epithelial–mesenchymal transition, and oncogenesis
(Astarita, Acton, & Turley, 2012; Martín-Villar, Yurrita, Fernández-
Muñoz, Quintanilla, & Renart, 2009; Thiery, 2002; Wicki &
Christofori, 2007). Owing to its wide tissue expression, it is now
recognized by several names which include podoplanin in kidney
podocytes, T1α in alveolar type 1 epithelial cells, PA2.26 in skin
keratinocytes, gp38 in lymphoid organs, and E11 in lymphatic
endothelial cells, osteoblasts, and osteocytes (Breiteneder-Geleff
et al., 1997; Farr, Nelson, & Hosier, 1992; Ramirez et al., 2003;
Scholl, Gamallo, Vilaró, & Quintanilla, 1999; Wetterwald et al., 1996).
The intracellular signaling mechanisms by which E11 influences
dendrite formation involve the activation of the small GTPase, RhoA,
and its downstream effector kinase, ROCK (Martín-Villar et al.,
2006). ROCK phosphorylates ezrin/moesin/radixin (ERM) and
influences the actin cytoskeleton and subsequently cell shape
(Martín-Villar et al., 2006, 2014; Sprague, Wetterwald, Heinzman,
& Atkinson, 1996). Much less, however, is known about the
upstream regulatory events, specifically those that influence levels
of E11 expression during osteocytogenesis. Nonetheless, clues from
other model systems have indicated that fibroblast growth factor 2
(FGF-2) is able to change chondrocyte gene expression in vitro,
including that of E11 (Chong et al., 2013). FGF-2, one of the earliest
members identified in the FGF polypeptide family, signals through
FGF receptors that have intrinsic tyrosine kinase activity (Powers,
Mcleskey, & Wellstein, 2000). In addition to chondrocytes, FGF-2 is
expressed by osteoblasts and is stored in the extracellular matrix
where it regulates bone formation via influence on progenitor cell
lineage commitment and/or osteoblast differentiation (Hurley,
Marie, & Florkiewicz, 2002; Montero et al., 2000; Sabbieti et al.,
1999; Xiao et al., 2010). Indeed, mice deficient in Fgf2 have
decreased bone mass and altered trabecular architecture whereas
Fgf2 transgenic mice present with increased bone mineral density
and cortical and trabecular thickness, as well as a variety of skeletal
malformations including shortening and flattening of long bones
(Coffin et al., 1995; Montero et al., 2000; Xiao et al., 2009).
Cognizant of FGF-2 stimulation of E11 expression in cartilage
explants and osteoblast-like cells, we, therefore, hypothesized that
FGF-2 may influence bone remodeling via increased osteoblast E11
expression and concomitant osteocyte dendrite formation (Chong
et al., 2013; Gupta, Yoo, Hebert, Niger, & Stains, 2010). Hence, the
aims of this current studywere to examine the effects of FGF-2 on E11
expression in osteoblasts during osteocytogenesis and to explore
putative signaling pathways controlling this process.
2 | MATERIALS AND METHODS
2.1 | Animals
FGF-2-deficient mice (KO) were originally created by Tom Doetsch-
man and obtained from the Jackson Laboratory, and were backcrossed
onto a C57BL/6J wild-type (WT) background (Chong et al., 2013).
Animal experiments were performed after obtaining ethical and
statutory approval in accordance with local policy. Mice were
maintained in accordance with UK Home Office guidelines for the
care and use of laboratory animals.
2.2 | MC3T3 cell culture
Murine MC3T3-E1 (subclone 14), pre-osteoblast-like cells (American
Type Culture Collection [ATCC], Manassas, VA) were plated at 1 × 104
cells/cm2 in six-well plates and cultured in α-MEM medium
supplemented with 10% (v/v) FBS (Invitrogen, Paisley UK) and
50 µg/ml gentamicin (Invitrogen) at 37°C in a humidified atmosphere
with 5% CO2 and the medium was changed every 2–3 days. Cell
viability was assessed using a commercially available Alamar Blue kit
(Invitrogen) and cell cytotoxicity using an LDH assay according to the
manufacturer's instructions (Promega, Southampton, UK).
2.3 | Primary osteoblast isolation
Primary calvarial osteoblastswere obtained from3-day-oldWTmice by
serial enzyme digestion of dissected calvarial bones according to
published procedure (Orriss, Hajjawi, Huesa, Macrae, & Arnett, 2014;
Staines, Zhu, Farquharson, & Macrae, 2014). In brief, calvaria were
digested in 1mg/ml collagenase type II (Thermo Fisher Scientific,
Loughborough, UK) in Hanks’ balanced salt solution (HBSS) for 10min
and the supernatant discarded; then repeat digestion in 1mg/ml
collagenase type II in HBSS for 30min; 4mM EDTA for 10min and
finally 1mg/ml collagenase type II in HBSS for 30min. After discarding
the first digest, the cells were re-suspended in growth medium
consisting ofα-MEMsupplementedwith 10% (v/v) FBS andgentamycin
at 50 μg/ml. Osteoblasts were seeded at a density of 1 × 104 cells/cm2,
and incubated at 37°C/5%CO2 with media changes every 2–3 days.
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2.4 | FGF-2 treatments
WhenMC3T3 cells and primary osteoblasts were confluent (day 0), the
culture media were replaced with α-MEM supplemented with 1% (v/v)
FBS, 50 µg/ml gentamicin and 0-50 ng/ml FGF-2 (PeproTech, London,
UK) in 0.1% bovine serum albumin (BSA). Each test condition was
completed in triplicate.
2.5 | Signaling inhibitors
MC3T3 cells were incubated with appropriate concentrations (specific
details in results) of the MEK1/2 inhibitor, U0126, the PI3K inhibitor,
LY294002 (InvivoGen, Toulouse, France), and the p38 inhibitor,
SB203580 (Cell Guidance Systems, Cambridge, UK). These inhibitors
have been reported to be selective for thesemolecules (Choi et al., 2008;
Hotokezakaetal., 2002;Macrae,Ahmed,Mushtaq,&Farquharson,2007).
Control cultures contained vehicle (0.1% dimethylsulfoxide, DMSO) only.
2.6 | RNA extraction and quantitative real-time PCR
(RT-qPCR)
Total RNA was extracted from MC3T3 cells and primary osteoblasts
using a Qiagen RNeasyMini kit (Qiagen, Manchester, UK) according to
the manufacturer's recommendations. The RNA samples were
reverse-transcribed into cDNA using Superscript II reverse transcrip-
tase (Invitrogen) according to the manufacturer's instructions.
RT-qPCR was carried out in a Stratagene Mx3000P cycler with each
reaction containing 50 ng template cDNA, 250 nM forward and
reverse primers (Supplementary Table S1), and PrecisionPlus Master-
mix (Primer Design, Chandler's Ford, UK). The cycle threshold (Ct)
values for the samples were normalized to that of Atp5b or Gapdh
(Supplementary Table S1) and the relative expression was calculated
using the 2ΔCt method (Livak & Schmittgen, 2001).
2.7 | Western blotting
Cells were scraped in RIPA lysis buffer containing protease inhibitors
(Roche, Germany), and protein concentrations were determined using
the Bio-RadproteinDCassay (Bio-Rad,HemelHempstead, UK). Protein
(8–15 µg)was separatedusinga10%Bis-Tris gel and then transferred to
a nitrocellulose membrane and probed with appropriate primary
antibody (Supplementary Table S2), and appropriate HRP-linked
secondary antibody (Supplementary Table S3). Immune complexes
were visualized by chemiluminescence using an ECL detection kit and
ECL film (GE Healthcare, Amersham, UK). HRP-conjugated anti β-actin
antibody (1:70,000, Sigma, Dorset UK) was used as a loading control.
Densitometry analysis of protein was performed using Image J (https://
imagej.nih.gov/ij/) (Baldari, Ubertini, Garufi, D'orazi, & Bossi, 2015).
2.8 | E11 immunofluorescence
MC3T3 cells were plated on cover slips at a density of 6.3 × 103 cells/
cm2 and following treatment with FGF-2, were fixed with 4%
paraformaldehyde (PFA) for 15min, washed in PBS and incubated in
blocking buffer (1× PBS, 5% normal donkey serum and 0.3% Triton
X-100) for 1 hr at room temperature (RT). E11 antibody (Supplemen-
tary Table S2) was added to each well (1:900 in 1× PBS, 0.3% Triton
X-100 and 1% BSA) overnight at 4°C. Control cells were incubated
with an equivalent concentration of goat IgG (Supplementary
Figure S1). Wells were subsequently incubated with AlexaFluor-
conjugated donkey anti-goat secondary antibodies (Supplementary
Table S3) in the dark for 2 hr at RT. Glass coverslipswere thenmounted
onto slides using ProLong Gold antifade reagent with DAPI (Thermo
Fisher Scientific) for nuclei staining (Dobie, Macrae, Huesa, Van't Hof,
& Ahmed, 2014). The slides were finally visualized using a Leica DMRB
fluorescence microscope and images were taken with a Leica DFC300
digital color camera (Leica, Milton Keynes, UK).
2.9 | Transfection of MC3T3 cells with E11 siRNA
E11 siRNA and scrambled siRNA stocks (Qiagen) were diluted to
10nM.MC3T3 cells were plated at 8 × 103 cells/cm2 andmaintained in
reduced serum medium. Cells were transfected as per manufacturer's
instructions with complexes of E11siRNA with HiPerFect (Qiagen),
while control cells were transfected with either complexes of
scrambled siRNA, with HiPerFect; or HiPerFect alone. After 24 hr
incubation at 37°C/5%CO2, FGF-2 (10 ng/ml) was added for a further
24 hr to the cells containing the siRNA/HiPerFect complexes or the
HiPerFect alone.
2.10 | Immunohistochemistry
The knee joints of 6-week-old male FGF-2 KO and WT mice (Chong
et al., 2013), were fixed in 4% PFA for 24 hr before decalcification in
10% ethylenediaminetetraacetic acid (EDTA) pH 7.4 for approxi-
mately 3 weeks at 4°C with regular changes. Tissues were
dehydrated and embedded in paraffin wax, using standard proce-
dures, after which they were sectioned at 6 µm. Sections were
dewaxed in xylene, rehydrated, and incubated at 37°C for 30 min in
1mg/ml trypsin for antigen demasking. Endogenous peroxidases
were blocked by treatment with 3% H2O2 in methanol. E11 and
sclerostin antibodies (Supplementary Table S2) were used with
appropriate IgG controls and secondary antibodies (Supplementary
Table S3). The Vectastain ABC universal kit (Vector Laboratories,
Peterborough, UK) was used according to the manufacturer's
instructions. The sections were dehydrated, counterstained with
haematoxylin and mounted in DePeX. Images were captured with
Nikon Eclipse Ni microscope (Nikon, UK), fitted with Zeiss Axiocam
105 color camera (Carl Zeiss). The number of positively stained E11
osteocytes within diaphyseal cortical bone were calculated as a
percentage of total osteocytes present.
2.11 | Phalloidin staining for cell culture
MC3T3 cells were seeded at 1 × 104 cells/cm2 and when sub-
confluent they were treated with 10 ng/ml FGF-2 or 0.1% BSA for
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control cultures. After 24 hr, the cells were fixed in 4% PFA,
rinsed in PBS and permeabilized in 0.1% (w/v) triton X-100 (Sigma)
in PBS for 10 mins, and then rinsed in PBS. The cells were
incubated in 200 μl of Alexa Fluor 488-conjugated phalloidin
(Thermo Fisher Scientific) (5 μM in PBS with 2% BSA) in the dark at
RT for 3 hr. The cells were imaged on a Zeiss Axiovert 25s inverted
microscope and digital imaging system (Carl Zeiss Microscopy, LLC,
Oberkochen, Germany).
2.12 | Phalloidin staining for histological sections
Femurs were decalcified as described above and then cryopro-
tected in 30% sucrose (w/v) at 4°C for 48 hr. The femora were cut
in the mediolateral plane in serial longitudinal 20 μm thick-sections
using a cryostat and thaw-mounted on gelatin-coated slides for
processing. Slides were dried at room temperature for 45 min,
washed in PBS twice for 5 min each, and incubated with 0.1%
Triton-X 100 (Sigma-Aldrich) for 30 min and then rinsed with PBS.
Slides were then incubated with Alexa Fluor 488-conjugated
phalloidin (1:20; Thermo Fisher Scientific) for 1 hr. Bone sections
were washed in PBS and mounted in VectaShield (Vector
Laboratories). Preparations were allowed to dry at room tempera-
ture for 12 hr. Sections were imaged on a Zeiss LSM 710 Laser
Scanning Confocal Microscope with 488 nm laser excitation and
detection settings from 493 to 634 nm. Z-stacks were produced
with optimal Nyquist overlap settings using a 63×/1.4na oil
immersion lens. Voxel sizes were 0.1 × 0.1 × 1.00 μm in x,y,z planes,
respectively. A comparable region of interest was analyzed for
osteocyte parameters in all samples located in the diaphyseal
cortical bone. Image stacks were imported into Bitplane Imaris 8.2.0
software and algorithms were created with Imaris FilamentTracer to
render and measure dendritic processes. Surface rendering was
used for osteocyte cell body measurements.
2.13 | Statistical analysis
Data are expressed as themean ± standard error of themean (S.E.M) of
at least three replicates per experiment. Statistical analysis was
performed by Student's t-test, one-way analysis of variance (ANOVA)
or a suitable non-parametric test. p < 0.05 was considered to be
significant and noted as *p values of <0.01 and <0.001were noted as **
and ***, respectively.
3 | RESULTS
3.1 | FGF-2 promotes osteoblast E11 gene and
protein expression
Treatment of MC3T3 cells with 10 ng/ml FGF-2 for 4, 6, and 24 hr
stimulated E11mRNA expression in comparison to control cultures, at
all time-points examined (p < 0.05, Figure 1a). We observed a
concomitant increase in E11 protein expression in these cells
(Figure 1b). Stimulation of E11 mRNA (p < 0.05, Figure 1c) and E11
protein (Figure 1d) expression by FGF-2 was similarly noted in primary
osteoblast cultures. The levels of FGF-2 induced E11mRNA and
protein were more prominent in the MC3T3 cells at the early time
points (4 and 6 hr), whereas in primary cells these increases peaked at
the later time points (24 hr) (Figure 1).
FIGURE 1 The effect of FGF-2 (10 ng/ml) on (a) E11 mRNA expression and (b) E11 protein expression in MC3T3 cells after 4, 6, and 24 hr
challenge, where (+) is FGF-2 treated cell, and (−) is untreated control. The effect of FGF-2 (10 ng/ml) on (c) E11 mRNA expression and (d)
E11 protein expression in primary osteoblast cells after 4, 6, and 24 hr challenge, where (+) is FGF-2 treated cell, and (−) is untreated control.
Results were normalized to the Atp5b housekeeping gene and β-actin for Western loading control. Data are presented as mean ± S.E.M for
n = 3; *p < 0.05; ***p < 0.001 compared to untreated cells
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3.2 | FGF-2 promotes osteoblast–osteocyte
differentiation
In light of the increased E11 expression by FGF-2, we next examined
the expression of known osteocyte and osteoblast marker genes to
determine whether exposure of osteoblast-like cells to FGF-2
promoted osteocytic differentiation. In MC3T3 cells, FGF-2 increased
the mRNA expression of the osteocyte marker Phex (phosphate
regulating endopeptidase homolog, X-linked) at 4 (p < 0.01), 6 (not
significant), and 24 (p < 0.001) hours (Figure 2a). Similarly, Dmp1
(dentin matrix protein 1) expression was significantly increased at both
6 and 24 hr in MC3T3 cells (p < 0.001; Figure 2b). In primary
osteoblasts, both Phex and Dmp1 mRNA expressions were also
increased by FGF-2 treatment, although the temporal changes were
slightly different to those observed in theMC3T3 cells. Specifically, the
stimulation of Phex expression by FGF-2was greater at late time points
whereas the up-regulation of Dmp1 was noted at earlier time points
when compared with MC3T3 cells (Figures 2c and 2d).
In contrast to the increased expression of osteocyte markers by
FGF-2, there was a consistent downward trend in the mRNA
expression of the osteoblast markers Col1a1 (collagen type 1), Bglap
(osteocalcin), Alpl (tissue non-specific alkaline phosphatase), and
Postn (periostin) in MC3T3 cells treated with exogenous FGF-2
(Figure 3a–d). This down-regulation of osteoblastic marker expression
was most consistently observed 24 hr after exposure to FGF-2,
although Alpl expression was also reduced at 4 (p < 0.001) and 6
(p < 0.01), as well as 24 (p < 0.001) hour time points (Figure 3c). A
similar down-regulation of Col1a1, Bglap, Alpl, and Postn expression
was also observed in FGF-2 treated primary osteoblast cells, whichwas
also most pronounced at longer (24 hr) times following FGF-2
challenge (Figure 3e–h). Together these data indicate that exposure
of MC3T3 as well as primary osteoblasts to exogenous FGF-2
promotes early expression of both E11 and osteocyte markers, with a
diminution in the expression levels of markers of the osteoblast
phenotype following only at later time points.
Assessment of cell viability in the FGF-2 treated MC3T3 cells by
the alamar blue assay revealed that after 24 hr of FGF-2 treatment
there was no significant differences between the control and FGF-2
treated cells (Figure 3i). We also observed a significant reduction in
LDH release in our FGF-2 treated cells (p < 0.05, Figure 3j) suggesting
that there is less cell death. Taken together, these data are consistent
with FGF-2 promoting E11 expression and osteoblast–osteocyte
differentiation in vitro.
3.3 | FGF-2 promotes E11 dependent osteocyte
dendrite formation
The differential regulation of osteoblast and osteocyte marker
genes, including E11, by FGF-2 strongly supports the tenet that
FGF-2 can induce osteocytogenesis. To examine this further, we
next investigated whether FGF-2 promotes the differentiation of
MC3T3 osteoblast-like cells into osteocytes with the adoption of
their characteristic dendritic appearance through alterations to the
intracellular cytoskeleton. We found that Phalloidin stained control
cells displayed a typical rounded morphology with little evidence of
dendrite formation (Figure 4a). In contrast, cells treated with FGF-2
for 24 hr displayed numerous delicate dendrites radiating from
individual cells and intertwining and connecting with dendrites from
neighbouring cells, in a manner characteristic of an osteocyte-like
phenotype (Figure 4b). To clarify E11 involvement in this FGF-2
FIGURE 2 The effect of FGF-2 (10 ng/ml) on the mRNA expression of (a) Phex and (b) Dmp1 in MC3T3 cells after 4, 6, and 24 hr challenge.
The effect of FGF-2 (10 ng/ml) on the mRNA expression of (c) Phex and (d) Dmp1 in primary osteoblast cells after 4, 6, and 24 hr challenge.
Results were normalized to the Atp5b housekeeping gene. Data are presented as mean ± S.E.M for n = 3; **p < 0.01; ***p < 0.001 compared to
untreated cells
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induced change to dendritic phenotype, MC3T3 cells were
challenged with FGF-2 for 24–72 hr and immunostained for E11
(Figure 4c). All FGF-2 treated MC3T3 cells exhibited modified
morphology with numerous E11 positive dendritic processes
radiating from the cell membrane (Figure 4c); these were only
rarely observed in control cells. Furthermore, the distribution of
intra-cellular E11 expression changed with both time in culture and
FGF-2 treatment. In control cells, it was mostly uniformly distributed
within the cytoplasm but after 72 hr in culture, cytoplasmic staining
appeared less strong and the predominant staining was associated
with focal accumulations at the cell membrane (Figure 4c). This
redistribution of E11 to the cell membrane was more obvious and
FIGURE 3 The effect of FGF-2 (10 ng/ml) on the mRNA expression of (a) Col1a1, (b) Bglap, (c) Alpl, and (d) Postn in MC3T3 cells after 4, 6,
and 24 hr challenge. The effect of FGF-2 (10 ng/ml) on the mRNA expression of (e) Col1a1, (f) Bglap, (g) Alpl, and (h) Postn in primary
osteoblast cells after 4, 6, and 24 hr challenge. Results were normalized to the Atp5b housekeeping gene. (i) Alamar blue assay for cell viability
and (j) LDH release assay in FGF-2 treated MC3T3 cells after 24 hr treatment. Data are presented as mean ± S.E.M for n = 3; *p < 0.05;
**p < 0.01; ***p < 0.001 compared to untreated cells
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more rapid in the FGF-2 treated cells, where it was achieved within
only 24 hr of treatment (Figure 4c). Similarly, FGF-2 promoted
dendrite formation and the re-distribution of E11 expression in
primary osteoblast cultures (Figure 4d). To determine if the
promotion of the osteocyte phenotype by FGF-2 was E11 mediated
we studied cells in which MC3T3 cells were transfected with E11
siRNA before being challenged with FGF-2 for 24 hr. E11 gene (77%
vs. mock control, 70% vs. scrambled control; p < 0.05; Figure 5a) and
protein (Figure 5b) expression were silenced successfully by E11
siRNA transfection. Immunofluorescence labeling for E11 and
phalloidin staining indicated that compared with mock or scrambled
control cell cultures, cells treated with FGF-2 developed less
dendrites after silencing of E11 expression (Figures 5c and 5d).
3.4 | FGF-2 cell signaling in MC3T3 cells is mediated
principally by phosphorylated ERK
FGF receptors (Fgfr) 1, 2, and 3, but not Fgfr4, were found to be
expressed by MC3T3 cells (data not shown). FGF-2 treatment had no
effect on Fgfr1 expression at all-time points studied (Figure 6a),
however, it reduced Fgfr2 (p < 0.01; Figure 6b) and Fgfr3 (p < 0.05;
Figure 6c) expression after 4 and 24 hr. Treatment of MC3T3 cells
with FGF-2 for 15 min revealed that of the pathways examined,
there was particularly marked ERK (p44/p42) activation (p < 0.001;
Figures 6d and 6e), while in comparison there was only slight
activation of both Akt (p < 0.01; Figures 6d and 6f) and p38 (p < 0.05;
Figures 6d and 6g), and no effect on JNK phosphorylation (Figures
FIGURE 4 The effect of FGF-2 (10 ng/ml) on MC3T3 osteoblast-like cell morphology. (a) Phalloidin staining for F-actin of control cultures,
and (b) FGF-2 treated cultures. Scale bar A & B = 150 μm). Immunofluorescence microscopy showing E11 expression and distribution in cells
treated with FGF-2 (10 ng/ml) for 24–72 hr in (c) MC3T3, and (d) primary osteoblasts. Note the arrows pointing at the dendrites. Images are
representative of three separate experiments. Scale bar c & d (i–vi) = 200 μm; c & d (vii–xii) = 150 μm)
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6d and 6h). Furthermore, the temporal expression of ERK activation
upon FGF-2 treatment revealed a sustained activation over a 48 hr
period (Figure 6i), which has been shown previously to be associated
with pathways leading to cell differentiation (Pellegrino & Stork,
2006). These data suggest that ERK activation, rather than
phosphorylation of alternative Akt, p38, or JNK mediated signaling
pathways is likely most influential in regulating E11 downstream of
FGF-2.
To further explore the likely role of MEK-ERK signaling in FGF-2
induced differentiation of osteoblast-like cells into osteocytes, we
next treated MC3T3 cells with the ERK inhibitor U0126 (25 μM) in
the presence or absence of FGF-2 (15 min). While ERK activation by
FGF-2 was blunted by U0126 (15 min) treatment (Figure 7a), the
prolonged treatment of cells with U0126 (24 hr) did not affect the
ability of FGF-2 to enhance E11 gene expression (Figures 7b and 7c).
Similarly, treatment of MC3T3 cells with p38 (SB203580) or PI3K
(LY294002) inhibitors did not affect the ability of FGF-2 to enhance
E11 expression (Figure 7d–g). Further investigations indicated that
Akt activation was increased in the presence of MEK inhibition by
U0126 and FGF-2 treatment (Figure 7h) and it is possible that this
FIGURE 5 The effect of E11siRNA transfection on FGF-2 (10 ng/ml) stimulation of E11 (a) mRNA. Results were normalized to the
Atp5b housekeeping gene. Data are presented as mean ± S.E.M for n = 3; *p < 0.05; ***p < 0.001 compared to untreated control cells;
#p < 0.05 refers to significant decrease of E11siRNA control when compared to the controls of scrambled and Mock treated cells (b)
The effect of FGF-2 (10 ng/ml) on E11 protein expression after E11 siRNA transfection, where (+) is FGF-2 treated cells, and (−) is
untreated cells. Results are normalized to β-actin for loading control. (c) Phalloidin staining for F-actin in E11 siRNA, mock and
scrambled cultures. Images are representative of three separate experiments. Scale bar = 100 μm. (d) Immunofluorescence staining for
E11 localization in E11 siRNA, mock and scrambled cultures. Images are representative of three separate experiments. Scale
bar = 150 μm
8 | IKPEGBU ET AL.
increased Akt signaling may be a compensatory change to allow
FGF-2 to promote E11 expression in the absence of full ERK
activation (Figures 7b and 7c). However, the combined inhibition of
MEK and PI3K signaling by the inhibitors U0126 and LY294002,
respectively, did not affect the ability of FGF-2 to enhance E11
protein expression (Figure 7i).
3.5 | Deletion of FGF-2 in vivo results in
dysfunctional osteocytogenesis
Finally, we used immunohistochemistry to examine whether FGF-2
KO mice exhibited altered skeletal E11 expression and distribution.
Unexpectedly, E11 staining in osteocytes situated within trabecular
FIGURE 6 The effect of FGF-2 (10 ng/ml) on the mRNA expression of (a) Fgfr1, (b) Fgfr2, and (c) Fgfr3 in MC3T3 cells after 4, 6, and 24 hr
challenge. Investigating the downstream signaling pathways involved in FGF-2 stimulation of E11 expression. (d) Western blotting analysis of
MC3T3 cells for phosphorylated and total p44/42 (ERK), Akt, p38, and JNK. Densitometry analysis of Western blotting revealed significant
upregulation of activated (e) p44/42, (f) Akt, and (g) p38 in treated MC3T3 cells with FGF-2 when compared to control cells. There was no
significant increase in (h) JNK expression in both cultures. (i) Western blotting analysis of MC3T3 cells for phosphorylated and total p44/42,
in MC3T3 cells treated with FGF-2 when compared to control cells showed an increase in phosphorylated p44/42 in the treated cells at all
time points. Results were normalized to the Atp5b housekeeping gene and β-actin for Western blotting loading control. Data are presented as
mean ± S.E.M for n = 4 and analyzed with student t-test. *p < 0.05; **p < 0.01; ***p < 0.001
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and cortical bone of FGF-2 KO mice appeared stronger than in
osteocytes from WT bones (Figure 8a–d). Quantification of the
number of E11 positive cells was, however, similar to those noted in
bones from WT mice (Figure 8e). No differences in sclerostin
expression or distribution in bones of FGF-2 KO mice in comparison
to those fromWT mice were observed (data not shown). Histological
analysis of osteocyte morphology in FGF-2 KO mice revealed
apparent increases in cell body volume (Figure 8a–d). To confirm and
extend these results, we performed phalloidin staining of osteocytes
in the cortical bone of FGF-2 KO and WT mice (Figures 9a and 9b).
We observed a significant increase in cell body volume (p < 0.05,
Figure 9c) in concordance with our histological observations. Despite
this, no differences in cell sphericity were observed (Figure 9d).
Similarly, the total number of dendrites (Figure 9e) and the dendrite
volume (Figure 9f) were unchanged between FGF-2 KO and WT
mice. We did, however, observe a significant decrease in average
dendrite volume in FGF-2 KO in comparison to WT mice (p < 0.01;
Figure 9g), suggestive of dysfunctional osteocytogenesis in FGF-2
KO mice.
4 | DISCUSSION
The transmembrane glycoprotein E11, has recently been recognized to
be an early driver of the osteoblast to osteocyte transition and the
acquisition of the dendritic phenotype (Gupta et al., 2010; Zhang et al.,
2006). Consistentwith previous data, herewe reveal that FGF-2 is able
to increase E11 expression and promotes osteocyte dendrite
formation, likely independent of intracellular signaling pathways that
may involve concomitant FGF-2 induced ERK activation.
Previous brief reports have shown that FGF-2 treatment of
osteoblast-like cells induces an increase in E11 expression and the
appearance of the osteocyte phenotype (Gupta et al., 2010;Miyagawa
et al., 2014). In this present study, we confirm and extend these
observations in both MC3T3 osteoblast-like cells and primary
osteoblasts. The significant upregulation of E11, Phex, and Dmp1
and down-regulation of Col1a1, Bglap, Alpl, and Postn in the FGF-2
treated cultures suggests that FGF-2 promotes the differentiation of
the osteoblast to the osteocyte stage. Concomitant with this,
fluorescence microscopy of cultured cells also disclosed altered E11
expression and localization within the differentiating osteoblast in
response to FGF-2. The presence of increased E11 in the cytoplasm
and perinuclear area suggests that FGF-2 not only stimulates E11
expression, but also facilitates the translocation of E11 toward the cell
membrane. Indeed, the ability of FGF-2 to alter subcellular protein
distribution is supported by a previous finding on the expression of
Twist and Spry4 proteins inmesenchymal stem cells (Lai, Krishnappa, &
Phinney, 2011). Here we observed E11 localization concentrated at
the base of the dendritic spikes of the osteocytes after 24–72 hr of
FGF-2 treatment. E11 immunofluorescence localization at osteocyte
dendritic projections has been reported inMLO-Y4 osteocyte-like cells
and primary osteocytes isolated from long bones (Stern et al., 2012). It
is, therefore, likely that this redistribution of E11 within the cell is
necessary for the transformation of the osteoblast from a cuboidal
shape to the osteocytic phenotype characterized by stellate-like
morphologywith long dendritic processes (Zhang et al., 2006).We also
reveal that these morphological changes do not occur because of
altered cell proliferation, nor do they precede cell death, therefore,
highlighting the role for FGF-2 in regulating E11 expression and
osteocyte differentiation in vitro.
FIGURE 7 (a) Western blot analysis of ERK signaling in the
presence (+) and absence (−) of U0126 (25 μm) incubation and
subsequent FGF-2 treatment. (b) Western blotting and (c) RT-qPCR
analysis of cells stimulated with FGF-2 for 24 hr, in the presence
or absence of U0126 (ERK inhibition). (d) Western blotting and
(e) RT-qPCR analysis of cells stimulated with FGF-2 for 24 hr, in the
presence or absence of LY294002 (Akt inhibition). (f) Western
blotting and (g) RT-qPCR analysis of cells stimulated with FGF-2 for
24 hr, in the presence or absence of SB203480 (p38 inhibition).
Effect of UO126 (25 μM) on Akt protein expression by (h) Western
blotting. (i) Effect of U0126 (25 μM) and LY294002 (10 μM), P-ERK,
and P-Akt inhibitors, respectively, on E11 protein expression.
Results were normalized to the Atp5b housekeeping gene and
β-actin for Western blotting loading control. Data are represented
as mean ± S.E.M for n = 3. Data are analyzed via one-way ANOVA;
p < 0.05 was considered to be significant. *p < 0.05
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The intracellular effects of FGF-2 are activated via binding to its cell
surface receptors, for example, FGFRs which have intrinsic receptor
tyrosine kinase activity. Signaling pathways downstream of FGF-2-
receptor binding are known to includeERK, p38, Akt, andPKC (Turner&
Grose, 2010). Of those examined in the present study, ERK showed the
most robust activation in response to FGF-2 in MC3T3 osteoblast-like
cells; although p38 and Akt phosphorylation was also significant.
Phosphorylation of ERK has been shown to mediate cell proliferation,
differentiation, andmatrixmineralization inhumanosteoblasts (Lai et al.,
2001; Marie, Miraoui, & Severe, 2012). The sustained activation of the
MEK-ERK pathway and phosphorylation of ERK over long time periods
suggests a central role for FGF-2 stimulation of cell differentiation
(Murphy, Mackeigan, & Blenis, 2003; Pellegrino & Stork, 2006). This is
supported by studies that report the importance of ERK signaling in
osteoblast initiation and commitment to the differentiation process (Lai
et al., 2001), and in osteocyte dendrite formation (Kyono, Avishai,
Ouyang, Landreth, &Murakami, 2012). Indeed, the conditional deletion
of ERK ablates the formation of osteocytes with characteristic dendritic
processes in vivo (Kyono et al., 2012).
Somewhat surprisingly, however, the MEK inhibitor, UO126 was
unable to block FGF-2's ability to promote E11 protein expression
despite a significant reduction in ERK activation. Similar results were
observed upon inhibition of PI3K/Akt and p38 signaling. These
results suggest that alternative pathways may exist by which FGF-2
is able to enhance E11 expression and osteocyte formation. Such
pathways may include the activation of p38 and Akt. Previous
reports have indicated that activation of p38 is involved in
osteoblast differentiation (Hu, Chan, Wang, & Li, 2003) whereas
Akt phosphorylation is associated with cell survival (Debiais et al.,
2004). The down regulation of Akt by FGF-2 has, however, also been
reported in human and mouse cells (Chaudhary & Hruska, 2001). In
our hands, however, the dual inhibition of Akt and ERK activation by
LY294002 and U0126, respectively, did not result in a block in E11
expression by FGF-2 and further work is required to unravel the
signaling pathways that mediate FGF-2 effect on the up-regulation
of E11 expression. The lack of JNK activation by FGF-2 in this study
is consistent with JNK phosphorylation (P-JNK) mediating late
osteoblast maturation (Matsuguchi et al., 2009).
Having shown that FGF-2 promotes E11 expression in MC3T3
osteoblast like-cells and murine primary osteoblasts, it was surprising
to note that E11 protein expression by early osteocytes appeared to be
increased in sections of bone from Fgf-2-deficient mice albeit no
FIGURE 8 Sections of (a and b) trabecular bone and (c and d) cortical bone osteocytes from Fgf-2 KO and WT mice immunostained for
E11. (a and b) Scale bar = 150 μm. (e) The number of E11 stained osteocytes was similar in cortical bone from Fgf-2 KO and WT mice. Images
are representative of three mice
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differences were noted in the number of E11 stained osteocytes. It is
recognized that heparin-like glycosaminoglycans can regulate the
signaling behavior of FGF-2 and, therefore, it is a possibility that in our
cell culture experiments FGF-2 is more available to the cells due to a
less mature extracellular matrix being formed (Padera, Venkataraman,
Berry, Godavarti, & Sasisekharan, 1999). Alternatively, the increased
E11 staining intensity in the osteocytes from Fgf-2-deficient mice is
maybe a compensatory response in an attempt to overcome the deficit
in FGF-2 related promotion of the osteoblast to osteocyte transition,
potentially through the upregulation of other members of the FGF
family. Similarly, it may simply be a consequence of the significantly
increased cell body volume observed in FGF-2 KO osteocytes. Indeed
FGF-2 has been reported to decrease chondrocyte hypertrophy in a
murine metatarsal organ culture model and as such, may play a similar
role in the formation of the osteocyte (Mancilla, De Luca, Uyeda,
Czerwiec, & Baron, 1998). Our phalloidin staining also revealed a
significant decrease in average dendrite length in FGF-2 KO mice
compared to WT mice; a similar phenotype to that observed in our
bone specific E11 conditional knockoutmice (Staines et al., 2017). This,
therefore, suggests that the absence of FGF-2 in vivo results in
dysfunctional osteocytogenesis.
In conclusion, these data taken together show that FGF-2
promotes the osteocyte phenotype and that this is mediated by
increased E11 expression which is redistributed within the differenti-
ating osteoblast. If further studies confirm this regulatory role for
FGF-2 in osteocyte formation, we will be in a better position to
understand the full repertoire of FGF-2 on bone cell function which
may provide insights into the etiology of skeletal disorders such as
osteoporosis and osteoarthritis.
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